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PART 1 

Chapter 1 
INTRODUCTION 
This thesis consists of two parts. In the first part 
(Chapters 1-4) adverse reactions to drugs are discussed: 
the history of the problem (Chapter 1), types of adverse 
reactions and detection of adverse reactions prior to the 
marketing of drugs (Chapter 2), and the different types of 
postmarketing studies (Chapter 3). In Chapter 4 a review is 
made of the methods and results of the voluntary reporting 
scheme in The Netherlands. 
In the second part (Chapters 5-12) the aims, methods and 
results are outlined of the studies which form the basis of 
this thesis. In Chapter 5 the objectives are formulated. 
The first objective was to demonstrate that suspected ad-
verse reactions to drugs - as reported to a national mon-
itoring centre employing voluntary reporting - can not only 
be used for the detection of unknown adverse reactions but 
can also be used for in-depth studies of series of cases. 
The latter would improve the knowledge of the clinicopatho-
logical pattern of a particular adverse reaction. The 
second objective was to demonstrate that the studies are 
not necessarily restricted to cases reported to a national 
centre but that cases from different countries may be used. 
In this thesis the adverse reaction which was studied was 
hepatic 1nJury. Glafenine, ketoconazole, nitrofuran 
derivatives and pirprofen are examples of drugs which may 
cause this adverse effect. The third objective of this 
thesis was to study the clinicopathological patterns of 
hepatic 1n]ury attributed to these drugs. The variety of 
patterns of drug-induced hepatic injury and methods for 
diagnosis are discussed in Chapters 6 and 7. The studies on 
the clinicopathological pattern of hepatic injury by three 
different drugs are given in Chapter 8 (glafenine) , Chapter 
9 (ketoconazole) and Chapter 10 (nitrofuran derivatives). 
These studies are the result of the first and third ob-
jective. The study of pirprofen-associated hepatic injury 
(Chapter 11) is the result of the second objective. The 
results are discussed in Chapter 12. 
HISTORY 
Phocomelia means "seal extremities", a congenital mal-
formation which consists of the absence of arms and legs. 
Normal or rudimentary hands and feet are directly attached 
to the trunk like the flippers of a seal. Phocomelia was -
and again is an extremely rare condition. Only a few 
cases of phocomelia had been noted between 1949 and 1959 in 
the various university pediatric clinics in the Federal Re-
public of Germany. Then there was an explosive growth with 
17 cases in 1959, 124 in 1960 and 477 in 1961. Viral 
causes, radioactive fall-out, X-ray exposure of the mother, 
food and its preservatives and contraceptives were con-
sidered but since the outbreak seemed largely confined to 
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the Federal Republic of Germany, none of these possible 
causes seemed to be likely. A German gynaecologist, Lenz, 
found retrospectively that 20 percent of his patients, who 
had recently been delivered of a baby with phocomelia, re-
ported to have taken the drug Contergan in early pregnancy. 
When he requestioned the mothers of these children approxi-
mately 50 percent of the mothers admitted taking Contergan. 
They had not mentioned using the drug at first because they 
considered the drug to be innocuous. At a pediatric meeting 
in Dusseldorf on 20 November 1961 Lenz brought his sus-
p~c~on of a drug-induced cause to public attention without 
mentioning the name of the product • 
..•...•.. That night a physician came up to him and 
said: "Will you tell me confidentially, is the drug 
Contergan ? I ask because we have such a child and my 
wife took Contergan". In the next few days he received 
a half dozen letters asking the same question and 
saying, "My wife took Contergan and we have such a 
child". A couple of days later it was generally known 
among the doctors that Contergan was the drug under 
suspicion ...... (1). 
Thalidomide (Contergan, Distaval, Kevadon, Softenon, 
Talimol) is a sedative and hypnotic. It was marketed in 
1956 in the Federal Republic of Germany and in 1958 in 
Great Britain and soon gained popularity since - unlike 
barbiturates an overdose was not fatal. It was even 
recommended in children ("Western Germany's baby-sitter") 
and mixed with several analgesic, antitussive and anti-
pyretic preparations. After its withdrawal from the market 
in 1961, the Ministry of Health in the Federal Republic of 
Germany estimated the number of babies with malformations 
attributed to maternal use of thalidomide during pregnancy 
at 10000 of whom 5000 survived. In Great Britain these 
figures were estimated at 500 and 275 respectively (9). 
This was not the first iatrogenic epidemic and it will 
probably not be the last. In the 19th century the toxicity 
of chloroform had led to its withdrawal from clinical use 
(2) and in the period 1920-1940 hepatic injury by cincho-
phen (3), and agranulocytosis by amidopyrine and related 
agents (4), were recognized. Following the thalidomide epi-
sode several drugs have been recognized as the cause of 
serious disease, e.g.chronic active hepatitis by oxypheni-
satin (5), acute hepatocellular necrosis by halothane (6) 
and sclerosing peritonitis (7) and oculocutaneous reactions 
(8) by practolol. 
The thalidomide disaster, however, was a breakthrough. It 
used to be easy to market almost any drug. As a result of 
this epidemic it was made mandatory to perform extensive 
preclinical and toxicological studies before a drug was 
marketed. Moreover it was recognized that the marketing of 
a drug is the decisive toxicological experiment which only 
stops when the drug is withdrawn from clinical use. In the 
developed countries national monitoring centres were star-
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ted, as the central post for feedback of unwanted experi-
ences with drugs, either as an initiative of medical asso-
ciations or health authorities. 
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Chapter 2 
ADVERSE REACTIONS TO DRUGS 
The use of drugs is a double-edged sword. Every drug with 
a pharmacological action may cause adverse reactions. The 
World Health Organisation defined an adverse effect as "one 
which is noxious and unintended, and which occurs at doses 
used in man for prophylaxis, diagnosis or therapy" (1). 
This definition has two aspects. On the one hand it dif-
ferentiates the wanted (therapeutic) effect from the un-
wanted one whereas on the other hand the latter is diffe-
rentiated from toxic effects by overdosage. 
There are several types of adverse effects. As a rule, 
one may say that every 'natural' disease may be mimicked by 
an adverse reaction. Several drugs, for instance sulphon-
amides which may cause a large variety of skin disorders 
(2), may produce a reaction indistinguishable from the mor-
billiform rash of measles. Other drugs, e.g. labetalol, may 
cause fever (3), which is usually attributed to infection 
before the reaction is recognized as drug-induced. Some 
clinical manifestations, however, are fairly specific for a 
drug-related cause. Anaphylactic shock, e.g. to ketocona-
zole (4) or glafenine (5), and agranulocytosis, e.g. to 
spironolactone (6) or dipyrone (7), are examples of reac-
tions which are often drug-induced. Adverse reactions have 
several aspects which may lead to different subdivisions 
(table 1) • A short review will be made of the first 2 as-
pects, on mechanisms and latent period, whereas for more 
information the interested reader is referred to the text-
books "Iatrogenic Diseases" (B) and "Textbook of Adverse 
Drug Reactions" (9) and to the comprehensive reference-book 
'Meyler's Side Effects of Drugs'(10), of which there is a 
Dutch version (11). 
1.a Adverse effects which are dose-related 
The large majority of drugs do not have a completely spe-
cific pharmacological action. Therefore their effects are 
not only beneficial. Drugs produce a variety of dose-rela-
ted effects of which the therapeutic action is usually the 
most important one. With increasing dose, wanted - but also 
dose-dependent unwanted effects - become more prominent. In 
principle these effects may occur in every patient. There-
fore the reaction is called 'predictable'. Dose-related ad-
verse effects are frequent but usually not very serious. 
Examples are an excessive therapeutic effect (e.g. hypogly-
cemia by insulin, hypotension by vasodilators), pharmaco-
logical adverse effects (e.g. dry mouth by tricyclic anti-
depressants), organ-specific toxicity (e.g. vestibular dam-
age and deafnes.s by aminoglycosides) and secondary effects 
(e.g.interference with bacterial flora by broad-spectrum 
antibiotics; infections during treatment with immunosup-
pressants). Sometimes an adverse effect in one situation is 
a wanted effect in another situation. An example is mor-
phine which causes constipation as an adverse effect when 
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TABLE 1 
SOME EXAMPLES OF THE DIFFERENT ASPECTS OF 
ADVERSE REACTIONS TO DRUGS 
Mechanism 
Latent period 
Localization of injury 
Reversibility 
Severity 
Objectivity 
dose-related 
metabolic 
not dose-related< 
immunoallergic 
short-term effects (e.g. rash) 
long-term effects (e.g. cancer) 
organ-specific (e.g. eye, kidney) 
generalized (multiple organs) 
irreversible damage (e.g. cirrhosis) 
recovery after discontinuation of drug 
(e.g. headache) 
fatal reaction 
serious but non-fatal 
trivial 
objective effects (e.g. elevation of serum 
creatinine) 
subjective effects (e.g. drowsiness) 
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employed as an 
rrhoea, however, 
use. 
analgesic. In the treatment of severe dia-
this adverse effect may find therapeutic 
l.b Adverse effects which are not dose-related 
These reactions are rare and unpredictable. They are not 
related to the dose but rather to a vulnerability of the 
individual who develops the reaction. These reactions may 
be divided into idiosyncratic reactions and immunoallergic 
reactions. Idiosyncratic reactions are often due to a ge-
netically based abnormality in drug metabolism, e.g. by a 
decreased quantity of certain enzymes. Typical examples are 
hemolytic anemia in patients with a deficiency of erythro-
cytic glucose-6-phosphate dehydrogenase treated with nitro-
furantoin and prolonged paralysis in patients with plasma 
cholinesterase deficiency receiving suxamethonium. 
Immunoallergic ("hypersensitivity") reactions are always 
secondary to antibody formation by the immune-system. Es-
pecially large molecules, e.g.dextran, give rise to immune-
allergic reactions but also small molecules may do so sec-
ondary to the formation of complexes consisting of proteins 
and drug metabolites. There are at least 4 types of immuno-
logical reactions (anaphylactic, cytotoxic, immune-complex 
and delayed type), which can usually be distinguished by 
their clinical manifestations (12). 
2. Latent period 
If adverse effects appear they usually do so shortly (<2 
months) after starting treatment. In these cases the tem-
poral relationship will make it relatively easy to ascer-
tain a causal relationship. Urticaria and collapse, for 
instance, appearing within 20 minutes after ingestion of 
glafenine or nalidixic acid leave little doubt as regards a 
causal relationship. In case of unwanted effects after 
long-term treatment (e.g.cancer, slow-onset intellectual 
impairment) a causal relationship with use of the suspected 
drug is usually very difficult to assess. The assessment of 
a causal relationship between a particular disease and the 
intake of a drug is based on three points: on the specifi-
city of the clinicopathological pattern, on the temporal 
relationship and on the exclusion of other potential causes 
(see Chapter 7). Very few patterns are specific for a drug-
induced cause and the temporal relationship is uninfor-
mative when assessing long-term effects. There are many 
unknown genetical-, environmental- and age-related factors 
which may be held responsible for a particular disease. A 
suspected drug is often only one of many potential causes. 
A number of these causes may be unknown and therefore im-
possible to exclude. When there is a long delay between use 
of a drug and the appearance of drug-induced injury none of 
the three aforementioned points are conclusive. In these 
cases epidemiologic studies should give the answer with 
prospective and controlled trials, cohort studies or case-
control studies. Examples are the association between long-
term use of drugs and certain forms of cancer, e.g.between 
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the use of oral contraceptives and hepatocellular carcinoma 
(13-17) and breast carcinoma (18-23). Disagreement on the 
result of these studies may occur and - even when properly 
performed - this may give rise to heated debates. 
Drugs may cause congenital malformations when used during 
pregnancy. The problems in assessing a causal relationship 
resemble those of long-term effects but are somewhat 
different. Although the teratogenic effect is usually not 
recognized before birth there may be a clear-cut temporal 
relationship between maternal use of the suspected drug and 
the congenital defect. Phocomelia by thalidomide, for in-
stance, is secondary to the use of this drug by the mother 
between 37-54 days after the first day of the last menstru-
ation. The latter is a clearly visible congenital defect. 
The evidence is much more difficult to deliver when the 
defect is very subtle or appears after a long delay. These 
effects may manifest themselves later in life, e.g. vaginal 
carcinoma in daughters of mothers treated with diethyl-
stilboestrol (23). The cause of most birth defects is un-
known which makes it difficult to exclude other potential 
causes. For obvious reasons it is unethical to test drugs 
during pregnancy and despite much experimental data in 
animals little is known about the teratogenic risk of drugs 
in humans. 
DETECTION OF ADVERSE REACTIONS TO DRUGS 
The value of a drug depends not only on its therapeutic 
effect. The potential adverse effects should not outweigh 
the wanted effects of a drug. In addition to this benefit/ 
risk ratio the nature of the underlying illness and the 
availability of alternative treatment are important. Bone 
marrow depression during treatment of cancer with anti-
neoplastic agents is often unavoidable and taken for 
granted but it is unacceptable when this adverse effect is 
caused by a simple analgesic. Because some years ago there 
was no alternative drug for salazosulfapyridine in the 
treatment of ulcerative colitis (with the exception of 
corticosteroids), desensitization was often attempted in 
patients with a hypersensitivity reaction to this drug. 
When a patient with an infectious disease develops a rash 
to penicillin, however, it is almost invariably possible to 
treat him with an alternative antibiotic. 
It will be clear that for an adequate treatment both 
therapeutic and adverse effects of a·drug should be known. 
What should we like to know about the adverse effects of a 
particular drug? In an ideal situation we know everything, 
i.e.: 
1. Every potential adverse effect of the drug, its poten-
tial severity, its reversibility and its risk-groups 
(qualitative aspect). 
2. The incidence of each adverse effect (quantitative as-
pect) . 
10 
3. Its treatment (besides discontinuation of the drug). 
Unfortunately the actual situation is far from ideal. 
What then do we know ? And what studies are done to obtain 
knowledge about adverse effects ? 
The development of a drug has several phases. Compounds 
which have been selected by pharmaceutical firms as poten-
tially successful are submitted to a rigorous test program 
of several years duration before the drug is marketed. 
There is a phase of animal testing and there are three 
clinical phases, which have to be passed successfully be-
fore widespread marketing of a drug is started. Promising 
compounds and large series of related chemicals are 
screened in animals for their biologic effects. Usually 
only a few potentially successful drugs remain after 
testing several thousands of investigational chemicals. 
Drugs are mostly tested in rats, mice, hamsters, rabbits 
and guinea pigs (24). For several, often commercial, 
reasons the use of dogs and apes is limited to second-line 
toxicity testing or to specific problems such as those in 
which biliary excretion plays a role in toxicity (25) . In 
animal toxicity testing data on the pharmacokinetic and 
pharmacodynamic effects of a drug are obtained. Toxic 
effects of the drug are assessed both after acute overdose 
(LDSO) and after chronic administration. Special emphasis 
is given to development of tumors and congenital defects. 
During or following this phase mutagenicity tests in cell 
cultures or in vivo are performed. Subsequently these drugs 
are tested in humans. Four phases are distinguished, of 
which the first 3 phases are usually successfully passed 
before marketing. The fourth phase starts when the drug is 
marketed. 
- Phase I -
In phase I the drug is tested on a small group of human 
volunteers in order to obtain data about the pharmacoki-
netics of the drug and its pharmacodynamic action. Usually 
it concerns a single administration. The subjects are under 
close clinical supervision. 
- Phase II -
As soon as toxicological studies in animals and phase I 
studies in · volunteers have been brought to a successful 
end, small groups of selected patients are studied after 
administration of the investigational drug. The therapeutic 
action is scrutinized and the optimal dosage assessed. Ad-
verse effects are carefully evaluated in every phase since 
negligence is not only dangerous for the patient but may 
lead to financial losses for the company when development 
has to be abandoned at a later stage. An example of a drug 
which successfully passed preclinical testing but proved 
hepatotoxic in humans is FPL 52757. This antiallergic drug 
which structurally resembles cromoglicic acid, passed 
animal toxicity testing and human volunteer studies without 
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TABLE 2 
TYPES OF ADVERSE REACTIONS WHICH ARE USUALLY 
KNOWN FROM PRE-MARKETING STUDIES* 
Dose-dependent 
- excessive therapeutic effect 
(e.g. insulin-hypoglycemia) 
- pharmacological side effect 
(e.g. dry mouth-tricyclic antidepressants) 
- secondary effect 
(e.g. infection-immunosuppressants) 
- organ damage 
(e.g. ototoxicity-aminoglycosides) 
Dose-independent 
- immunoallergy 
(e.g. rash-penicillin) 
- idiosyncrasy 
(hepatitis-isoniazide) 
Other types 
~ long-term effect 
(e.g. liver adenoma-oral contraceptives) 
- teratogenic effect 
(e.g. phocomelia-thalidomide) 
- interactions 
(e.g. rifampicin-coumarines) 
- effect on risk-groups 
(e.g. benoxaprofen-hepatic injury) 
++ - very well-documented 
+ - well-documented but not all effects known 
-!+ - insufficiently documented 
- unknown 
Known 
++ 
+ 
-!+ 
-!+ 
-!+ 
-!+ 
-!+ 
-!+ 
*Adapted from van Dijke CPH. 'Postmarketing surveillance': 
een instrumentvoorveiligheid? Pharm. Weekbld. 1987; 122:139. 
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problems but caused an incidence of liver enzyme elevations 
in patients of 20 percent (25). Another drug discontinued 
because phase II and III studies showed hepatotoxicity is 
oxmetidine, an H2-antihistamine (26). This was, however, 
also demonstrable in rat hepatocyte cultures (27) and in 
isolated rat hepatocytes (28, 29). 
- Phase III -
subsequently large studies are performed in which many 
patients are enrolled in prospective controlled clinical 
trials with the aim to test the therapeutic effects of the 
drug. In this phase the most frequently encountered adverse 
effects are assessed. Because of the enormous cost of the 
development of a new drug only one to several thousands 
(usually up to approximately 4000) of patients are tested 
during a limited period. Therefore data are only obtained 
about adverse effects with a relatively high incidence and 
appearing after relatively short periods of administration. 
Moreover drugs are tested in restricted groups of patients. 
Some patient-groups, e.g.pregnant or elderly patients or 
children, are not the subject of these tests but may never-
theless be exposed to the drug after marketing. 
- Phase IV -
After acceptance by the regulatory authorities of a coun-
try the drug is marketed. Even after years of use new the-
rapeutic effects of a drug may be discovered. Postmarketing 
studies, however, are especially important for the early 
detection of unknown adverse effects. Although premarketing 
studies (phases I-III) give some insight into the pharmaco-
logical and toxicological, dose-dependent effects of a drug 
many important adverse effects are unknown at the moment of 
marketing. Table 2 shows which type of adverse effects are 
generally known at the moment of marketing. It is clear 
that adequate data fail on 5 important topics, i.e. the 
dose-independent (immunoallergic and idiosyncratic) reac-
tions, effect in risk groups (elderly, pregnant women, 
children etc.), interactions, teratogenic and long-term 
effects. It is clear that these adverse effects may change 
the benefit/risk ratio of a drug and may even lead to 
withdrawal from the market. This has been the case with 
several drugs in the recent past, e.g,benoxaprofen (hepatic 
injury) , zimelidine (Guillain-Barre syndrome) , nomifensine 
(hemolytic anemia) and tienilic acid (hepatic injury) . In 
the next chapter types of postmarketing studies are re-
viewed. 
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Chapter 3 
MONITORING OF ADVERSE REACTIONS TO DRUGS 
It is clear that at the moment of marketing (Phase IV) 
knowledge about the adverse effects of a particular drug is 
scanty. This means that the final experiment with a drug is 
the marketing itself, an experiment which only stops when a 
drug is no longer in use. There are many examples of drugs 
which were proven as a cause of a particular adverse effect 
only after widespread marketing. The, discovery that sali-
cylates could induce hepatic injury (1) took almost 60 
years of clinical use whereas on the other hand broncho-
spasm and bleeding tendency were already mentioned in a 
pharmacological handbook in 1901 (2) . Liver damage by cin-
chophen was reported for the first time in 1923 (3) whereas 
the drug had been introduced in 1908. Another striking 
example of a long delay is the association between use of 
phenacetin and nephropathy. This drug was introduced in 
general medicine in 1887 but its toxic effect on the kid-
neys was not reported until 1953 (4). A short delay between 
marketing and discovery of an adverse effect is mostly 
possible when the observed clinical effect is very rare. 
This makes it easy to recognize a sudden increase in the 
incidence, as was the case with phocomelia by thalidomide 
and sclerosing peritonitis by practolol. Also when the in-
crease is restricted to a particular geographical area the 
cause may be recognized relatively easily. An example of 
this was the sudden increase of cases of obstructive pul-
monary hypertension in switzerland, Germany and Austria, 
which proved to be caused by the anorectic drug aminorex 
(5). Also important are the extent of use of the drug and 
the presence of a 'system' to pool and discuss suspected 
adverse reactions to drugs (e.g. congresses, medical jour-
nals, monitoring centres). Unfortunately many adverse 
events have a high spontaneous occurrence (e.g.headache) 
and many other (often unknown) causes, so that only a 
positive reaction to rechallenge can prove a causal rela-
tionship. Although there are exceptions to this rule a 
rechallenge is in most cases unethical, especially when it 
concerns severe adverse events. Therefore this type of con-
clusive proof is rarely obtained, and then often accident-
ally. Some reactions are so infrequently caused by a par-
ticular drug that they are discovered only after years of 
general use. Pancreatitis by methyldopa (6.7), for in-
stance, and agranulocytosis by spironolactone (8) were 
demonstrated for the first time more than 20 years after 
marketing. 
By definition, 'postmarketing surveillance' includes 
studying of wanted as well as unwanted effects (9). This 
chapter, however, will focus on the latter. There are 
several methods for studying adverse reactions to drugs 
after marketing of a drug. Four sources may be distin-
guished, which are important for the detection of unknown 
adverse effects, the analysis of associations between 
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diseases and suspected drugs, andjor . the description of 
adverse reactions to drugs (Table 3). Generally speaking, 
most adverse reactions are detected with the help of repor-
ting in the medical literature, of voluntary reporting and 
of cohort studies. The first two of these are useful for 
descriptive studies of the clinical and histological 
pattern of a particular adverse effect based on single 
cases or series. The analysis of associations between 
diseases and suspected drugs is most effectively performed 
with cohort and case-control studies. When a monitoring 
system is staffed by capable scientists and ·when several 
complementary methods are employed it should be possible to 
discover and prevent drug-induced epidemics at an early 
stage. Even then, however, an unknown adverse effect may be 
missed and it should be realized that none of these systems 
is an absolute guarantee against unrecognized drug-induced 
disease. 
A short review of these methods follows (table 4). The 
interested reader is referred to the books of Inman (10) 
and Stephens (9). Invariably the aim is to detect unknown 
adverse effects as early as possible, andjor to estimate 
their incidence, andjor to determine predisposing or pre-
cipitating factors. 
LITERATURE REPORTING 
An adverse effect remains unknown unless it is recognized 
as such by someone. This will mostly be the patient, the 
medical practitioner or pharmacist. The recognized adverse 
effect may be reported in the literature andjor to the 
national monitoring centre. Although exact figures are not 
available most postmarketing data on unknown adverse 
effects are probably published by the medical practitioner, 
either as 'letter to the editor' or 'short report' or as a 
small series of cases. Van Dijke found that almost 80% of 
reports, published between 1981 and 1986 as "Bijwerkingen 
van geneesmiddelen" in the Dutch medical journal "Neder-
lands Tijdschrift voor Geneeskunde", consisted of reports 
by medical practitioners or pharmacists (11). This makes 
medical journals an important source of information, es-
pecially since computer retrieval facilitates easy access 
to these data. Reports are usually limited to one or two 
case-histories since the relatively low incidence of a 
particular adverse effect complicates generation of large 
series of cases. Sometimes, however, larger series are 
generated by co-operation between university medical 
centres, or by studying manufacturers data (12,13). 
VOLUNTARY REPORTING 
Most developed countries have an agency which evaluates 
adverse effects as reported by medical practitioners or 
pharmacists. Usually these monitoring centres are affili-
ated with the regulatory authority or inspectorate of drugs 
but in some countries (e.g.in the Federal Republic of Ger-
many) these are run by the medical association. In a mi-
nority of countries (e.g. Sweden) it is mandatory to report 
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TABLE 3 
RELATIVE EFFICACY OF METHODS FOR DETECTION, ANALYSIS 
AND DESCRIPTION OF ADVERSE REACTIONS TO DRUGS 
Detection Analysis Description 
Cases Series 
Literature reporting ++ ++ + 
Voluntary reporting ++ + ++ ++ 
Cohort studies + ++ 
Case-control studies ++ 
++ = effective 
+ = may be effective on some occasions 
= usually not effective 
TABLE 4 
CURRENTLY EMPLOYED AND SUGGESTED METHODS FOR STUDYING 
ADVERSE REACTIONS TO DRUGS 
Literature reporting 
Voluntary reporting 
Cohort studies 
Case-control studies 
Patient-oriented: - Intensive hospital monitoring 
- Out-patient monitoring 
- Medical record linkage 
Drug-oriented: - Prescription event monitoring 
- Postmarketing study by manufacturer 
- Registered/Monitored/Restricted release 
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serious adverse reactions. Most national monitoring centres 
also have other activities but these are not discussed 
here. The disadvantage of voluntary reporting is the fact 
that only a minor part of adverse effects is reported. This 
means that voluntary reporting gives no insight into the 
incidence of adverse effects. Not every clinical event is 
recognized, not every identified clinical event is recog-
nized as an adverse reaction to a drug, not every recog-
nized adverse reaction is reported and sales figures are 
kept confidential by the manufacturer. This means that both 
numerator and denominator of the incidence assessment are 
unknown. The advantage of voluntary reporting schemes is 
that they are simple to operate, may rapidly react to an 
alert, are relatively cheap and include the complete popu-
lation of a country, which means that also rare idiosyn-
cratic and immunoallergic reactions can be discovered. 
Moreover they can be used for the 'pooling' of patients 
with a particular adverse effect, groups which can be used 
for further studying. An other important advantage of 
voluntary reporting schemes is that they function as "feed-
back receiver". As already mentioned marketing of a drug is 
the final experiment and it is very important that the 
medical practitioner has an address where he can report his 
suspicions of a drug-induced effect. Especially this func-
tion makes a voluntary reporting system indispensable. 
· Voluntary reporting schemes usually act on a nationwide 
basis. There are, however, also a few systems acting on a 
regional basis. A successful example of the latter is the 
West-Midlands Centre for Adverse Drug Reaction Reporting 
(Dr.L.Beeley). 
Variants of the system of voluntary reporting are the 
monitoring systems specialized on one organ, e.g. the 
National Registry of drug-induced ocular side effects 
(Prof.Dr.F.T.Fraunfelder) (14) and the File on Drug Re-
action to the Skin (Dr.W.Bruinsma) (15). Sometimes volun-
tary reporting schemes are' specialized on a particular 
group of drugs, e.g. radiological contrast media (16) and 
radiopharmaceuticals (17). Another example is the Fede-
ration of Dutch Thrombosis Service Centres, which records 
interactions with coumarine anticoagulants. 
The World Health Organisation has a system, the WHO Col-
laborating Centre for International Drug Monitoring, which 
accumulates reports from the national monitoring centres in 
an abstracted form. Every adverse effect reported to a par-
ticipating national centre receives a 'preferred term' and 
is put into a computer data base, which is located in Upp-
sala, sweden. The most important aim is to generate early 
signals as regards adverse effects (18). 
Some medical practitioners and pharmacists report their 
suspicions concerning adverse reactions both to the na-
tional monitoring centre and to the manufacturer. Most 
manufacturers have their own adverse reaction monitoring 
department. Their data are often kept confidential and are 
rarely published after the drug has been marketed, unless 
as :part of the revision of a data sheet. 
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COHORT STUDIES 
As may be seen in table 2, there are several types of 
cohort studies. Cohort studies may be performed prospec-
tively as well as retrospectively. These are disease-
oriented when the cohort is based on a group of patients 
with a particular illness (hereafter called 'patient-
oriented') and drug-oriented when all patients on a par-
ticular drug form the cohort. In the latter case it means 
that all patients using a particular drug are enrolled,in a 
study in which all adverse events are recorded and compared 
with a control group. A usual advantage of cohort studies 
is the fact that the absolute and relative risk can be 
estimated fairly accurately and that several adverse 
effects can be studied concomitantly. Moreover unsuspected 
risks and benefits may be discovered. Disadvantages are the 
costs, the limited population and the limited period over 
which such studies can be performed prospectively. When 
performed retrospectively data may be incomplete and un-
reliable and data collection difficult. When performed 
prospectively bias may be introduced by patient and control 
selection. 
PATIENT-ORIENTED 
- Intensive hospital monitoring (19-21) 
This system consists of the registration of all ingested 
drugs and all observed suspected adverse effects in a par-
ticular (hospital-based) population. The advantage of this 
system is that it is relatively easy to estimate the in-
cidence of a particular adverse effect. Moreover the ad-
verse effect can readily be studied by the medical assessor 
and it is easy to record all relevant data. Disadvantages 
are the limited period of observation, the fact that the 
population is usually too small for the detection of un-
known - mostly rare - adverse effects and the fact that the 
costs are relatively high. Another disadvantage is that 
patients in a hospital often receive many drugs concom-
itantly and are commonly the subject of several procedures 
(e.g. operations) which may complicate the assessment of a 
causal relationship. Intensive hospital monitoring may be a 
local initiative or be a part of a multicentre study (e.g. 
the Boston Collaborative Drug Surveillance Program) . 
Although most intensive hospital monitoring schemes are 
patient-oriented these may be drug-oriented as well. 
- out-patient monitoring (22,23) 
Some Health Maintenance Organizations in the U.S.A. - the 
Kaiser-Permanente system (22) and the Medicaid Management 
Information System (23) register all prescriptions and 
adverse reactions. By linking these data (also discussed 
below: medical record linkage) it is attempted to prove a 
causal relationship between the use of drugs and an adverse 
event, not only by statistics but also by subsequent evalu-
ation of the original medical records. The first system is 
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much smaller than the second, which made it unsuitable for 
relatively rare reactions, e.g. the incidence-comparison of 
erythromycin estolate with other erythromycines. With the 
larger systems, however, it may be more cumbersome to re-
turn to the original medical records. 
- Medical record linkage (24,25) 
Medical record linkage refers to the bringing together of 
different records of individuals, mostly by linkage of two 
data registe~s. The register of patients on drug X, for in-
stance, may be linked with the register of malignancies. 
Then the frequency of a particular diagnosis can be com-
pared between users and non-users. There are several advan-
tages. By systematically searching for associations between 
drugs and events, unknown adverse effects (but also bene-
ficial effects) are detected and hypotheses arising from 
other sources may be tested. The relative risk of de-
veloping an adverse effect may be estimated. Unlike other 
systems record linkage may demonstrate the safety of a drug 
as soon as other sources cause public alarm. With this 
system it is possible to detect long-term effects of a 
drug. An important drawback is the price but this may be 
kept low when the medical record linkage system is part of 
a large health security system. Medical record linkage sys-
tems operate successfully in the United Kingdom (29) and in 
Finland (20) and gave important results on practolol and 
rash/conjunctivitis, and clozapine and agranulocytosis 
respectively. 
DRUG-ORIENTED 
- Prescription event monitoring (26) 
In the United Kingdom, Inman started a new type of post-
marketing surveillance. When a new drug is prescribed 
copies of the forms are obtained from the Prescription 
Pricing Authority which, as part of the system for reim-
bursing pharmacists, collects all prescriptions on behalf 
of the Department of Health and Social Security. Via these 
forms the general practitioners who have prescribed a par-
ticular drug are approached with the request to give data 
about all events (including not only adverse events and 
their consequences but also unexpected therapeutic effects) 
which have happened to the patient during the period of 
intake and after discontinuation of the drug. The events 
after discontinuation are compared to those during treat-
ment. As a control the same procedure is done with one or 
two older drugs from the same therapeutic class. The nature 
and frequency of adverse events between the two or three 
groups are compared. The advantage of this system is that 
it may discover at relatively low costs both new adverse 
reactions and the incidence but also previously unknown 
therapeutic effects. Other advantages are the introduction 
of a sort of control-group (albeit not randomized) by the 
comparison with a similar drug and the avoidance of discus-
sions about causality since all events are included. The 
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system is most suitable for the detection of adverse reac-
tions to drugs which are ingested for a longer period. Dis-
advantages of Prescription Event Monitoring are the fact 
that only a limited number of drugs can be investigated at 
a particular moment and that only prescriptions of general 
practitioners are included. Rare reactions (e.g.with an in-
cidence of 1:10.000) may be missed and even if present 
these may get lost in the enormous number of events. An 
other disadvantage is that adequate estimation of the in-
cidence may be jeopardized by a low response rate in the 
group of doctors, who consider themselves as responsible 
for an adverse effect. Others may be unwilling to report 
complicated patient histories because of a lack of time. 
All this may result in a difference between the incidence 
of adverse events in patients of general practitioners who 
respond and those who do not respond to the enquiry. Since 
a study can only start after a sufficient number of pres-
cription data has been generated, prescription event mon-
itoring may be slower in the detection of adverse effects 
than voluntary reporting schemes. Nevertheless prescription 
event monitoring is a sophisticated system. It is, beyond 
doubt, a promising type of postmarketing study. 
- Postmarketing studies by the manufacturer 
Ideally, of all patients who receive the drug all adverse 
events (not necessarily drug-induced) are recorded and the 
possible causal relationship with the drug is assessed. 
This may be an expensive method since it usually requires a 
large medical, pharmaceutical and clerical staff to do a 
follow-up of several thousands of patients. The population 
studied should be much larger than the population of the 
clinical trials in order to discover the more rarely en-
countered adverse effects. The follow-up should be pro-
longed to detect any long-term effects. Postmarketing 
studies are not mandatory. Nevertheless some pharmaceutical 
industries have attempted to perform such studies. 
- Registered (27)/Monitored (28)/Recorded (9) release 
These systems were proposed in order to facilitate close 
supervision on the marketing of new drugs. In registered 
release free sales are permitted as soon as a registered 
quota has been completed and patients are followed for five 
years. Also with the other release systems a follow-up is 
done of all patients (9) or only of the hospital and 
outpatient department attendances and fatal cases (28). 
There are more differences but these are not discussed 
here, mainly because these systems are currently not in 
use. Disadvantages are the costs and lack of controls. 
According to Stephens many pharmaceutical companies 
initiated monitored release schemes on new drugs but up 
till now with little success (9). 
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CASE-CONTROL STUDIES (29) 
Case-control studies start with the disease. A group of 
patients with the disease ('cases') is compared to a group 
of matched controls. The exposure rate to (a) particular 
drug(s) in cases is compared to controls. This may be done 
retrospectively or prospectively, on an on-going basis. Ad-
vantages of case-control studies are the fact that they can 
be performed relatively quickly and are relatively inexpen-
sive. Problems are the data collection which may be unreli-
able or incomplete, especially when the study is done ret-
rospectively. An important disadvantage is formed by the 
potential biases (e.g. •selection' bias, 'recall' bias). 
case-control studies are very suitable when adverse events 
are involved with an incidence which is too low for detec-
tion by cohort studies. 
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Chapter 4 
THE NETHERLANDS CENTRE FOR MONITORING OF ADVERSE REACTIONS 
TO DRUGS 
Before changing to the subject of this doctoral thesis it 
is important to give a short review of the objectives and 
methods of the monitoring centre where the studies were 
performed. Indirect activities of the centre, such as func-
tioning as a drug information centre, advising as regards· 
data sheets, and educational activities, are not discussed 
here. The reason for this review is that the studies are 
based on the data generation by the Netherlands Centre for 
Monitoring of Adverse Reactions to Drugs (NARD). For more 
information the reader is referred to the reviews by Mey-
boom (1,56). 
As a reaction to the thalidomide affair the NARD was 
founded in 1963 by a joint action of the Dutch Medical 
Association, the Inspectorate for Pharmaceuticals and the 
Medical Inspectorate (1,2). At the same time the evaluation 
of therapeutic and toxic effects of new drugs before mar-
keting was started by the newly formed Committee for the 
Evaluation of Medicines (CEM) . Functionally both the NARD 
and the CEM have been a part of the Ministry of Health and 
Environmental Hygiene, later the Ministry of Welfare, 
Health and Culture. The objective of the NARD has always 
been to discover unknown adverse reactions at an early 
stage in order to prevent an epidemic of drug-induced 
injury. 
From all over the country the NARD receives reports of 
suspected adverse reactions to drugs, either by post or by 
telephone. The number of suspected adverse reactions is 
approximately 1000 per year. In every case a careful evalu-
ation is made of essential data and in approximately one 
third of all reports additional data are requested. The re-
porting practitioner is often encouraged to publish all new 
and adequately documented and demonstrated adverse effects, 
either alone or in combination with other reporting prac-
titioners or with one of the medical officers of the NARD. 
Reporting to the NARD is done voluntarily. Unlike in 
Sweden, reporting of serious adverse reactions is not man-
datory in The Netherlands. No system can function without 
feedback. Basis of reporting suspected adverse reactions is 
the awareness that also the system of drug marketing is in-
complete without feedback. Medical practitioners employing 
new drugs are in need of a central non-commercial office 
where they can report their unexpected experiences with 
these drugs. 
The idea is that a cluster of reports of a particular 
adverse event in patients on a particular drug and origi-
nating from different parts of the country may reflect an 
adverse reaction to that drug. This is based on the assump-
tion that the reporting practitioners are unbiased, i.e. 
not aware of each others reports. Since coincidence is not 
excluded, especially not with events which have a high 
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spontaneous incidence and which are non-specific (e.g. 
headache) , all reports require careful evaluation and fol-
low-up. Via this method it can be made likely that unex-
pected events are adverse effects, even when in each in-
dividual case a causal relationship with the intake of the 
suspected drug is not fully established. In exceptional 
cases an unknown adverse effect can be proven on the basis 
of a single case, e.g. because the adverse effect is very 
specific for a drug-induced cause or recurs on readmini-
stration. Of course functioning of the system depends on 
alert medical practitioners, who not only have to recognize 
the clinical event as a suspected adverse reaction to a 
drug, but also have to report their suspicions. Unfor-
tunately this is done by a minority of medical prac-
titioners in The Netherlands. Although especially in the 
English-speaking and in the Nordic countries the reporting 
rate is significantly higher, also there reporting is done 
by a minority (1). Apart from the reasons that a medical 
practitioner might not be willing to co-operate with a 
gouvernmentally-related monitoring centre or requires pay-
ment for his reports several reasons have been given for 
non-reporting, known as the "seven deadly sins" (3): 
Complacency the mistaken belief that only safe drugs 
are allowed on the market. 
Fear 
USA. 
of involvement in litigation, especially in the 
Guilt because harm to the patient has been caused by 
the treatment the doctor has prescribed. 
Ambition to collect and publish a personal series of 
cases, a common human failing that may lead to serious 
delays in recognition of a hazard. 
Ignorance of the requirements for reporting, perhaps 
as a result of failure in communication between the re-
porting centre and the professions. 
Diffidence about reporting mere suspicions which 
might perhaps lead to ridicule. 
Lethargy, an amalgam of procrastination, lack of in-
terest or •time', inability to find a report-card and 
other excuses. 
Of course the doctor may not be aware of the fact that 
the patient used the drug because of an incomplete drug-
hist~ry or use of 'over the counter' drugs. According to an 
enqu~ry, involving British general practitioners, there 
were several reasons for non-reporting. The fact that the 
adverse effect was well-known or trivial, insecurity about 
a causal relationship and a lack of feedback from the mon-
itoring centres to practitioners were given as the most im-
portant reason for underreporting (4,5). 
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TABLE 5 
ADVERSE REACTIONS AS PUBLISHED BY THE NETHERLANDS CENTRE FOR 
MONITORING OF ADVERSE REACTIONS TO DRUGS 
amiodarone (Cordarone) 
ant/asthmatics 
aprindine 
benzydamine (Tantum) 
captopril (Capoten) 
camazepam (Aibego) 
cimetidine (Tagamet) 
co·trimoxazole (Bactrim, Eusaprim) 
dietary products (vit. K·containing) 
dipyrone 
doxycycline (Doxymycin, Vibramycin, Dagracycline) 
emeproniumbromide (Cetiprin) 
ethambutol (Myambutol) 
flunarizine (Sibelium) 
flurbiprofen (Froben) 
glafenine (Giifanan) 
griseofulvin 
ketamine (Ketalar) 
ketoconazole (Nizoral) 
labetalol (Trandate) 
mazindol (Teronac) 
methyldopa (Aidomet, Sembrina, Mulfasin) 
mianserin (Tolvon) 
nalidixic acid (Neg ram) 
nitrofurantoin (Furadantine, Furophen Tc, Ceduran) 
oral contraceptives 
paracetamol (Finimal, Hedex, Panadol) 
phenprocoumon (Marcoumar) 
pinaveriumbromide (Dicetel) 
pirenzepine (Abrinac, Gastrozepin) 
pirprofen (Rengasil) 
practolol 
propylthiouracil 
pyrazinamide 
scopolamine (Scopoderm TTS) 
spironolactone (Aidactone) 
terfenadine (Triludan) 
ticlopidine 
valproate (Depakine) 
thyreostatic agents 
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interaction with coumarines (6) 
sudden death (7) 
agranulocytosis (8, 9) 
psychic effects (1 0) 
polymyositis, myocarditis (11) 
rash (12) 
interstitial nephritis (13) 
interaction with coumarines (14) 
interaction with coumarines (15) 
bone marrow suppression (16) 
oesophageal ulceration (17, 18) 
oesophageal ulceration (19) 
optic neuropathy (20) 
parkinsonism, depression (21) 
interaction coumarines (22, 23) 
anaphylactic reactions (24), hepatic injury (25·27) 
interaction oral contraceptives (28) 
apnoea (29) 
hepatic injury (30, 31 ), anaphylactic reactions (32) 
fever (33) 
testicular pain (34) 
pancreatitis (35) 
leucopenia, thrombocytopenia (36) 
thrombocytopenia (37) 
several adverse effects (38), parotitis (39) 
interaction other drugs (40) 
hypersensitivity reactions (41) 
hepatic injury (42) 
oesophageal ulceration (43) 
agranulocytosis, thrombocytopenia (44) 
hepatic injury (45) 
sclerosing peritonitis (46) 
agranulocytosis (47) 
fever (48) 
paradoxic effects (49) 
agranulocytosis (50) 
skin reactions (51) 
thrombocytopenia (52, 53) 
hepatic injury, hyperammonaemia (54) 
absence of congenital skin defects (55) 
Underreporting not only means that an important new and 
unknown adverse effect may be missed. If underreporting was 
a constant factor (e.g.lO%) it would be possible to obtain 
the absolute frequency by a ten times multiplication (1). 
Then drugs could be compared as regards their adverse 
effects related to sales figures. Unfortunately the repor-
ting rate depends on the type of drug, on the age of the 
drug, the importance of the reason for use, on the type of 
adverse effect and probably on other unknown factors. 
Therefore it is difficult to estimate the incidence and it 
is generally accepted that voluntary reporting schemes are 
useful for the detection of unknown adverse effects (quali-
tative aspect) but not for establishing incidence figures 
(quantitative aspect). 
In the past period the NARD has proved its usefulness as 
regards the former. Table 5 tabulates adverse effects which 
have been the subject of publication by the NARD, often as 
a so-called 'first report'. 
Additional activities of the NARD include studies concer-
ning mechanisms (e.g.testing of drug-dependent antibodies 
against granulocytes, thrombocytes and erythrocytes), eti-
ologies (e.g. a case-control study concerning a possible 
relationship between intake of drugs and the Guillain-Barre 
syndrome) and in-depth studies of series of cases (e.g. he-
patic injury by glafenine (chapter 8), ketoconazole (chap-
ter 9), nitrofurantoin (chapter 10), valproic acid and 
other anticonvulsants, and salicylate-related Reye syn-
drome) . If necessary the NARD contacts laboratories in 
other countries, e.g. for testing serum as regards halo-
thane-dependent antibodies in patients with postoperative 
jaundice. 
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PART2 

Chapter 5 
OBJECTIVES OF THIS THESIS 
The objectives of this thesis are: 
To investigate whether a voluntary reporting scheme can 
be used to study series of cases and, if so, whether it 
is possible to obtain reliable data concerning the cli-
nicopathological pattern of a particular adverse reac-
tion. 
To investigate whether "Intensive Case Monitoring" is 
also possible with reports from other countries. 
To investigate the clinicopathological patterns of he-
patic injury to glafenine, ketoconazole, and nitrofuran 
derivatives. 
What can be done with the data collected by a voluntary 
reporting system apart from the early detection of adverse 
reactions to drugs? In principle already one well-documen-
ted case-history might prove a causal relationship, al-
though as a rule this is relatively uncommon. Are we able 
to do more with a series of such cases, in addition to the 
discovery of unknown adverse effects ? 
It is generally accepted that drug-induced injury can 
m1m1c practically every disease, a fact which is attributed 
to the limited number of patterns with which the body re-
acts to an exogenous harmful stimulus (1). This means that 
a drug is only one of the alternatives in a differential 
diagnosis. If the study of a series of cases gives insight 
into the most frequently found patterns of injury it may 
help us to differentiate drug-induced injury from other 
causes of injury. 
This study is focused on drug-induced hepatic injury. 
Drug-induced hepatic injury includes many different pat-
terns varying from necrosis or cholestasis to vascular and 
neoplastic disorders. These may present acutely or in-
sidiously after years of use of the suspected drug. Some 
drugs are the cause of a mainly hepatocellular pattern of 
injury (e.g.methyldopa), whereas the pattern caused by 
other drugs is predominantly cholestatic (e.g. contracep-
tive steroids) (2). The diagnosis 'drug-induced hepatic 
injury' is often made by exclusion of other potential 
factors. Unlike several forms of viral hepatitis where 
serologic investigation may confirm the diagnosis (e.g. 
hepatitis A and B, infectious mononucleosis), in cases of 
drug-induced hepatic injury a specific marker is usually 
absent. Knowledge about the pattern of hepatic injury which 
is most frequently caused by a particular drug would be a 
help in the differential diagnosis. 
One of the problems is that most cases of drug-induced 
hepatic injury are secondary to either an immunoallergic 
reaction or an (metabolic ?) idiosyncratic reaction. Thus 
the reaction is rare and unpredictable and it is therefore 
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difficult to generate enough cases for studying the com-
plete spectrum of hepatotoxicity of a particular drug. As a 
consequence most papers about drug-induced hepatic injury 
reported in the medical literature concern the medical his-
tories of 1-3 cases. It is likely that this does not 
guarantee a reliable picture of the actual situation. Even 
review articles, including all cases reported in the me-
dical literature, may yield a false picture because several 
unknown factors may cause the preferential reporting of a 
particular pattern. This is illustrated by the fact that 
most cases of nitrofurantoin-associated hepatic injury re-
ported in the medical literature concerned chronic active 
hepatitis whereas acute hepatitis is probably more frequent 
(Chapter 10). 
Hepatic injury is a serious adverse reaction, irre-
spective of whether it concerns the acute or chronic type, 
and it is unlikely that medical practitioners preferably 
report one type of hepatic injury. This means that, whereas 
a report in the medical literature of a particular type of 
hepatic injury may provoke publication of similar cases, it 
is more likely that a voluntary reporting scheme reflects 
the actual situation, i.e. a variety of patterns. 
In Chapter 11 four cases of pirprofen-associated hepatic 
injury are described, which were guided to publication by 
the NARD from the early stages of patient care, thereby 
demonstrating the value of "Intensive case Monitoring" on a 
European scale. One of the advantages of adverse reaction 
monitoring in The Netherlands is that - since it is a small 
and densely populated country - a relatively large number 
of adverse reactions will occur in a small area. This fa-
cilitates "Intensive case Monitoring". This term is used at 
our centre when one of the medical officers actively par-
ticipates in establishing the diagnosis "drug-induced dis-
ease", starting in the early phase of the disease. In con-
sult with the reporting practitioner it is decided which 
diagnostic procedures can produce conclusive data. The ad-
vantage of a small and well-developed country is that a 
medical officer can receive an important report of an ad-
verse effect and visit the reporting medical doctor and (if 
necessary) the patient on the same day. It will be clear 
that this may have an important impact on the quality of 
the report since the NARD can advise at an early stage 
which additional investigation could improve the documen-
tation of the report. The obvious reason is that compre-
hensive documentation is indispensable, especially in the 
case of unknown adverse effects. Thanks to a well-developed 
motorway, railway and communication system it is easy to 
visit the reporting medical practitioner, make a telephone 
call to the local laboratory for additional data or obtain 
blood for assessment of drug-dependent antibodies or lym-
phocyte stimulation testing. This "Intensive Case Monitor-
ing" may result in a joint publication of several well-
documented cases. When at a particular moment there are too 
few cases in one country, the co-operation with other na-
tional monitoring centres may enlarge the covered popula-
tion. 
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The covering of a large population by a voluntary repor-
ting scheme has a second advantage. There are many rare ad-
verse effects of which the appearance in a particular indi-
vidual can not be predicted. The consequence is that it is 
very difficult to study the mechanisms of a particular ad-
verse effect and to develop diagnostic methods. By covering 
a large population over several years enough cases may be 
gathered for further study. In a way the voluntary repor-
ting system sorts out patient groups with certain charac-
teristics. 
Before discussion of the chapters on hepatic injury by 
glafenine, ketoconazole and nitrofuran derivatives it is 
essential to review in general the patterns of hepatic in-
jury which have been associated with the use of drugs 
(Chapter 6) and to outline the guidelines for making the 
diagnosis 'drug-induced hepatic injury' (Chapter 7). 
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Chapter 6 
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Drug-induced hepatic injury 1985;lst ed. Elsevier 
Amsterdam New York 

I. PATTERNS OF DRUG-INDUCED HEPATIC 
INJURY 
Generally speaking, patterns of drug-induced hepatic injury are not very 
specific, showing characteristics identical to those of non-drug-related 
injury. However, there are important exceptions to this rule (see Section 
III: 'Diagnosis and Analysis of Drug-Induced Hepatic Injury'). 
A short description of known patterns is given below. It is based on 
the assumption that the reader is familiar with the indications and inter-
pretation of diagnostic procedures. Table 1 gives an overview of the pat-
terns. 
Mild and transient elevation of serial liver enzyme levels without 
TABLE 1 Patterns of drug-induced hepatic injury 
Acute 
Chronic 
Hepatocellular A. Steatosis 
B.l. Degeneration 
2. Necrosis 
C. Granulomas 
Cholestatic A. Pure cholestasis 
B. Cholestatic hepatitis 
Hepatocellular A. Steatosis and fibrosis 
B. Lipid storage disease 
C. Chronic persistent/active hepatitis 
D. Cirrhosis 
Cholestatic A. Chronic intrahepatic cholestasis 
B. Biliary cirrhosis 
Vascular disorders 
A.l. Veno-occlusive disease 
2. Occlusion of large hepatic veins 
B. Sinusoidal dilatation/peliosis hepatis 
C. Hepatoportal sclerosis, perisinusoidal fibrosis 
Tumors 
A. Hepatocellular adenoma 
B. Hepatocellular carcinoma 
C. Cholangiocarcinoma 
D. Angiosarcoma 
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symptoms and histological signs of injury is not uncommon after starting 
drug therapy. It is uncertain whether this reflects minimal injury to the 
hepatocyte or enzyme leakage without injury. Although usually without 
clinical significance, a follow-up in such cases is advised since it may 
precede symptomatic hepatic injury in a number of patients. 
ACUTE 
HEPATOCELLULAR 
A. Steatosis (e.g. methotrexate, tetracycline, alcohol, valproic acid etc.) 
Fatty change of hepatocytes involves either small droplets without dis-
placement of the nucleus (microvesicular, e.g. tetracycline, valproic 
acid) or large globules displacing the nucleus to the cell border (macrove-
sicular, e.g. methotrexate). Inflammatory cells are often scanty but may 
be present when necrosis coexists. Steatosis may predominate in the cen-
trilobular (e.g. alcohol) or periportal (e.g. ethionine) region. Sometimes 
fatty cells coalesce to form fatty cysts, resulting in lipogranulomas. 
Biochemical alterations depend on the degree of steatosis and (if pre-
sent) necrosis. Aminotransferase and alkaline phosphatase levels may be 
normal but are mildly/moderately raised in most cases of acute toxic 
steatosis. Hypolipemia and hypocholesterolemia are present. Acute 
steatosis may present with acute .hepatic failure (coagulation disorders 
etc.). 
Symptoms may show the same spectrum of severity as in necrosis (see 
below). Irnmunoallergic manifestations are absent. Acute steatosis may 
have a rapidly fatal course (e.g. tetracycline). 
B.l. Degeneration (e.g. many hepatotoxic drugs in low doses) 
Hepatocellular unrest is seen with bi/trinucleation, mitotic figures, bal-
looning and acidophilic bodies; there is minimal infiltration, mainly by 
mononuclear cells. 
Mild elevation of liver enzymes (ALAT/ASAT, alkaline phosphatase 
etc.) may occur. 
Clinical symptoms are usually absent; sometimes there are vague, 
non-specific complaints. 
B.2. Necrosis (many drugs, e.g. paracetamol, methyldopa, halothane, 
isoniazide etc.) 
Necrosis varies in severity (focal/massive) and pathogenesis (toxic/idio-
syncratic) determined by type of drug, status/localization of metaboliz-
ing enzymes and individual susceptibility. Necrosis is mainly zonal, but 
rarely massive in the toxic form. In the idiosyncratic form, necrosis is 
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Fig.l: 
Fig.2: 
(HE 320x) NARD-case 86/916. Etretinate-associated 
microvesicular and mild macrovesicular steatosis 
(HE 320x) NARD-case 83/109. Salicylate-associated 
Reye syndrome with panlobular microvesicular stea-
tosis (by courtesy of Professor J.Huber) 
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Fig.3: 
Fig.4: 
(HE 125x) NARD-case 83/1016. Allopurinol-associ-
ated bridging necrosis (by courtesy of Dr.M.M.van 
de Sandt) 
(HE 320x) 
fig.3; a 
accumulation 
(arrows) 
NARD-case 83/1016. Same case as in 
pseudogranuloma consisting of focal 
of histiocytes and many eosinophils 
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diffuse (immunoallergy?) or zonal (metabolic variant?). Necrosis may 
also vary in localization: although mostly centrilobular (Zone III, Rappa-
port; e.g. paracetamol), necrosis may predominate in the midzonal (furo-
semide overdose, rats) or periportal region (e.g. FeS04 ). Severe necrosis 
may cause bridging (central-central/central-portal/portal-portal) often 
with collapse of the reticular framework. Massive necrosis is caused 
mainly by idiosyncrasy, not toxicity. In immunoallergic hepatitis, nec-
rotic sites and portal areas are infiltrated by mononuclear cells, which 
sometimes have a granulomatous appearance. Toxic injury may give a 
less densely, more neutrophilic infiltrate. Although eosinophilic infiltra-
tion is not highly specific, it is often associated with an immunoallergic 
pathogenesis. Necrosis around the central vein may result from severe 
hypotension or congestive heart failure, in the latter accompanied by 
edema, extravasation of blood and dilated sinusoids. 
The extent of necrosis is usually paralleled by an equivalent rise in ser-
um aminotransferase levels, although a sudden decline indicates hepatic 
failure when accompanied by a sharp rise in serum bilirubin and prolon-
gation of the prothrombin time. Alkaline phosphatase and bilirubin le-
vels in serum are less markedly elevated. Hypoprothrombinemia is fre-
quent. Many other liver enzymes ar!3 elevated (e.g. y-glutamyl 
transferase, 5-nucleotidase etc.). No markers of viral hepatitis are pre-
sent. Eosinophilia in the blood may indicate an immunoallergic patho-
genesis. In intoxication, blood levels of drug/metabolites confirm a caus-
al relationship. 
Symptoms vary depending on severity and susceptibility. They may be 
absent, mild (malaise, anorexia etc.) or severe (jaundice, bruising). 
Extrahepatic manifestations may be prominent, both toxic (e.g. renal, 
CCl4 ) and immunoallergic (rash, fever, arthralgia). The latter can also 
occur as prodromal signs of viral hepatitis, which should be excluded. 
Sometimes minor hepatic injury is secondary to extrahepatic drug-in-
duced hypersensitivity reactions (e.g. Stevens-Johnson syndrome, myo-
carditis, pneumonitis). In some cases a picture arises resembling that of 
infectious mononucleosis with fever, rash, generalized lymphadenopathy 
and atypical lymphocytes. Mortality of acute hepatocellular necrosis is 
high. It depends on which drug is responsible and is estimated at 50% 
for some drugs. 
C. Granulomas (e.g. allopurinol, phenylbutazone, sulfonamides) 
Drug-induced granulomas usually appear within the first 4 months of 
therapy, either with mild cellular swelling/cholestasis or without accom-
panying hepatocellular injury. Occasionally liver injury is more severe. 
Drug-induced granulomatous hepatitis is often pericholangitic. Granu-
lomas may appear in portal, lobular and pericentral areas invariably ac-
companied by portal inflammation with lymphocytes, histiocytes, plasma 
cells and eosinophils; the eosinophils may be very numerous. 
Portal granulomas are usually discrete with a surrounding mononuc-
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lear infiltrate but may also be part of a diffuse portal inflammation ex-
panding into the lobules. Granulomas are always non-caseating, al-
though occasionally there is central nuclear fragmentation. Giant-cell 
formation may be marked. Eosinophilic infiltration may be prominent, 
especially in the early phase. There are no biochemical abnormalities un-
less hepatic injury is present. The diagnosis can only be made by biopsy. 
Granulomas are often non-symptomatic. However, as part of a general-
ized hypersensitivity reaction, immunoallergic signs and symptoms (e.g. 
rash, eosinophilia, fever, arthralgia) may be prominent. Disappearance 
after discontinuation of therapy suggests a drug-induced cause. It is ad-
visable to exclude at least sarcoidosis and infectious causes (especially 
tuberculosis, schistosomiasis). 
CHOLESTATIC 
A. Pure cholestasis (e.g. anabolic steroids) 
B. Cholestatic hepatitis (e.g. chlorpromazine, erythromycin) 
Predominantly centrilobular bile-staining of hepatocytes and bile casts 
is seen in (sometimes distended) canaliculi. Bile 'lakes' as seen in extra-
hepatic obstructive jaundice are absent. It may occur without (pure cho-
lestasis) or with minor/moderate hepatocellular unrest/necrosis (choles-
tatic hepatitis). In the former, inflammatory cells are virtually absent; 
in the latter there is a mononuclear and eosinophilic infiltrate, rich in 
the portal zones, moderate at necrotic sites; some bile duct multiplica-
tion is often present. A pattern exists characteristic of both acute choles-
tatic and hepatocellular hepatitis (mixed pattern). 
Serum bilirubin, alkaline phosphatase, 5-nucleotidase and y-glutamyl 
transferase levels are high while aminotransferase levels are normal or 
moderately elevated (the latter especially in cases of cholestatic hepati-
tis). Imaging procedures (e.g. ultrasound, cholegraphic imaging, comput-
ed tomography) show normal extrahepatic bile ducts. 
Jaundice and pruritus are outstanding features. Cholestatic hepatitis 
may be accompanied by rash, fever and arthralgia, manifestations that 
are usually absent in pure cholestasis. Mortality is low (estimated at less 
than 1 %) especially in cases of pure cholestasis. Occasionally, recovery 
from cholestasis takes a long time(> 1/ 2 year). 
CHRONIC 
HEPATOCELLULAR 
A. Steatosis and fibrosis (e.g. methotrexate, alcohol etc.) 
The same pattern is seen as for acute steatosis. If however accompanied 
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Fig.5: 
Fig.6: 
Fig.7: 
(HE 320x) NARD-case 74/249. Lipofuscin accumu-
lation in a case of phenacetin abuse (by courtesy 
of Dr.M.van Wijhe) 
(HE 125x) NARD-case 84/681. Methyldopa-induced 
postnecrotic macronodular cirrhosis (by courtesy 
of Dr.A.T.Ariens) 
(HE 125x) alcoholic hepatitis and micronodular 
cirrhosis (by courtesy of Professor D.J.Ruiter) 
49 
Fig.8: (19840x) NARD-case 84/845. Amiodarone-induced 
phospholipidosis of human liver. This picture 
shows parts of 2 hepatocytes separated by their 
cell membrane (lm) and a bile canaliculus (be). 
Many lamellar lysosomal inclusion bodies (arrows) 
are seen in this pericanalicular area. Dilated 
smooth endoplasmic reticulum as well as small 
mitochondria with electron-dense matrix can also 
be observed (electron-micrograph supplied by 
Professor U.J.G.M.van Haelst) 
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by necrosis, prolonged administration of the responsible hepatotoxin 
will eventually lead to fibrosis and cirrhosis. In some patients, prolonged 
administration of a hepatotoxin causes a sudden exacerbation into an 
acute hepatitis (alcohol!) which may present either a hepatocellular or 
cholestatic pattern. 
All liver enzyme levels may be elevated, mostly mildly; signs of meta-
bolic dysfunction occur (e.g. hyperlipemia, hyperuricemia, hypoglycemia 
etc.). If necrosis starts early and fibrosis and cirrhosis develop, hepatic 
dysfunction (hypoalbuminemia, hyperammonemia etc.) may occur. 
Often there are no symptoms or only non-specific complaints (malaise, 
anorexia etc.), unless acute necrosis or cholestasis is present. 
B. Lipid storage disease (e.g. 4,4'-diethylaminoethoxyhexestrol, amio-
darone, perhexiline) 
Drug-induced lipid storage disease usually consists of phospholipidosis 
although ganglioside accumulation has also been mentioned in the liter-
ature (e.g. perhexiline). Hepatocytes, Kupffer cells, endothelial and bili-
ary epithelial cells but also extrahepatic cells, e.g. blood and nerve cells 
and lung tissue, are involved. 
Liver cells are enlarged and have a foamy appearance. Electron mi-
croscopy reveals multilamellated ('fingerprint') and crystalloid lysoso-
mal inclusion bodies. In advanced cases, fibrosis and cirrhosis may ens-
ue. The lysosomal inclusions resemble those seen in Niemann-Pick's and 
Fabry's disease, but the clinical setting differs. 
Biochemical abnormalities are usually absent, but elevation of liver 
enzyme levels after prolonged treatment may reflect severe chronic he-
patic injury. Hypertriglyceridemia and elevation of free fatty acids may 
present early. Lysosomal inclusion bodies in peripheral blood lympho-
cytes may be indicative and diminish the need for a biopsy. 
Symptoms are usually absent but extrahepatic manifestations may in-
dicate toxicity (e.g. neuropathy due to perhexiline or amiodarone, skin 
discoloration by amiodarone). Immunoallergic signs are absent. Malaise 
and hepatosplenomegaly, weight loss and hypoglycemia may precede or 
accompany liver damage. 
C. Chronic persistent/active hepatitis (CPH/CAH) (e.g. oxyphenisa-
tine, methyldopa, nitrofurantoin etc.) 
Periportal rosette-formation and 'piece-meal' necrosis is seen with a 
rich portal and periportal infiltrate of lymphocytes and plasma cells. A 
more active state may be reflected by mild/moderate necrosis and infil-
tration around the central vein. Bridging necrosis occurs, connecting 
portal areas. Periportal fibrosis develops and may eventually progress to 
cirrhosis. In chronic persistent hepatitis (a less aggressive form), inflam-
matory cells in the portal area do not cross the limiting plate so that ne-
crosis is absent. 
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Most liver enzyme levels are elevated, but are occasionally normal. 
Serum gammaglobulin levels are elevated, especially IgG. Immunologi-
cal tests are positive, especially smooth muscle antibodies. If progres-
sive, signs of severe hepatic dysfunction develop. 
Symptoms may be absent or non-specific; they may arise suddenly or 
insidiously. In advanced cases, jaundice, portal hypertension with ascit-
es and hepatic failure are present. Prognosis is good after discontinua-
tion of the causative agent unless damage is too advanced and cirrhQsis 
develops. Since immunoallergic symptoms usually lead to early discon-
tinuation of the causative drug, these symptoms are uncommon in cases 
of chronic(> 6 months) drug-induced hepatic injury. 
D. Cirrhosis (e.g. CC14 , alcohol etc.) 
Diffuse fibrosis occurs with nodules ofhepatocytes, alteration of the nor-
mal lobular structure, regeneration and necrosis. Either small (micro-
nodular) or large (macronodular) nodules are present. Drugs capable of 
producing chronic active hepatitis (see above) or any other chronic form 
of hepatic injury may eventually lead to cirrhosis. 'Cardiac cirrhosis' is 
not a usual type of cirrhosis but a pericentral fibrosis with 'reversed lo-
bulation' caused by prolonged hepatic venous congestion. Theoretically, 
it may be induced by drugs aggravating congestive heart failure, but this 
is probably not of much practical significance. 
Liver enzyme levels are elevated and amino acid patterns are changed. 
Hepatic failure occurs with hypoalbuminemia, hypoprothrombinemia, 
hyperammonemia etc. 
Ascites, splenomegaly, jaundice etc. supervene. Defective coagulation, 
metabolic disturbances, encephalopathy, portal hypertension with eso-
phagearvarices and gastrointestinal blood loss present the main thera-
peutic problems. They are not present in every patient, however. Portal 
hypertension may be seen without cirrhosis in hepatoportal sclerosis 
(e.g. inorganic arsenicals). 
CHOLESTATIC 
A. Chronic intrahepatic cholestasis 
B. Biliary cirrhosis (e.g. chlorpromazine, testosterone) 
Centrilobular, midzonal and periportal cholestasis are seen with bile 
staining of hepatocytes, bile casts and duct dilatation, periductal inflam-
mation and fibrosis. Interlobular and septal bile ducts finally disappear 
with periportal necrosis and fibrosis, ending in biliary cirrhosis. Accord-
ing to some authors, the drug-induced form of biliary cirrhosis has more 
scanty portal inflammation and bile duct destruction than primary bili-
ary cirrhosis. 
High levels of alkaline phosphatase and cholesterol are found in the 
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serum, but bilirubin and aminotransferase concentrations are moderate-
ly elevated. Antimitochondrial antibodies, present in almost every case 
of primary biliary cirrhosis, were often not assessed in the older reports 
of drug-induced cases of biliary cirrhosis so that few data are available. 
Serum lgM may be elevated. 
Jaundice, pruritus etc. and dermal xanthomata are found. The progno-
sis is better than in primary biliary cirrhosis, since discontinuation of 
treatment in the early stages is often followed by improvement. Never-
theless, some fatal cases have been described. The data, however, are bas-
ed on very few cases. 
VASCULAR DISORDERS 
Although the Budd-Chiari syndrome is often used as a synonym for 
thrombosis of the large hepatic veins, any obstruction of venous outflow, 
including veno-occlusive disease, causes this syndrome. 
A.l. Ven<rocclusive disease (e.g. urethane, pyrrolizidine alkaloids, 
tioguanine, dacarbazine) 
Occlusion of the centrilobular and sublobular hepatic veins occurs due 
to disruption and edema of the venous wall and surrounding tissue 
(acute) or to fibrotic tissue (chronic). There are no lesions or thrombosis 
of larger veins. Congestion is found in surrounding dilated sinusoids 
with hemorrhagic necrosis ofhepatocytes. There is collapse of the reticu-
lar framework around the central vein and fibrosis. Collateral vessels de-
velop in the surrounding parenchyma. 
There is elevation of bilirubin and liver enzyme levels in the serum de-
pending on the extent and number of obliterated veins. 
The onset of painful hepatomegaly and ascites is sudden, sometimes 
with circulatory shock. Collateral abdominal veins may be prominent. 
Occasionally there is mild jaundice. Mostly prompt clinical recovery oc-
curs unless the drug is continued. Some cases develop recurring ascites, 
finally developing into cirrhosis. 
A.2. Occlusion oflarge hepatic veins (e.g. contraceptive steroids) 
This may lead to the Budd-Chiari syndrome resulting from occlusion of 
the main hepatic veins or their smaller branches (v. sushepatica) or of 
tne inferior vena cava, mostly caused by thrombosis. There is centrilobu-
lar necrosis and congestion, sinusoidal dilatation and extravasation of 
blood; there are secondary thrombi in different stages of organization. 
Chronic cases show centrilobular fibrosis and periportal regeneration. 
Serum albumin, alkaline phosphatase, bilirubin and aminotransferase 
levels are moderately elevated. Scintigraphy may show reduced uptake, 
with maximum uptake in the caudate lobe. Arteriography may show mul 
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tiple space-occupying areas resembling metastases. Venography shows 
obstruction and a lace-like pattern in the liver. 
Abdominal pain, hepatomegaly, gross ascites and sometimes mild jaun-
dice occur; collateral veins may be visible on the abdomen; the onset may 
often be insidious. The course may be slow with resistent ascites, portal 
hypertension, cirrhosis and death from liver failure/gastrointestinal 
hemorrhage in 3-4 years or rapid with acute hepatic failure in several 
months. 
B. Sinusoidal dilatationfpeliosis hepatis (e.g. contraceptive and ana-
bolic steroids) 
Dilatation of sinusoids occurs, sometimes resulting in blood pools. There 
is a phlebosclerotic form with endothelial or fibrous lining, draining into 
central veins/sinusoids, and a parenchymal type without a lining com-
municating with sinusoids. Especially the latter is associated with the 
use of anabolic and contraceptive steroids. Both forms may be present 
concurrently. 
Peliosis hepatis is often secondary to other conditions (e.g. hepatic 
adenoma) which dominate the clinical and biochemical pattern. 
C. Hepatoportal sclerosis, perisinusoidal fibrosis (e.g. arsenicals, vi-
tamin A) 
Idiopathic portal hypertension may originate from fibrous thickening of 
the portal veins and/or perisinusoidal fibrosis. There are varying degrees 
of portal fibrosis and intimal thickening and sclerosis of portal vein 
walls. There is often perisinusoidal fibrosis with collagen deposition in 
the space of Disse and fibers infiltrating between hepatocytes. In cases 
of vitamin A intoxication there is a marked increase in Ito cells, which 
may be the only histological feature. 
Biochemical values are normal or slightly abnormal unless severe fi-
brosis and cirrhosis are present. In cases of intoxication, high levels of 
arsenic or vitamin A in liver tissue are diagnostic; vitamin A has a fluor-
escent appearance under the microscope. 
Although initially without symptoms, prolonged portal hypertension 
will cause splenomegaly, ascites and collateral venous circulation, often 
clearly visible on the abdomen. For subsequent cirrhosis and hepatic fail-
ure the above-mentioned considerations apply. Extrahepatic manifesta-
tions of intoxication may facilitate the assessment of a causal relation-
ship with the suspected agent. 
TUMORS 
A. Hepatocellular adenoma (e.g. anabolic and contraceptive steroids) 
Hepatocellular adenoma is a non-malignant tumor of cells resembling 
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hepatocytes. These cells are arranged in tightly packed trabeculae, 2-3 
cells thick, separated by compressed slit-like sinusoids. The cells are 
slightly larger than hepatocytes and are glycogen-rich, with uniform nu-
clei and little variation in size and shape; canaliculi are normal, bile 
ducts absent. The tumor is very vascular with dilated, thin-walled blood 
vessels which are randomly distributed. 
a-Fetoprotein tests are negative. Diagnosis is only possible from the 
pathology. Liver scanning and ultraso·.:.ad are helpful. Angiography 
shows a highly vascularized tumor with an arterial supply originating 
peripherally with multiple parallel vessels coursing towards the center 
of the tumor. 
Anorexia, nausea and abdominal discomfort occur. The tumor is often 
palpable. Approximately 1/ 3- 1/4 of patients present with hemoperiton-
eum/rupture of the tumor. 
B. Hepatocellular carcinoma (e.g. thorium dioxide, contraceptive ster-
oids?) 
Hepatocellular carcinoma is a malignant tumor composed of hepatocyte-
like cells, often in combination with cirrhosis of the liver. Local vascu-
lar/lymphatic metastases may be present, having a typical appearance 
('planet with satellites'). Since there are several variants of the basic tra-
becular pattern (pseudoglandular, solid, scirrhous, pleomorphic and 
clear cell), differentiation from other primary hepatic tumors may be di-
fficult. In 'Thorotrast cases' brown-black particles are visible. 
Mostly high levels of a-fetoprotein ( > 400 ng/ml) are found. High alka-
line phosphatase or mildly elevated bilirubin levels in serum may occur 
but are non-specific. Elevated liver enzymes may reflect underlying cir-
rhosis. Angiography, ultrasound, isotopic scanning and computed to-
mography may be helpful by showing a rich arterial supply with clusters 
of bizarre tumor vessels and focal defects. Proline hydroxylase and chor-
ionic gonadotropin levels may be elevated. Erythrocytosis and dysfibrin-
ogenemia are rare. HbsAg is negative in drug-induced cases. 
Abdominal pain and weight loss occur; symptoms may reflect cirrhosis 
with portal hypertension/(bloody) ascites. Hemoperitoneum by rupture 
may occur. 
C. Cholangiocarcinoma (e.g. thorium dioxide) 
Cholangiocarcinoma is a malignant tumor of cells resembling biliary epi-
thelium. It is a firm grayish tumor growing along neighboring bile ducts 
in an otherwise normal liver. There are glandular mucus-secreting 
structures with much fibrous stroma or there is a papillary form. If a tra-
becular pattern is present, the tumor may be indistinguishable from he-
patocellular carcinoma. However, a-fetoprotein is usually normal. In 
'Thorotrast cases', brown-black particles are present. 
Functional hepatic impairment occurs late in course. Diagnosis IS 
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from the pathology. Angiography usually shows a less vascularized tu-
mor than in cases of hepatocellular carcinoma, although intermediate 
forms are not uncommon. Ultrasound and liver scanning are helpful. 
Patients may present with obstructive jaundice and weight loss or may 
have symptoms mimicking hepatocellular carcinoma. 
D. Angiosarcoma (e.g. thorium dioxide, inorganic arsenicals) 
Angiosarcoma is a malignant tumor of spindle-shaped cells lining vascu-
lar spaces. Multiple hemorrhagic nodules and blood-filled cysts are seen. 
Growth is tectorial on the surface of the liver cells. The tumor cells are 
elongated with ill-defined borders and with hyperchromatic nuclei vary-
ing in size and shape. There is an abundance of reticular fibers in the 
sinusoids. There is hematopoiesis. In 'Thorotrast cases', brown-black 
particles are demonstrable. 
, There are non-specific liver function abnormalities and hematological 
abnormalities. Angiography, ultrasound or computed tomography are 
useful for localization of the tumor. 
There is progressive hepatomegaly, with hematological abnormalities 
(pancytopenia, hemolytic anemia, disseminated intravascular coagu-
lation and terminal jaundice). Occasionally the tumor may rupture. The 
course is rapidly fatal. 
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III. DIAGNOSIS AND ANALYSIS OF DRUG-
INDUCED HEPATIC INJURY 
Roughly speaking, the evaluation of drug-induced hepatic injury occurs 
in two stages. Firstly, clinical, biochemical and other features of a partic-
ular case are gathered and a diagnosis is made. Such a procedure may 
resemble the algorithm shown in Figure 1. Several analogous diagnostic 
scheme9>, however, have been published in the past and since the reader 
of this book will probably be familiar with the more common diagnostic 
procedures, this algorithm is not discussed in detail. 
Secondly, when several reports of suspected drug-induced hepatic in-
jury incriminate a particular drug, monitoring centers will usually per-
form an in-depth analysis of such cases. To guarantee a consistent ap-
proach to the assessment of a causal relationship between hepatic injury 
and drug use, an analytical scheme may be used (see Fig. 2). Such an ap-
proach may be useful as a tentative strategy for decision-making and ca-
tegorization. It should be realized, however, that such schemes are based 
on current knowledge and need regular updating. Moreover, a scheme 
should never be so rigid or so rigidly interpreted that completely new pat-
terns are discounted as unlikely when these do not conform to current 
knowledge. 
An explanation of the schema shown in Figure 2 is given below. 
AN ANALYTICAL SCHEMA FOR DRUG-INDUCED HEPATIC 
INJURY 
The analytical schema is based on 3 points: 
1. Specificity of the clinicopathological pattern and its course 
2. The temporal relationship between intake/discontinuation of the sus-
pected drug and onset/disappearance of the hepatic injury 
3. The exclusion of other possible causes for the observed patterns. This 
is complementary to the specificity. The less specific a pattern is, the 
more important does this factor become 
The clinicopathological pattern is defined as the combination of clinical, 
histological, biochemical, immunological, toxicological, experimental 
and other variables by which the pattern may be specified. 
The model assesses the degree of certainty of a causal relationship be-
tween hepatic injury and the intake of a drug. There are several levels. 
A and B (see Fig. 2) represent the highest degree of certainty because of 
a highly specific pattern/course and course/temporal relationship ('posi-
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Jaundice or other symp· 
toms suggesting hepatic 
injury 
Discontinue all drugs 
except those essential 
to life (e.g. insulin) 
----
___ _, 
,-------
1 
I 
I 
I 
I 
I 
If tumors/vascular 
disorders are suspected: 
ultrasound, liver scan, 
angiography 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
Inquire of patient: Complete drug history (compliance, other 
drugs, previous drug use/reactions, 'over the counter'/'street' 
drugs etc.), parenteral procedures (transfusions, heroin, tat-
too~), hepatitis in contacts, previous hepatitis, jaundice etc. 
Symptoms: gastrointestinal/influenza-like prodromi; fever, 
rash, arthralgia etc. 
Examine patient: Jaundice, hepato(spleno)megaly, hepatic 
tenderness/form/density, ascites, spider naevi, erythema 
palmare, rash, veno-jugular pressure etc. 
! 
Assess: 
bilirubin total/conjugated 
ALAT/ASAT/APh + follow-up of 
-y-GTP/5-NT 
albumin abnormal values 
-y-globulin 
PTT, full blood count (eosinophils?) 
Cholestatic, /~H~-biochemical biochemical 
pattern pattern 
Exclude: Exclude: 
extrahepatic biliary 
and/or hepatitis A, hepatitis B, disease (ultrasound, infectious mononucleosis, 
ERCP, PTC etc.) cytomegaly 
~/ 
Drug-induced injury suspected, 
freeze serum for research: 
a) when liver enzymes are 
maximal 
b) idem .when normalized 
! 
If pattern remains unclear or if chron-
----
icity is suspected: biopsy, unless PTT 
prolonged, severe thrombocytopenia, 
abscess, hemangioma, parasitic cysts 
FIG. 1 The diagnostic 'tree'. 
-FIG. 2 Analytical procedure for cases of suspected drug-induced hepatic injury. 
If hepatic injury is probably or definitely drug-induced but 2 or more drugs are 
equally suspected, a causal relationship per drug is possible. 
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A ~----------_:+:__ ________ _. Definite 
positive 
Rechallenge B Definite 
Rechallenge 
Rechallenge Unlikely/Possible 
not 
Possible/Probable 
performed 
c l Acute hepatic 11 injury, mainly 
cholestatic Specific + Clear/consistent + Probable 
CP pattern temporal relationship 
4 Acute hepatic ~ 1- -injury, mainly 
parenchymatous Clear/consistent + Other possible + 
D 
Probable 
temporal relationship causes excluded 
t- f.-Other possible + 
causes excluded Possible 
~-
Unclassified 
Disappears after 
discontinuation + ~ CAH/CPH, chronic 
of the drug f-intrahepatic E Probable 
cholestasis ~-
Other possible 
+ causes have been 
r----... excluded 
Possible 
UnclaL;ed 
V eno-occlusive Probable 
disease y Vascular y H:patic Budd-Chiari I disorders vems syndrome Thrombosis of large F Possible 
hepatic veins 
Sinusoidal L..J Sinusoids dilatation 
II Peliosis hepatis 
Perisinusoidal 
fibrosis 
y Portal vein I Hepatoportal ~ +branches I sclerosis 
Compatible ~ L-.(Tumors temporal G Possible 
relationship 
T-
Unlikely 
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tive rechallenge') respectively. This makes it easy to differentiate from 
non-drug-related causes. C, D, E, F and G represent less certain situa-
tions in which the causal relationship is assessed on the basis of a combi-
nation of (relative) specificity, temporal relationship and the exclusion 
of other possible causes. These levels are discussed below. 
LEVEL A 
A clinicopathological pattern and/or course is highly specific when it 
has unique features which make it possible to differentiate it from other 
causes. This may be by demonstration of the responsible agent in toxic 
amounts or of a unique histological pattern, but also a characteristic 
course in combination with a proven history of chronic intoxication 
(Table 1). 
LEVELB 
Renewed hepatic injury after (often unintentional) rechallenge. There is 
an obvious temporal relationship between the intake of the drug and the 
occurrence of hepatic injury, especially a prompt recrudescence after re-
challenge. Between challenge and rechallenge, liver enzyme levels 
(especially serum aminotransferases) should have returned to normal. 
The latter is necessary to help differentiate it from fluctuating non-A, 
non-B viral hepatitis. When a rechallenge is positive but a clear tempor-
al relationship is absent, the causal relationship may be termed 'prob-
able', or 'possible' if it is suspected to be coincidental (e.g. with a flare-up 
of underlying illness). 
A negative rechallenge suggests that a causal relationship is unlikely; 
TABLE 1 Highly specific pattern/course 
Histology 
Demonstrable 
agent 
Unique course 
In a certain age-group 
Deposits at site of 
injury 
Specific combination 
with extrahepatic 
lesion 
Phospholipidosis in adults (e.g. 
4,4'-diethylaminoethoxyhexestrol) 
(Coralgil) (1), amiodarone (31,32) 
Thorium dioxide (Thorotrast) (33) 
Polyvinyl pyrrolidone (30) 
Phenacetin pigmentation (2) 
and renal papillary necrosis 
Toxic blood-levels of hepatotoxins 
(e.g. paracetamol) (3); residue in 
stomach of hepatotoxins in combina-
tion with a characteristic course (e.g. 
Amanita phalloides, phosphorus, fer-
rous sulfate poisoning) (4) 
Well-documented case of prolonged 
intoxication (e.g. alcoholic 
hepatitis/cirrhosis) 
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however, it may be a false-negative because of 'desensitization' (immun-
oallergic type), the use of a lower dose (toxic type) or too short a chal-
lenge period (metabolic idiosyncratic type). In these cases a causal rela· 
tionship may still have been present. 
LEVELS C AND D 
Here, the clinicopathological pattern is called 'specific' when its most 
characteristic cause is an adverse reaction to a drug. Because a specific 
pattern does not constitute proof of a drug-induced cause (in which case 
it would be highly specific), it needs a clear or consistent temporal rela-
tionship to produce a 'probable' causal relationship. One should realize 
that the following clinical signs are not specific per se; but in combina-
tion with hepatic injury and drug use. Moreover, even when the observed 
pattern is specific for a drug-induced cause, it will remain necessary to 
exclude other- less likely - causes. 
Specific patterns (Levels C and D) 
Clinical 
Rash and hepatic injury (e.g. allopurinol (5), para-aminosalicylic acid 
(6)) 
Rash should accompany hepatic injury. The latter is important since rash 
may be a prodromal sign of viral hepatitis and it subsides when the he-
patic injury reaches full expression, i.e. jaundice. In drug-induced inju-
ry, however, the rash, when present, remains even after jaundice has ap-
peared. The pattern of rash and serious hepatic injury without an 
abnormal blood picture and/or preceding pharyngitis is easy to differen-
tiate from infectious mononucleosis. Rash may. occur in the immuno-
allergic form of drug-induced hepatic injury in adults. In children, this 
form seems less frequent and, if present, has a wider differential diagno-
SIS. 
Peripheral eosinophilia and hepatic injury (e.g. phenytoin (7), erythromy-
cins (8)) 
Significant eosinophilia of the blood ( ~ 7% eosinophils) should accom-
pany hepatic injury and drug intake and should have been demonstrated 
on at least 2 successive occasions. This is relatively rare in viral hepati-
tis and is characteristic of the immunoallergic form of drug-induced in-
jury, especially in combination with a prominently eosinophilic infiltra-
tion of the portal area and parenchyma. Helminthic infections should be 
excluded. 
Fever and hepatic injury (e.g. methyldopa (9), nomifensine (10)) 
Hepatic injury in combination with high fever ( > 39°C) in the absence 
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of sepsis is fairly specific of a drug-induced cause. An elevation in tem-
perature may precede viral hepatitis but is usually mild and it subsides 
when jaundice appears. Fever should have a close temporal relationship 
to the intake of the suspected drug and it usually persists even after jaun-
dice appears. There are, of course, other causes to be considered (e.g. acute 
cholangitis, alcoholic hepatitis). 
Hepatic injury and other extrahepatic manifestations 
Occasionally, hepatic·injury is accompanied by blood disorders (e.g. he-
molytic anemia- methyldopa (9), agranulocytosis- chlorpromazine (ll)), 
renal disorders (e.g. methoxyflurane (12)) or pulmonary disorders (e.g. ni-
trofurantoin (13)), myocarditis (e.g. methyldopa (14)), parotitis (e.g. phen-
ylbutazone (15)), vasculitis (e.g. allopurinol (5)) or Lyell syndrome/Ste-
vens-Johnson syndrome (e.g. ibuprofen (16)). 
N.B. A pattern with rash, fever, lymphadenopathy and atypical lympho-
cytosis seen with some drugs (e.g. sulfasalazine (17), phenytoin (7)) is less 
specific and should at least be differentiated from infectious mononucleo-
sis. 
Histological 
Pure cholestasis (e.g. C-17 alkylated steroids (6)) 
Intrahepatic cholestasis is seen, with bile staining of hepatocytes and 
bile casts in the canaliculi without parenchymal necrosis/infiltration. 
There is no portal infiltrate. Cholestasis predominates in the centrizonal 
area but may extend into the midzonal and periportal areas when the 
drug is continued. This pattern strongly suggests a drug reaction but 
may be seen in other conditions (e.g. postoperative cholestasis). 
Zonal necrosis 
Necrosis predominates in the centrizonal (e.g. paracetamol, CC14 (4)), 
midzonal (e.g. furosemide (31)) or periportal area (e.g. ferrous sulfate (4)) 
often surrounded by steatosis. There is little (mainly neutrophilic) or no 
infiltration. 
Cholestatic hepatitis with eosinophilic infiltration (e.g. chlorpromazine 
(18)) 
The pattern is the same as that of pure cholestasis but with a prominent-
ly eosinophilic portal infiltrate and minimal parenchymal inflammation 
and necrosis. Especially the combination with blood eosinophilia strong-
ly suggests drug-induced cholestasis. 
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Granulomatous hepatitis with eosinophilic infiltration (19) 
Portal and/or lobular non-caseating granulomas with a prominently eo-
sinophilic infiltrate are fairly specific of a drug-induced cause, especial-
ly if combined with peripheral eosinophilia and portal eosinophilic infil-
tration. Parasitic diseases should however be excluded. Sarcoidosis and 
tuberculosis may easily be excluded. 
Experimental 
Hepatic injury + a positive lymphocyte stimulation .test (LST) (20, 22) 
The LST usually yields inconsistent results and is insignificant when 
negative because of many possible interfering factors. However, when a 
well-performed and controlled LST is positive only if the drug or a meta-
bolite is added, it may be regarded as fairly specific. Although a positive 
LST in this situation only means that the drug is immunologically recog-
nized (which may be compatible with almost any immunological form of 
drug-induced injury), it may be regarded as specific if it is combined with 
an intake-related course of hepatic injury, especially if the LST becomes 
negative after recovery. Analogous considerations apply to comparable 
in-vitro techniques (e.g. leukocyte-migration inhibition)(21). 
Hepatic injury + miscellaneous techniques 
Less experience has been gained with some newer techniques which 
promise to develop into specific assessment methods, such as the demon-
stration of drug/metabolite-dependent antibodies by indirect immunof-
luorescence, drug/metabolite-dependent cytotoxicity assay (23) or possi-
bly the demonstration of drug/metabolite in circulating immune-
complexes (24) in the serum-sickness-like form of hepatic injury. 
Temporal relationship (Levels C and D) 
The temporal relationship between the intake of a suspected drug and 
the onset of hepatic injury should be obvious, e.g. promptly after the in-
take of toxic agents in overdose and within 6 weeks after initial intake 
of immunoallergic agents. Or the reaction should be consistent with a 
well-known pattern and/or course of the particular drug. Isoniazid, for 
instance, usually produces hepatic injury after a longer latent period (1 
to several months) (25) and the temporal relationship should be compati-
ble with this characteristic. The usual onset will depend on the patho-
genesis (see Table 2). It is important to emphasize that an usually long 
latent period does not mean that a causal relationship is unlikely, but 
merely that the probability is more difficult to establish. In that case, 
'probable' may become 'possible' but certainly not 'unlikely'. 
Very rapid recovery after discontinuation of the suspected drug 
strongly favors a drug-related cause. The sudden disappearance of anti-
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TABLE 2 Usual temporal relationship 
Acute toxicity 1-3 days 
1-6 weeks 
>6 weeks 
Immunoallergy, metabolic idiosyncrasy 
Metabolic idiosyncrasy, chronic toxicity 
gen may even suggest a faster recovery than with non-drug-related 
causes. Of course, this is not always true since recovery also depends 
upon regenerative ability, the pharmacokinetics of the drug (some drugs 
remain in the body for a very long time) and the reversibility of the le-
sion. Especially jaundice due to prolonged cholestasis may take a long 
time-to disappear. 
Exclusion of other possible causes (Levels C and D) 
If no specific pattern is present, other possible causes should be excluded. 
Attention should be paid to the criteria shown in Table 3. 
LEVELE 
Disappearance of chronic inflammatory hepatic injury after discontinua-
tion of the suspected drug is highly suggestive of a causal relationship. 
It constitutes no proof because spontaneous remissions may occur (e.g. 
chronic active hepatitis). No normalization after discontinuation does 
not prove the absence of a causal relationship because the process may 
be irreversible in some cases and at some stages. 
TABLE 3 Criteria for assessment of cholestatic and parenchymatous pat-
terns of hepatic injury 
Mainly cholestatic pattern 
Normal bile ducts, gallbladder and pancreas 
No pregnancy, no recent operation 
No history of cholestasis/jaundice without the use of drugs, no underlying 
liver disease 
No malignancy (e.g. Hodgkin's lymphoma!), no sepsis, no alcohol abuse 
Mainly parenchymatous pattern 
Viral causes excluded. At least HA V, HBV, Epstein-Barr virus and 
cytomegalovirus 
No lymphadenopathy/lymphocytosis 
No recent operation, no transfusions, no parenteral exposure (e.g. tattoos, 
heroin), high-risk sexual practice or other suspected exposure to viral 
hepatitis 
No preceding hypotension/cardiac failure 
No sepsis, no malignancy, no underlying liver disease 
No alcohol abuse, no professional or other exposure to toxic substances (e.g. 
paraquat, 'glue sniffing') 
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LEVELS F AND G 
In cases of suspected drug-induced vascular disorders, the exclusion of 
other possible causes yields too little additional information to have a 
decisive effect on the causal relationship, mostly because there are too 
many unknown factors. V eno-occlusive disease is always chemically in-
duced and/or iatrogenic (e.g. alcoholism (26), pyrrolizidine alkaloids (27), 
cancer chemotherapy (28), irradiation (29)), so that the causal relation-
ship is always probable. 
The causes of large hepatic vein thrombosis, like veno-occlusive dis-
ease leading to the Budd-Chiari syndrome, are often unknown and it is 
therefore impossible to exclude them all. 
Both may present acutely or after a prolonged period. Accordingly, the 
temporal relationship plays a less decisive role in the causality assess-
ment. The other vascular disorders arise largely after long-term use. The 
temporal relationship between initial intake and appearance should be 
compatible in these cases. Especially a latent period which is too short 
(e.g. 1 month) suggests that the abnormalities were already present be-
fore the intake of the suspected drug. The same applies to hepatic tu-
mors. 
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ABSTRACT - Glafenine was associated with hepatic injury in 38 cases. The causal 
relationship was assessed on the basis of the temporal relatiollShlp with drug use, 
course and exclusion of other causes. In 27 cases a causal relationship was considered 
likely, i.e. 'probable' (12 cases) or 'possible' (15 cases), whereas in 11 cases it was 
either unlikely or unclassifiable. In both the 'probable' and 'possible' groups 60-70% 
of individuals were women. Jaundice was present in three-quaners of cases in both 
groups. Eosinophilia was more frequent in the group of 'probable' cases, and this 
group b,ad the highest case-fatality rate (42%). Onset varied from 2 days (after a 
rechallenge) to 8 months, but most cases appeared between 2 weeks and 4 months 
after starting therapy. Histology in 22 cases showed a predominantly hepatocellular 
pattern, varying from spotty panlobular necrosis, centrilobular and (sub)massive ne-
crosis (acute pattern) to fibrosis and cirrhosis (chronic pattern). The chemical structure 
of glafenine and the clinicopathological pattern it induces resemble that of cinchophen. 
The incidence is unknown. Either metabolic idiosyncrasy or an immunoallergic mech-
anism seems to be responsible. 
Accepted for publication 10 January 1986 
Glafenine is a 4-aminoquinoline derivative and is 
structurally related to chloroquine but lacks anti-
inflammatory properties. It has been in use in The 
Netherlands since 1967 as an analgesic agent. The 
drug is an important cause of allergic reactions, 
and of the several hundreds of reports of anaphyl-
actic reactions. reported to the Netherlands Cen-
ter for Monitoring of Adverse Reactions to Drugs 
(NARD), a significant number consists of shock. 
From 1976 up to and in::luding 1984. the NARD 
received 38 reports of hepatic injury associated 
with the use of glafenine in therapeutic amounts 
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(up to 800 mg/day). Of these 38 reports some 
have been reported in detail in the Dutch medical 
literature (1-4). Besides these articles, other case 
histories have been published, varying from mild 
liver enzyme elevations with predominantly extra-
hepatic adverse effects to severe and irreversible 
liver damage (6-12). 
The following study was carried out to outline 
the nature of the liver injury produced by glafen-
ine. It includes clinical, biochemical and histologi-
cal details of the 38 cases and a review of the 
literature. 
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Material and methods 
All reports of glafenine-associated hepatic injury, re-
ceived by the NARD through its nationwide voluntary 
reporting scheme between January 1976 and January 
1985, were included in the study. All reports came from 
general practitioners, specialist doctors or hospitals. Full 
details were requested for each reported case, either by 
telephone or by a personal visit by the first author in 
order to study the original medical record. This was 
mostly done within 1 month after receiving the report. 
Minimally requested were data about the age and sex of 
the patients, dose and duration of use, concomitant drug 
use, underlying illness (e.g. chronic liver disease, cardiac 
failure), preceding events (e.g. operation), clinical signs 
and symptoms, biochemical test results, other possible 
causes of hepatic injury (e.g. hepatitis A and B, infectious 
mononucleosis, cytomegaly, transfusions) and the course 
and duration of the disease. 
To ensure that the original diagnosis of glafenine-
induced hepatic injury was not at variance with sub-
sequent patient data, a follow-up was made of all cases, 
sometimes up to 9 years after the original report had 
been received. For all 38 reports, the clinical, biochemi-
cal and histological data were carefully reviewed, and 
for each case the causal relationship berween drug use 
and hepatic injury was assessed. The causal relationship 
was considered 'probable' when there was an adequately 
documented reaction to rechallenge or a compatible tem-
poral relationship with drug use in combination with the 
well-documented exclusion of other possible causes. A 
causal relationship was considered 'possible' when there 
was a temporal relationship compatible with drug use 
but other potential causes were insufficiently excluded. 
A causal relationship was considered 'unclassifiable' or 
'unlikely', respectively, when too few data were available 
or when more likely causes were found. 
Results 
Of the 38 cases a causal relationship was con-
sidered unclassifiable in six. In three of these six 
cases too few data were available; in fact, in one 
Table I 
of these it was impossible to determine whether 
liver damage or hemolysis was the cause of jaun-
dice, whereas in another case glafenine was used 
because of abdominal pain in a patient with liver 
metastases. In three other patients a causal role 
of glafenine was not impossible but was difficult 
to assess because of scanty data about intake and 
concurrent administration of other potentially he-
patotoxic factors (other drugs, transfusions, etc.). 
In five cases a causal relationship between he-
patic injury and use of glafenine was considered 
unlikely. One patient had had liver enzyme elev-
ations on two occasions preceding the use of 
glafenine. In another patient there was improve-
ment de~pite continuation of int~ke of glafenine 
and later- after discontinuation - a relapse; also, 
in a third patient, follow-up revealed aggravation 
of injury despite discontinuation of glafenine. In 
the fourth and fifth cases glafenine was used be-
cause of abdominal pain, in the former possibly 
associated with preexistent haemochromatosis, 
whereas in the latter there were gallstones, a nega-
tive reaction to rechallenge with glafenine, and a 
biopsy which showed hepatic venous congestion. 
Clinical and biochemical pattern 
In 27 cases a ·causal relationship was considered 
probable or possible. Since some of the cases in 
the 'possible' group may have had other causes 
(which complicates detection of a consistent pat-
tern), symptoms have been separated per 'caus-
ality-group'. 
Table 1 shows the clinical features of the group 
of 'probable' cases. The incidence of jaundice was 
the same in both the 'probable' and the 'possible' 
Symptoms and biochemical pattern of 12 'probable' cases of glafenine-associated hepatic injury 
Jaundice 
Nausea/vomiting 
Hepatomegaly 
Anorexia/malaise 
Eosinophilia 
Fever 
Abdominal pain 
Drowsiness 
9/12 (75%) 
7/12 (58%) 
6/12 (50%) 
3/12 (25%) 
3/12 (25%) 
2/12 (17%) 
2/12 (17%) 
1/12 (8%) 
Hepatocellular pattern• 
Mixed cholestatic-hepatocellu!ar•• 
Cholestatic pattern••• 
Liver enzyme elevations•••• 
Fatal course 
ALT>AST 
9/12 (75%) 
2/12 (17%) 
1/12 (8%) 
5/12 (42%) 
11/12 (92%) 
• AST/ALT>7txnonnal, APh<3xnonnal; •• AST/ALT>7txnonnal, APh>3xnormal; ••• AST/ 
ALT<7t x normal, APh> 3 x normal; •••• AST/ALT<7t x normal, APh< 3 x normal. 
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Table 2 
Clinical and biochemical features of glafenine-associated hepatic injury: 12 (highly) probable cases 
NARD Time to onset Peak of assessed biochemical Rechallenge 
case Daily dose/ first values (U/1) Other (lime to 1st Outcome 
no. Age/sex duration signs/sympl. AST ALT A Ph Bili. (tot.) drugs sign) (lime) 
2 33/F 600-800 mg/ 2 weeks 760 1240 Normal 2111molfl + Recovered 
5 days (N <50) (N <50) (2 weeks) (5 months) 
4 30/F 600-800 mg/ 3 months 186 225 33 11molfl Oral con- + (2x) Recovered 
3 months (N<l2) (N < 12) tracepl. (<5 days) (4! months) 
5 74/F Dose("!)/ 2 months 380 425 168 15ll'molfl Propranolol Same reaction Recovered 
2 months (N <27) (N<27) (N<lOO) frusemide to glafenine (approx. 2! 
nitrazepam 3 years before months) 
6 53/F 400-600 mg/ 24 days 145 255 272 24 l'mol/1 Methyldopa Recovered 
2 weeks (N<27) (N <27) (N<lOO) epilizide/ (approx. 2 
triamterene months) 
9 33/F Irregular/ 8 months 558 606 9711moljl + Recovered 
-I 8 months (N < 15) (N<l8) (<3 days) (3! months) w 
13 32/F 400-600 mg/ 45 days 1030 1130 - 630 f!moljl Death 
59 days (N<50) (N <50) Gl 
r 
15 66/M 600 mg/d for Approx. 2100 3150 635 11moljl Death )> 
., 
1 week followed 2 months (N<30) (N <20) m z by irregular use z 
25 46/F 200 mg/ Approx. 985 700 1071 f!mol/1 Lorazepam Death m }. 
approx. 3 months 3 months (NS) (NS) bromhexine (J) 
28 66/M Varying dose up 4 months 913 1360 128 282f!mol/1 Thyroxine Death (J) 0 
to 800 mg/4 months (N<20) (N <30) (N<90) () 
32 51/M 400 mg/2 days 2 days 474 7Il 714 <20 f!mol/1 Phenpro- + Recovered ~ m (N<20) (N<26) (N <70) coumon (2 days) (6 months) 0 
36 47/M 600-800 mg/ Approx. 580 825 282 680 11mol/l Recovered :I: m 
approx. 4 months 4 months (N<l8) (N<25) (N< 105) (approx. lJ 
2j months) ~ 
38 87/F 400 mg/31 months 3! months 410 515 394 395 llmOl/1 An unknown Death 0 
(N<l8) (N<25) (N<I05) homeopathic z <-
medicine c 
:IJ 
-< 
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groups. There were differences in the incidence 
of abdominal pain, hepatomegaly and anorexia/ 
malaise, but the figures were too small to produce 
conclusive results. Lymphadenopathy was absent 
in five 'probable' and six 'possible' cases; in the 
other cases its presence/absence was not men-
tioned. Eosinophilia was more frequently re-
ported in the 'probable' group, although in one 
of these cases it was discovered when liver en-
zymes had almost normalized again. There was a 
clear difference in biochemical pattern. which was 
assessed largely according to Zimmerman's cri-
teria (13). 
The pattern was mainly hepatocellular in the 
group of 'probable' cases, whereas the group of 
'possible' cases showed a variety of patterns. Since 
the former group is the more important one, de-
tails about these cases are given in Table 2. 
In the 'probable' group 8 out of 12 patients 
were women (67%), whereas the 'possible'-group 
consisted of 9 women out of 15 patients (60%). 
The mean age in the 'probable' group was 51.5 
year (range: 30-87) with a mean age for men of 
57.5 year (range: 47-66) and for women of 48.5 
year (range: 30-87-). In the 'possible' group the 
mean age was 57 year (range: 25-91) with a mean 
age for men of 57.7 year (range: 30-91) and for 
women of 56.7 year (range: 27-79). 
In the 'probable' group the daily dose ranged 
from 200 to 800 mg, and in the 'possible' group 
from 200 to 1600 mg. The latent period between 
first use and onset of first symptoms was mostly 
between 0.5 and 4 months (mean: 2.7; range: 2 
days to 8 months) in the 'probable' group. This 
was also the case in the 'possible' group, although 
Table 3 
here data about duration of use were somewhat 
less well-documented. 
In the 'probable' group. five cases had a fatal 
course (42%) as against two cases in the 'possible' 
group (13%). The overall case-fatality rate was 
26%. All fatal cases exhibited hepatic failure, ei-
ther isolated or in combination with renal failure, 
gastrointestinal haemorrhage or arrhythmia as the 
primary cause of death. 
Most patients in both groups used glafenine 
because of dental pain, headache or neuralgic 
pain. Concurrent drugs were used in 8 of 12 pa-
tients in the 'probable' group, several of which 
have been associated with hepatic injury before. 
However in Case 2, oral contraceptives were not 
used during the rechallenges. In Cases 5 and 32, 
recovery followed discontinuation of glafenine de-
spite continuation of other drugs. Patient 5 had 
also used ibuprofen during the first episode of 
hepatic injury but not during the rechallenge 3 
years later. The drugs used in Case 6 had been 
used safely for over a year and this fact, especially 
in the absence of fever, makes methyldopa an 
unlikely cause ( 17). Patients 25 and 28 were on 
long-term treatment with drugs which are not (or 
perhaps very rarely) associated with hepatic in-
jury. Whereas some non-orthodox medicines (es-
pecially herbal agents which contain pyrrolizidine 
alkaloids) are hepatotoxic, homeopathic medi-
cines (Case 38) are highly diluted and therefore 
an unlikely cause of hepatic injury. 
In the 'possible' group several patients used 
other drugs concurrently, but these were either 
unknown as a cause of hepatic injury or continued 
without problems. Only in Case 14 (diazepam, 
Histological patterns of hepatic injury in 22 'probable' and 'possible' cases studied by the authors•• 
Predominating pattern of injury Probable Possible Total 
Steatosis 
Cholestasis 
'Spotty' necrosis 
Centrilobular/submassive 
Massive 
Fibrosis/cirrhosis 
Undetermined 
Total 12 
•• The underlined numerals refer to the NARD nos. of the study. 
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26 
ll:.~ 
33 
!.l 
14. 37 
]1.~ 
10 
I (5%) 
3 (13%) 
2 (9%) 
7 (32%) 
4 (18%) 
4 (18%) 
I (5%) 
22 
GLAFENINE-ASSOCIATED HEPATIC INJURY 
Fig. 1. (Case 32) Spotty necrosis. Varying degrees of ballooning and binucleation. Note acidophilic degeneration 
(arrow) (HE 250 x) (by courtesy of A. H. Lely and H. Barrowclough). 
pipotlazme, secobarbital), Case 21 (ibuprofen), 
Case 22 (paracetamol, diazepam, chlordiazepox-
ide, acetylsalicylic acid), Case 27 (chlortalidone) 
and Case 35 (ajmaline, phenprocoumon, halo-
thane) may other drugs also have been respon-
sible. 
Histopathology 
In 33 of the 38 cases a biopsy and/or autopsy was 
performed. The original slides were requested by 
us from the reporting medical practitioners and/ 
or the involved pathologists, who kindly co-oper-
ated in all cases. However in three cases it was 
impossible to obtain the original slides. In two 
other cases a biopsy was not successfully per-
formed. Of the remaining 28 biopsies/autopsies. 
12 consisted of 'probable' and 10 of 'possible' 
cases (see Table 3). All material had been stained 
with hematoxylin-eosin, whereas most slides had 
been stained with Gomori or Gordon & Sweet's, 
Azan, periodic acid Schiff(PAS) with and without 
diastase and Perl's or Turnbull's iron reaction. 
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Cholestasis. One 'probable' and two 'possible' 
cases demonstrated a mainly cholestatic pattern, 
varying from almost pure cholestasis in Case 21 
(however, with many ceroid-laden Kupffer cells, 
thereby suggesting past necrosis) to cholestatic 
hepatitis with bile staining and plugging, focal 
infiltration with lymphocytes and eosinophils, bal-
looning and acidophilic bodies in zone III, as seen 
in Case 6. In Case 22 cholestasis in zones II and 
III was accompanied by panlobular ballooning, 
spotty necrosis, infiltrated by a mixed lympho-
cytic/neutrophilic infiltrate, and moderate steato-
sis. There was no Mallory's hyaline or a pattern 
of alcoholic steatosis. Liver architecture was pre-
served in all cases. 
Spotty necrosis. One 'probable' and one 'pos-
sible' case showed a pattern of pan lobular spotty 
necrosis with occasional cell drop-out and acido-
philic bodies, mostly surrounded by a predomi-
nantly lymphocytic infiltrate (Fig. 1). There was 
a varying degree of ballooning in all areas and a 
few foci of steatosis. Cholestasis was absent and 
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Fig. 2. (Case 38) Centrilobular area with much cell drop-out and ballooning. Predominantly mononuclear infiltration 
(HE 250x). 
Fig. 3. (Case 5) Bridging necrosis. Cell drop-out and central-central bridging. Ballooning in zones I and II. 
Predominantly mononuclear infiltration. (HE 100 x) (by courtesy of L. van Leeuwen and M. Th. M. Sindram). 
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Fig. 4. (Case 15) Massive necrosis. Panlobular necrosis with haemorrhage and a mixed mononuclear/neutroplrilic 
infiltrate. (HE I 00 x) On the right, a small island of relatively preserved hepatocytes. 
the architecture was preserved. There was portal 
expansion and moderate infiltration mainly with 
mononuclear cells; Kupffer cell hyperplasia was 
moderate. 
Centrilobularfsubmassive necrosis.' In five 'prob-
able' and two 'possible' cases there was centrilo-
bular (zone III) to submassive (zones II and III) 
necrosis (Fig. 2 and 3), often with many erythro-
cytes in zone III. In three cases there was a sharp 
margin between complete cell drop-out in zone II 
and/or III and the relatively well-preserved zone 
I. Ballooning of varying severity, however, was 
present in most non-necrotic areas. In all cases 
there was collapse of the reticulin framework with 
passive septum formation. varying from a single 
bridge to extensive central-central and central-
portal bridging. The infiltrate was predominantly 
mononuclear in all cases. mainly lymphocytic, but 
always mixed with a mild to moderate number 
of neutrophils and eosinophils. Cholestasis was 
present in Case 36 and 38. in the latter ac-
companied by marked bile duct proliferation. Ste-
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atosis was absent in all cases. In Case 2 a control 
biopsy 5 months later showed much improvement, 
however with persistence of some intralobular fo-
cal areas of necrosis, fibrotic bridges and mild 
piecemeal necrosis. Follow-up in Cases 3, 9 and 
36 within I year after admission showed normaliz-
ation but with rests of fibrotic bridging in all. 
Massive necrosis. In four cases there was mas-
sive necrosis (zones I-III). In Case I 3 the presence 
of a small and collapsed liver at autopsy suggested 
massive necrosis, but the slides obtained con-
tained too little material for diagnosis. In the 
other cases no normal liver cells were visible be-
tween areas of cholangiolar proliferation. Cell de-
bris and many erythrocytes were present in necro-
tic areas (Fig. 4). In Cases 14 and 15 there were 
also some areas of submassive necrosis with wide 
bridges of collapsed fibres and the beginning of 
fibrosis. In all cases infiltration was relatively 
moderate, predominantly lymphocytic but with 
many neutrophils and some eosinophils. In one 
case Kupffer cell hyperplasia was very prominent. 
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Fibrosis/cirrhosis. Two 'probable' and two 'pos-
sible' cases had marked fibrotic changes in their 
biopsies. In Case 35 there was cholangitis with bile 
duct destruction and proliferation with marked 
steatosis and periportal. perivenular and perisinu-
soidal fibrosis. There was a mixed mononuclear/ 
eosinophilic infiltrate. In Cases 25 and 28 there 
was nodular regeneration separated by wide fi-
brotic bridges, but no micronodular cirrhosis at 
autopsy. Case 38 had a pattern of micronodular 
cirrhosis without signs of active necrosis at autop-
sy, performed 2 months after a biopsy showed 
submassive necrosis. portal fibrosis, bile duct pro-
liferation and areas of perisinusoidal fibrosis. This 
patient, however, had no history of exposure to 
arsenicals, high-dose vitamin A, vinylchloride, 
thorium dioxide or cytostatic agents. In Case 16 
the first half of the biopsy was fibrotic, whereas 
the 'deeper' part showed centrilobular necrosis 
and ballooning with formation of fibrotic bridges. 
A control biopsy, 4 years later, showed normal 
liver tissue with minimal fibrotic rests. 
Discussion 
It is clear from this study that glafenine may in-
duce severe hepatic damage. Although the less 
consistent pattern in the group of 'possible' cases 
suggests that in some cases another cause may 
have been responsible, this is unlikely to have 
played a role in the group of 'probable' cases. In 
the latter group, cases were either 'rechallenge-
proven', thereby suggesting a highly probable cau-
Table 4 
sal relationship, or no other causes such as hepa-
titis A, B, infectious mononucleosis, cytomegaly, 
cardiac failure. sepsis, malignancy or underlying 
liver disease were demonstrated. The high AST-
values in combination with an ALT/AST-ratio 
greater than I and the absence of alcoholic liver 
disease on biopsy excludes alcohol as a cause in 
the 'probable' group. The absence of lymphade-
nopathy/lymphocytosis and the fact that no 
transfusions had been given, make any viruses 
other than the aforementioned hepatotropic vi-
ruses (e.g. NANB viral hepatitis) less likely causes. 
Only Patient 32 had received a transfusion preced-
ing the second period of administration of glafen-
ine, but liver enzymes were already elevated before 
the transfusion. 
The pattern was predominantly hepatocellular, 
especially in the 'probable' group. This is of im-
portance since the pattern was not used as a cri-
terion for inclusion in one of the groups and there-
fore it seems that glafenine-induced hepatic injury 
is primarily hepatocellular. Unlike viral hepatitis, 
which often consists of spotty necrosis randomly 
distributed panlobularly, glafenine-induced he-
patic injury is predominantly centrizonal and 
mostly severe with (sub)massive necrosis. The cli-
nicopathological pattern may be distinguished 
from other drugs in the same pharmacotherapeu-
tic group (Table 4). 
The chemical structure of glafenine shows some 
resemblance to cinchophen, an uricosuric agent 
used as an analgesic in the early decades of this 
century and dropped from clinical use because of 
Comparison of characteristics of hepatic injury induced by some analgesicsfantirheumatics 
Glafenine Salicylates" Phenylbutazone" Cinchophen 1' 
Jaundice 75% rare 50%* 100%** 
Rash/fever 17% 50% II% 
Eosinophilia 25% (?) (?) 
Pattern' H LE M/H H 
Granulomas + 
Latent period 0.5-4 mo. <I wk. <6 wk. 0.5-4 mo. 
Dose dependency + -I+ 
C11.se-fatality rate 42% low 22-28% 52% 
• Approximation based on serum bilirubin levels (total) above 3 mgfdl (51 j.lmol/1). 
•• Overrepresented because of the absence of sensitive assessment methods. Therefore the number of fatal cases 
was probably overrepresented too. 
Pattern hepatocellular (H), mixed cholestatic-hepatocellular (M) or non-symptomatic liver enzyme elevations. 
Salicylate-associated Reye-like syndrome is not included. 
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its ability to induce severe hepatic necrosis ( 13). 
The basis of both drugs is the quinoline structure. 
but their side-chains differ. Relatively little is 
known about their metabolism. Both agents cause 
the same clinical and histological pattern of hepa-
tocellular injury with a fatality-rate of approxi-
mately 50%. lmmunoallergic phenomena such as 
rash, fever or arthralgia occur in 10-15% of cases 
of hepatic injury associated with the use of both 
drugs. 
In the (old) literature about cinchophen eosino-
philia was not mentioned. Possibly at that time 
no special attention was paid to this clinical sign, 
since cinchophen-induced hepatic necrosis was the 
first recognized example of the idiosyncratic, non-
dose-related (i.e. 'non-toxic') type of drug-induced 
hepatic injury. Most cases of cinchophen-associ-
ated hepatic injury appeared between 2 weeks 
and 4 months after starting therapy (14). This is 
analogous to the latent period in this study. 
Besides the cases discussed in this study, eight 
cases of hepatic injury associated with glafenine 
have been described in the medical literature 
(6-12). They concerned six women (mean age: 
69 year) and two men (mean age: 52 year). In 
three cases, hepatic injury consisted of mild liver 
enzyme elevations (7, 9, 12) and eosinophilia (7, 
12), which both recurred after rechallenge (7, 12). 
In one of these three cases fever, pulmonary in-
volvement and eosinophilia accompanied liver en-
zyme elevations (12). In another case AST/ALT-
elevation was trivial when compared to severe 
intravascular coagulation and renal failure (9). In 
a fourth cases serum ALT was up to 37 times 
normal value and accompanied by hemolysis and 
renal failure; however, biopsy I day later showed 
bile staining of hepatocytes in the absence of ne-
crosis (8). The remaining four cases comprised a 
pattern varying from a mixed cholestatic-hepato-
cellular to a hepatocellular pattern with the first 
symptoms appearing between 0.5 and 3 months 
after starting therapy (6, 10-12). A rechallenge, 
performed in three cases, was positive within a 
period of 7-9 days (6, 10, 12). In one case no 
biopsy was performed but biochemistry suggested 
recovery within 2 months (6). One patient ex-
hibited a pattern of cirrhosis and fatal hepatic 
failure I month after starting the second period 
of administration of glafenine (I 0). In another 
GLAFENINE-ASSOCIATED HEPATIC INJURY 
case a biopsy, performed 5 months after discon-
tinuation. suggested post-necrotic cirrhosis and 
showed chronic active hepatitis (12). With the 
exception of one case with a weakly positive baso-
phil degranulation test (9), immunologic tests gave 
negative results. 
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The mechanism of glafenine-induced hepatic 
injury is unknown. The reaction is unpredictable, 
dose-independent and seems to be relatively rare. 
We are not aware of any animal toxicity studies 
suggesting a hepatotoxic effect. Therefore a direct 
toxic effect seems unlikely. Glafenine is a frequent 
cause of anaphylactic reactions, and it seems 
plausible that these, when accompanied by shock, 
may cause transient elevations of liver enzymes. 
In those cases where extrahepatic clinical features 
dominate, other immunological mechanisms may 
also play a role, as in the patient with hemolysis, 
renal failure, liver enzyme elevations and circula-
ting immune-complexes (8). In the cases where 
hepatic injury is the only sign, however, other 
mechanisms may be responsible. The delayed on-
set. the infrequent presence of rash, arthralgia and 
fever, and the neg~tive immunologic tests seem 
compatible with a metabolic type of idiosyncrasy. 
On the other hand, eosinophilia was fairly fre-
quent and there was an accelerated reaction to 
rechallenge. Although, in our opinion, the latter 
may also be compatible with 'metabolic idiosyn-
crasy' when the period between dechallenge and 
rechallenge is short, it seems that an immunoaller-
gic component cannot be excluded. 
Our study like other studies suggests a higher 
incidence in women. Since we are not aware of 
any reliable consumption data, it is impossible to 
say whether this is related to a more frequent use 
of analgesics in this group, or to an increased 
vulnerability of females; the latter has been sug-
gested in many other studies of drug-induced he-
patic injury. 
If we compare the 117 cinchophen-associated 
cases. collected by Weir eta!. (14) from the U.S.A. 
(population in 1932: 125 million individuals) with 
the 32 likely and unclassified cases in this study 
(population of The Netherlands in 1984: 14.5 mil-
lion individuals), we have the impression that 
glafenine-associated hepatic injury may be equally 
frequent. Weir et a!., however, collected mostly 
cases reported in the medical literature. These 
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were almost always symptomatic since more sensi-
tive methods of liver injury assessment (serum 
liver enzymes) were not available at that time. 
Even if we compare only the 12 symptomatic cases 
of glafenine-associated hepatic injury described or 
summarized in the Dutch medical literature (1-5. 
12) with Weir's collection. it seems reasonable 
to assume that glafenine-associated hepatic injury 
may be as frequent as cinchophen-induced hepatic 
injury. According to Zimmerman (13), the latter 
had an incidence of up to 0.1 %. It should be 
realized, however, that some cases may remain 
unrecognized whereas some others may be wron-
gly associated with other causes. Since underre-
porting of adverse effects to National Monitoring 
Centers is a widely recognized problem, and since 
sales figures are unknown to us, it is difficult to 
estimate the incidence of glafenine-induced he-
patic injury. 
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Summary 
Fifty-five cases of ketoconazole-associated hepatic injury, reported to the Netherlands Centre for Monitoring 
of Adverse Reactions to Drugs, were analysed in detail. In 50 cases a causal relationship was considered likely, 
i.e. 'probable' (27 cases) or 'possible' (23 cases). Eight-four % of individuals were women. Forty-six % of pa-
tients were over 50 years of age which suggests that, considering the lower prescription rate in this age group, the 
elderly are more vulnerable to ketoconazole. In 60% of all cases hepatic injury appeared within the first 6 weeks 
of therapy but in the group of 'probable' -cases the onset was mostly later. Jaundice was present in 44% of all cas-
es but in 63% of the group of 'probable'-cases. Eosinophilia (10% ), fever (6%) and rash (2%) were uncommon. 
Biochemically the pattern was hepatocellular in 54%, cholestatic in 16% and mixed cholestatic-hepatocellular in 
30%. Histology (14 cases) showed a predominantly" hepatocellular pattern in 57% with extensive centrilobular 
necrosis and mild to moderate bridging. In 43% cholestasis predominated. None of the cases had a fatal course. 
The incidence of symptomatic hepatic injury may be estimated at approximately 1:2000 but is probably higher. 
The mechanism of ketoconazole-induced hepatic injury seems to be based on metabolic idiosyncrasy although it 
is not excluded that in some patients an immunoallergic mechanism is causative. 
Introduction 
Ketoconazole is an antimycotic agent introduced 
in 1981. Several case-reports have been published in 
the medical literature of mild to severe hepatic injury 
[1-21,23] and 2 studies of cases have been made 
[20,21]. These studies, however, partly cover the 
same cases and include only 2 biopsies and 1 autopsy. 
In addition to the first cases, reported to the Nether-
lands Centre for Monitoring of Adverse Reactions to 
Correspondence address: B.H.Ch. Stricker, Medical Officer, Netherlands Centre for Monitoring of Adverse Reactions to Drugs, 
P.O. Box 439, 2260 AK Leidschendam, The Netherlands. 
0168-8278/86/$03.50 © 1986 Elsevier Science Publishers B. V. Biomedical Division) 
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Drugs (NARD) and published [12], 50 cases have 
been reported. Since cases of hepatic injury are in-
tensively monitored, the majority of cases of ketoco-
nazole-associated hepatic injury are well-docu-
mented and include histopathology of 16 cases. Four 
of these 50 cases have been published before 
[10,11,13]. Here we outline the clinicopathological 
pattern of 50 'probable'- and 'possible'-cases of keto-
conazole-associated hepatic injury and review the 
literature. 
Material and Methods 
The study includes all cases of ketoconazole-asso-
ciated hepatic injury reported to the NARD between 
1981 and April 1986. All reports came from medical 
APh(xnormal value) 
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doctors. Of each case full details were requested, 
mostly within 1 month after receiving the report: age/ 
sex, dose/duration of use, concomitant drugs, pre-
ceding events (e.g. recent operations/transfusions, 
hepatitis in contacts), underlying illness (e.g. chronic 
liver disease, cardiac failure), signs/symptoms, physi-
cal examination, imaging procedures, liver enzyme 
assessments and exclusion of other possible causes 
(e.g. HAY, HBV, cytomegaly, infectious mononu-
cleosis). A follow-up was made of all cases. All clini-
cal, biochemical and available histological data were 
carefully evaluated and for each case the causal rela-
tionship between use of ketoconazole and hepatic in-
jury was assessed. It was considered as 'definite' 
when there was a well-documented reaction to re-
challenge and as 'probable' when there was a compa-
tible temporal relationship between onset of hepatic 
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Fig. 1. Biochemical pattern in 26 probable cases (based on refs. [21,28] with a modification by the authors). Numericals refer to biopsy 
numbers in text. Cases of pure cholestasis encircled. 
I =Liver enzyme elevation {alkaline phosphatase (APh) < 3X normal, aspartate/alanine aminotransferase (ASAT/ALAT) < 8X 
normal, bilirubin< 2X normal). 
Pure cholestasis (as above but bilirubin > 2 x normal). 
II = Hepatocellular(APh<3X normal,ASAT/ALAT>Sx normal). 
III = Cholestatic hepatitis (APh > 3x normal, ASAT/ALAT < 8X normal). 
IV = Mixed cholestatic-hepatocellular (APh > 3x normal, ASAT/ALAT > 8x normal). 
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injury and drug use in combination with adequate ex-
clusion of other possible causes. When there was a 
compatible temporal relationship but insufficient ex-
clusion of other potential causes the causal relation-
ship was considered to be 'possible'. In 5 patients a 
more likely cause than ketoconazole was found and 
these cases were omitted. 
Results 
A causal relationship was considered as likely in 50 
cases, i.e. 'definite' in 1 case (hereafter included in 
the group of 'probable' -cases), 'probable' in 26 cases 
and 'possible' in 23 cases. With the exception of ab-
dominal pain signs/symptoms were less frequently re-
ported in the group of 'possible' -cases. In none of the 
50 likely cases lymphadenopathy was reported; in-
deed its absence was emphasized in 28 reports. One 
of the reports mentioned rash, starting 1 week after 
discontinuation of ketoconazole. Eosinophilia (~7%) 
was present in 2 out of 22 'probable'-cases in which a 
differential count was mentioned. Eosinophilia was 
present in 3 'possible'-cases but clearly stated as ab-
sent in 6 cases. In 3 'probable'-cases hepatic injury 
was accompanied by fever, low grade in 2 and high 
(39.5 oq in 1 case. The biochemical pattern (Fig. 1) 
was hepatocellular in 18 'probable'- ( 67%) and 9 
'possible'-cases (39% ). In the group of 'possible'-
cases most reports concerned mild to moderate liver 
enzyme elevations (48%). In the 'probable'- and 
'possible'-group 81.5% and 87% of patients respec-
tively were female. The mean age in the 'probable'-
and 'possible'-group was 48.4 years (range: 24-76) 
and 53 years (range: 34-99) respectively without a 
significant difference in age between both sexes. 
Twenty-seven patients (54%) used ketoconazole be-
cause of onychomycosis and 15 (30%) because of 
dermatomycosis. The daily dose was 200 mg in 90% 
of cases. The mean latent period between first intake 
of ketoconazole and onset of first symptoms in the 
'probable'- and 'possible'-group was 68 days (range: 
1 week-71!z months) and 52 days (range: 16 days-
6Vz months) respectively. In 44% and 79% respec-
tively onset was within the first 6 weeks. None of the 
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TABLE 1 
SYMPTOMS AND SIGNS IN 27 PROBABLE CASES OF 
KETOCONAZOLE-ASSOCIATED HEPATIC INJURY 
Jaundice 63% Abdominal pain 4% 
Malaise 59% Rash 4% 
Nausea/vomiting 41% Excessive perspiration 4% 
'lnfluenza'-like 11% Headache 4% 
Fever 11% Amenorrhoea 4% 
Anorexia 11% Hepatomegaly 33% 
Eosinophilia 9% ALAT>ASAT 89% 
No symptoms 11% 
50 cases had a fatal course. In the group of 'proba-
ble' -cases 13 individuals ( 48%) also used other drugs 
but these were either continued or reinstituted with-
out aggravation or relapse of hepatic injury. We ex-
plicitly asked for ingestion of griseofulvin in the 6 
TABLE 2 
CLINICOPATHOLOGICAL FEATURES OF 99 CASES 
OF KETOCONAZOLE-ASSOCIA TED LIVER INJURY 
Female 
>50 year 
Latent period 
,;;6weeks 
>6weeks 
Biochemical pattern 
hepatocellular 
cholestatic 
LEE/mixed 
Histology (predomi-
nating pattern) 
necrosis 
cholestasis 
Clinical pattern 
jaundice · 
eosinophilia 
fever 
rash 
Fatal course 
Literature 
[1,3,6-9, 
14-19] 
(n = 16) 
50% 
44% 
38% 
62% 
75% 
25% 
(n = 9) 
100% 
56% 
13% 
19% 
a Includes references [5,23] 
b Includes references [10-13]. 
Lewis et 
al. [21]" 
(n = 33) 
67% 
61% 
66% 
34% 
55% 
15% 
27% 
(n = 3) 
100% 
82% 
3% 
This 
studyb 
(n =50) 
84% 
46% 
60% 
40% 
54% 
16% 
30% 
(n = 14) 
57% 
43% 
44% 
10% 
6% 
2% 
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Fig. 2. Biopsy No. 1. Centrilobular cholestasis, no necrosis, no infiltration, bile plugs encircled. HE, X 100. 
months preceding use of ketoconazole in all 'proba-
ble'-cases in which hepatic injury appeared in the 
first 6 weeks of therapy. In none of these cases gri-
seofulvin had been used. Only 2 of 50 cases had pre-
viously developed an idiosyncratic reaction to an 
other drug (4% ). Forty had not whereas in 8 cases a 
reaction to other drugs was not mentioned or un-
known. 
Histopathology 
Two 'possible'- and 3 'probable'-cases exhibited a 
mainly cholestatic pattern. One 'probable'-case (No. 
2) showed almost pure cholestasis, however, with 
some ceroid-laden Kupffer cells. Cases 1 (Fig. 2) and 
3 showed an analogous pattern but with moderate 
portal and minimal lobular mononuclear infiltration. 
Another 'possible'-case showed, besides cholestasis, 
many acidophilic bodies and discrete cholangiolitis 
with many eosinophils. Biopsy 10 showed distinct 
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cholangitis without significant cholestasis in the ab-
sence of necrosis or lobular infiltration. 
Biopsy 4 showed a pattern varying from mild foci 
of necrosis to moderate, sharply demarcated, centri-
lobular necrosis surrounded by some acidophilic 
bodies. Infiltration was mainly mononuclear but 
mixed with some neutrophils. Zones I and II were 
well-preserved, however, with occasional balloon-
ing. Biopsies 5-9 showed more extensive, but also 
sharply delineated, necrosis with confluence of ne-
crotic zones and bridging by collapse of the reticulin 
framework. Bridging was relatively mild in biopsies 5 
(Fig. 3), 7 and 9. In biopsies 6 (Fig. 4) and 8 signs of 
beginning fibrosis were present. Biopsies 5-9 exhi-
bited moderate to dense portal infiltration, mainly 
with lymphocytes but often mixed with some neutro-
phils. Most biopsies showed a mild degree of bile duct 
proliferation. Occasional areas of 'piece-meal' ne-
crosis were also present in most biopsies but in case 9 
KETOCONAZOLE-ASSOCIATED HEPATIC INJURY 
Fig. 3. Biopsy No. 5. Sharply demarcated centrilobular necrosis. HE, x 100. 
this was accompanied by an increase in portal and 
periportal fibrosis. None of biopsies 4-9 showed bile 
plugging. Biopsy 6 showed minimal steatosis. In 
biopsy 9 there was hyperplasia of perisinusoidallipo-
cytes, especially in the parenchyma surrounding ne-
crotic areas; an increase in perisinusoidal fibrotic fi-
bres, however, was absent. Biopsies of 2 'possible'-
cases showed a hepatocellular pattern. In one of 
these extensive, sharply demarcated, centrilobular 
necrosis and mild bridging were present. The second 
biopsy showed acidophilic bodies and focal areas of 
necrosis in zones II and III with some portal areas 
showing 'piece-meal' necrosis. 
Discussion 
It is important to distinguish 'probable'- from 'pos-
sible' -cases since it is especially the former group 
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which gives insight into the clinicopathological pat-
tern by a particular drug; 'possible'-cases are mostly 
less well-documented. The absence of a history of he-
patitis in contacts, recent operations and parenteral 
procedures make NANB viral hepatitis a less likely 
cause. Although some mycotic infections may cause 
hepatic injury, this is rare and unlikely as a cause in 
these patients since ketoconazole was mostly used 
because of uncomplicated onycho- or dermatomyco-
sis. Moreover, hepatic injury developed in these pa-
tients during use of ketoconazole instead of during 
the more active phase of the infection before inges-
tion. 
The pattern was mostly hepatocellular but choles-
tatic hepatitis and even pure cholestasis may occur. 
Most cases in the medical literature [1-21] consisted 
of a mainly hepatocellular pattern and a biopsy in 
some of these cases showed predominantly necrosis, 
varying from mild to moderate [1,6,8,9,19,21] and 
B.H.Ch. STRICKER et al. 
Fig. 4. Biopsy No. 6. Centrilobular necrosis with beginning central-portal bridging. HE, x 100. 
more extensive bridging necrosis [7] to massive ne-
crosis [15, 17 ,21]. lmmunoallergic signs such as high 
fever, rash and eosinophilia were uncommon. In The 
Netherlands (1982-1986) approximately 60% of in-
dividuals treated with ketoconazole were women 
[30]. Since this included treatment of mycotic vagini-
tis, the male to female ratio of patients treated for 
skin- or nailmycosis may be estimated at approxima-
tely 50/50. Even if we exclude mycotic vaginitis, 
more than 80% of patients was female. Since we are 
not aware of any other reason for this overrepresen-
tation this suggests that females are more likely to de-
velop ketoconazole-induced hepatic injury. Forty-six 
percent of individuals was over 50 years old. It seems 
likely that the elderly are more susceptible since in 
The Netherlands (1982-1986) only 14-19% of all 
tablets were prescribed to patients of 55 years and 
older [30]. Most of our cases appeared within the first 
6 weeks. When we distinguished, however, between 
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'probable'- and 'possible'-cases, it came out that 
'probable'-cases mostly appeared between 6 weeks 
and 7Vz months after starting treatment. Most of our 
patients recovered within 3 months after discontinua-
tion of ketoconazole but in 2 'possible'-cases there 
was still a progressive but temporary increase in liver 
enzymes after discontinuation. This was also noted in 
some other cases [6,7,9,16], in one of which adminis-
tration of corticosteroids was followed by rapid re-
covery [9]. The low mortality in Lewis eta!. [21] and 
our studies is remarkable, especially since there is no 
doubt that ketoconazole-associated hepatic injury 
may be fatal [15,17,21,22]. Moreover, the very high 
ASAT/ALAT-levels in several of our patients seem 
to indicate that the reaction is potentially lethal. The 
high number of patients with a history of hepatitis 
(26%) or idiosyncrasy to other drugs (29%) in the 
study by Janssen et a!. [20] was not confirmed-in our 
study and we do not think that it has any relationship 
KETOCONAZOLE-ASSOCIATED HEPATIC INJURY 
with the problem. The high number of patients with 
preceding use of griseofulvin ( 45%), mentioned by 
Janssen et a!. [20], seems related to the underlying 
mycotic infection rather than being a predisposing 
factor since our specific enquiry revealed no cases in 
which use of griseofulvin preceded use of ketocona-
zole. 
The incidence of ketoconazole-associated liver en-
zyme elevations has been varyingly reported as 6% 
[20] and approximately 12% [21] although some 
studies give higher figures [21] and some much lower 
[25,26]. The incidence of symptomatic hepatic injury 
was estimated at 1:10 000 [20] and later at 1:15 000 
[22] by the manufacturer. No correction was made 
for the reporting-rate, however, which was estimated 
in the U.K. at 11-20% of serious and non-trivial ad-
verse effects [29]. Moreover, the estimation was 
solely based on cases known to the manufacturer 
which excludes many cases reported to regulatory 
authorities. Hence the real incidence may be esti-
mated at 1:1000-3000 but is probably higher. Were-
alize that voluntary reporting schemes are not suit-
able for calculations of incidences. Nevertheless we 
cannot discard the fact that ketoconazole was the 
most frequently reported suspected cause of hepatic 
injury (NARD-period: 1982-1985: 22% of all re-
ports of drug-induced hepatic injury) suggesting that 
ketoconazole-associated hepatic injury is a serious 
clinical problem. 
The fact that mild liver enzyme elevations may dis-
appear despite continuation of therapy has been ex-
plained as a Herxheimer-like reaction, reflecting re-
lease of hepatotoxic mycotoxins and accompanying 
disappearance of the mycotic organism [20]. In 2 cas-
es from the literature [3,19] hepatic injury disap-
peared despite continuation of ketoconazole in the 
same, or a lower, dose but this may as well mean that 
another cause was responsible. Moreover a Jarisch-
Herxheimer reaction develops very early after start-
ing treatment but not after several weeks. High doses 
(121-139 mg/kg body weight) induced significant he-
patic injury fn several experimental species after 2-4 
weeks administration [21]. This high-dose hepatotox-
icity, however, is not relevant for the use of thera-
peutic amounts in man. Moreover acute overdosage 
(5.8 g) in an 18-year-old person had no measurable 
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effect on the liver [24] and we know of 1 case treated 
for several months with 1200 mg daily without liver 
enzyme elevations. Moreover clinical trials with 
daily doses up to 800 mg did not reveal a higher inci-
dence of liver enzyme elevations [25 ,26]. This ab-
sence of dose-dependency makes a direct toxic effect 
an unlikely mechanism in these cases. Lewis et a!. 
[21] suggested metabolic idiosyncrasy as a more like-
ly mechanism than hypersensitivity although they did 
not dismiss the possibility that the latter contributed 
in some cases. Indeed the uncommon hypersensitivi-
ty signs, variable latent period and absence of a more 
severe and immediate ( <48 h) response to rechal-
lenge are in favour of such a mechanism. Even the ac-
celerated reaction to rechallenge as seen in one of 
our cases and in the literature [1 ,6] does not necessar-
ily point at an immunoallergic reaction since it is like-
ly that, if the time between two treatment-periods is 
too short, an accumulated toxic intermediate has not 
been removed from the body completely and may 
lead to a more rapid relapse after rechallenge. A pos-
itive lymphocyte stimulation test [6] and immunoal-
lergic signs/symptoms in a small minority suggests 
that hypersensitivity may play an (additional?) role 
occasionally. 
We advise monitoring of liver enzymes during 
treatment with ketoconazole at weekly intervals for 
the first 2 months, especially since mild liver enzyme 
elevation during this period may normalize sponta-
neously but may as well progress to symptomatic liv-
er injury. Later, assessment every 2 weeks and after 
6 months monthly assessment of liver enzymes seems 
justified. 
Although ketoconazole is a very useful antimycot-
ic agent re-evaluation of its need for long-term treat-
ment of simple onychomycosis seems warranted. 
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SUMMARY 
Fifty cases of nitrofurantoin-associated and two cases of 
nifurtoinol (hydroxymethylnitrofurantoin)-associated hepa-
tic injury reported to the Netherlands Centre for Mon-
itoring of Adverse Reactions to Drugs were analysed in 
detail. In 38 cases a causal relationship was considered 
likely, i.e. 'highly probable' (n=4), 'probable' (n=23) or 
'possible' (n=ll). In 25 cases hepatic injury was of the 
acute type whereas 13 cases presented a chronic type of 
reaction. Both types were more common in the elderly. The 
female preponderance (89%) in this study largely reflected 
the higher incidence of urinary tract infections in this 
group. Eighty percent of the acute reactions appeared with-
in the first 6 weeks of treatment and these were sometimes 
accompanied by fever (28%), rash (12%) and eosinophilia 
(16%). Biochemically the pattern was mainly hepatocellular 
(32%), whereas mixed cholestatic-hepatocellular (4%) and 
cholestatic (4%) patterns were uncommon. Although mild to 
moderate liver enzyme elevations (60%) were common these 
were mostly symptomatic. The reaction was fatal in one 
'acute' and one 'chronic' case. In the chronic cases 
nuclear (82%) and smooth muscle (73%) antibodies and LE-
cells (50%) were frequently present. HLA typing showed no 
increase of the HLA B8 or HLA DRw3 haplotype. HLA DR2 (56%) 
and HLA DRw6 (56%) were more frequent than in controls 
(both 29%) , but this was not statistically significant. 
Histology showed mainly necrosis, varying from spotty to 
massive, in the acute cases and a pattern consistent with 
chronic active hepatitis in the chronic cases. The in-
cidence of symptomatic nitrofurantoin-induced hepatic in-
jury in The Netherlands may be estimated at approximately 
1:3000-5000 (0.020-0.035 %) . The mechanism of nitrofuran-
toin-induced hepatic injury seems to be immunoallergic. 
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Nitrofurantoin was introduced in the early fifties and 
proved to be an effective agent against infections of the 
lower urinary tract. Related furan derivatives, e.g. nitro-
furazone, nifuroxime and furazolidone, have been employed 
as topical or gastrointestinal antibacterials. Nitrofuran-
toin may rarely cause idiosyncratic (e.g. hemolysis in 
patients with a deficiency of G6PD, enolase or glutathione 
peroxidase) and immunoallergic reactions (e.g. fever, rash 
or acute pneumonitis). Other adverse effects, e.g. poly-
neuropathy, are based on a toxic mechanism in which cases 
the incidence depends upon dose, tissue level and renal 
function {1). Several cases of acute andjor chronic hepa-
titis have been attributed to use of nitrofurantoin (2-42), 
nifurtoinol {43) and furazolidone {16,44-49). Since these 
reports mostly consisted of single cases we studied 52 
cases of hepatic injury associated with the intake of 
nitrofurantoin (50 cases) or nifurtoinol {2 cases) as 
reported to the Netherlands Centre for Monitoring of Ad-
verse Reactions to Drugs (NARD) . Some of these cases have 
been described previously {9,29-31). 
MATERIALS AND METHODS 
Since 1963 the NARD receives reports of suspected adverse 
reactions to drugs from medical practitioners and sometimes 
from pharmacists through a nationwide voluntary reporting 
scheme. All reports of hepatic injury associated with the 
use of the urinary tract antibacterials nitrofurantoin and 
nifurtoinol (hydroxymethylnitrofurantoin), and received 
since 1963, were included in this study. All reports came 
from general practitioners or specialists. Of each report 
we requested full details about: age and sex of the 
patient, dose and duration of use, concomitantly used 
drugs, underlying illness (e.g.congestive heart failure, 
chronic liver disease), events preceding the onset of 
hepatic injury (e.g. operation, transfusions, hemodialy-
sis), all clinical signs and symptoms, biochemical test 
results, course and duration of hepatic injury, and the 
exclusion of other possible causes of hepatic injury (e.g. 
gallstones, hepatitis A and B, cytomegalovirus infection, 
infectious mononucleosis). We reviewed the original liver 
slides of patients who had undergone biopsy or on whom 
autopsy had been performed. A follow-up of all cases was 
done for two reasons: firstly, to exclude the possibility 
that another causative factor was present and secondly, to 
determine whether irreversible damage occurred. 
The clinical, biochemical and histological data were 
scrutinized and for each case the causal relationship 
between drug use and hepatic injury was assessed. The 
causal relationship was considered 'highly probable' when 
there was a well-documented reaction to (unintentional) 
rechallenge. If there was a compatible temporal relation-
ship with drug use in combination with well-documented 
exclusion of other possible causes, the causal relationship 
was considered 'probable'. When the temporal relationship 
was compatible but other causes were insufficiently exclu-
ded the causal relationship was considered 'possible'. If 
too few data were available or if more likely causes were 
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found, the causal relationship was considered •unclassi-
fiable' or 'unlikely' respectively. 
In 9 out of 13 chronic cases HLA typing was performed 
according to previously described methods (50,51). 
RESULTS 
In 10 cases the causal relationship was unclassifiable. 
Although it is not excluded that nitrofurantoin played a 
causative role in these cases, they were omitted because of 
a lack of data. In 4 cases a causal relationship was un-
likely. In one patient serum liver enzymes were already 
abnormal before use of nitrofurantoin. In two of these 4 
patients liver enzymes did not normalize after discontinu-
ation of nitrofurantoin (one patient had ulcerative coli-
tis) . The fourth patient probably had autoimmune chronic 
active hepatitis (CAH) . Table 1 presents the demographics, 
symptoms, biochemical patterns, immunological and protein 
test results, and temporal relationships of drug use to 
hepatic reactions in the 38 remaining cases in which a 
causal relationship was found to be 'highly probable', 
'probable' or 'possible'. Also included in this table is 
parallel information from 53 cases reported in the litera-
ture. 
CLINICAL AND BIOCHEMICAL PATTERN 
In 4 cases a causal relationship was considered 'highly 
probable' and in 23 'probable'. In 11 cases a causal rela-
tionship was 'possible'. Since some of the cases of the 
latter group may have had other causes we have separated 
the symptoms per group. 
The 27 'highly probable' and 'probable' cases (hereafter 
referred to as probable-group) were used to outline the 
clinical pattern (table 2). Most patients were female. The 
mean age in the probable-group was 64 years (range: 34-79) . 
All patients used nitrofurantoin or nifurtoinol because of 
urinary tract infections, often of a recurring or chronic 
type, but none of them had an impaired renal function as 
judged by serum urea or creatinine levels. In all cases the 
daily dose ranged from 100 to 400 mg. The majority (85%) of 
the chronic cases in the 'probable' group had a delay 
period of approximately 6 months or more of use before 
onset of symptoms. In the cases of acute hepatitis in this 
group, onset of symptoms occurred within the first 6 weeks 
of nitrofurantoin treatment in 86 %, and in approximately 
half, symptoms appeared within the first week of treatment. 
Jaundice was the most common symptom, followed by abdominal 
pain, malaise, nausea and anorexia (table 2). Hepatomegaly 
was present in 13 of the 23 cases in which presence or 
absence of this feature was clearly stated. None of the 
reports mentioned lymphadenopathy as a clinical feature and 
its absence was emphasized in 20 of 27 cases. Eosinophilia 
was present in five (20%) of 25 cases in which this sign 
was specified. Rash and fever were relatively uncommon. 
However, when only the acute cases in the 'probable' group 
were examined, eosinophilia was present in only 14%, rash 
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TABLE 1 
COMPARISON OF NARD-CASES WITH CASES FROM THE LITERATURE 
2-8, 11, 12, 14-18, 20-28, 32-43 
Literature This study* 
Acute (n = 17) Chronic (n = 36) Acute (n = 25) Chronic (n = 13) 
AGE 
< 20 years 12% 
3%] 
8% 0% 
21-40 18% 42  20% 0% 
41-60 58% 49 % (n=33) 20% 15% 
61-80 12% 6% 52% 85% 
SEX 
Female/Male 10/7 29/4 22/3 12/1 
SYMPTOMS/SIGNS 
Fever 65% 24% 28% 0% 
Rash 59% 3% 12% 0% 
Eosinophilia 47% 9% 16% 23% 
Jaundice 47% 64% 44% 77% 
Hepatomegaly 47% 36% 16% 62% 
Malaise 35% 52% 32% 69% 
Anorexia/weight loss 24% 27% (n=33) 12% 46% 
Myalgia/arthralgia 18% 18% 4% 0% 
Abdominal discomfort 18% 18% 24% 31% 
Pulmonary signs 18% 21% 12% 23% 
Nausea/vomiting 18% 9% 32% 31% 
Lymphadenopathy 12% 0% 0% 0% 
Fatal course 12% 12% (n=36) 4% 8% 
BIOCHEMICAL PATTERN** 
Liver enz. elevation 35% 
27%] 60% 8% Cholestatic 41% 3% 4% 0% 
Hepatocellular 18% 45 % (n =33) 32% 62% 
Mixed chol. -hepatoc. 6% 18% 4% 23% 
IMMUNOLOGY+ PROTEINS 
ANF 0% (n= 2) 81% (n=32) 25% (n= 4) 82% (n= 11) 
ASMA 71% (n=24) 0% (n= 2) 73% (n= 11) 
LE-cells 0% (n= 1) 14% (n= 7) 0% (n= 3) 50% (n= 6) 
Hypoalbuminemia 60% (n= 10) 72% (n = 25) 18% (n= 11) 67% (n= 12) 
Hypergammaglobulin. 29% (n= 7) 88% (n = 26) 0% (n= 12) 100% (n= 12) 
TIME-INTERVAL 
< 1 week 41% 0% 52% 0% 
1-6 weeks 47% 0% 28% 0% 
6 weeks-6 months 12% 8% 0% 15% 
> 6 months 0% 92% 4% 85% 
Undetermined 0% 0% 12% 0% 
Includes references 9, 29-31 
See legends figure 
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Fig. 1: Biochemical pattern in 27 probable cases. Numericals refer to biopsy 
numbers in text. Cases of pure cholestasis encircled. 
Liver enzyme elevation (alkaline phosphatase (APh) < 3 X normal, 
asparate/alanine aminotransferase (ASAT/ALAT) < 8 X normal, 
bilirubin < 2 X normal). 
11- Hepatocellular (APh < 3 X normal, ASAT/ALAT > 8 X normal). 
Ill Cholestatic hepatitis (APh > 3 X normal, ASAT/ALAT < 8 X normal). 
IV Mixed cholestatic-hepatocellular (APh > 3 X normal, 
ASAT/ALAT > 8 X normal). 
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TABLE 2 
SYMPTOMS/SIGNS of 27 'HIGHLY PROBABLE' 
and 'PROBABLE' cases of NITROFURANTOIN· 
ASSOCIATED HEPATIC INJURY 
Jaundice 16/27 (59%) 
Abdominal pain 11/27 (41 %) 
Malaise 10/27 (37%) 
Nausea/vomiting 10/27 (37%) 
Anorexia/weight loss 9/27 (33%) 
Dyspnoea/coughing 5/27 (19%) 
Pruritus 4/27 (15%) 
Fever 4/27 (15%) 
Rash 3/27 (11 %) 
Myalgia 1/27 ( 4%) 
Headache 1/27 ( 4%) 
Excessive perspiration 1/27 ( 4%) 
Tongue pain 1/27 ( 4%) 
No symptoms 3/27 (11 %) 
Hepatomegaly 13/23 (57%) 
Lymphadenopathy -/20 
Eosinophilia 5/25 (20%) 
Fatal course 1/27 ( 4%) 
ALAT >ASAT 61/97 (63%) 
TABLE 3 
HISTOLOGICAL PATTERNS of HEPATIC INJURY in 19 'PROBABLE' and 'POSSIBLE' 
CASES STUDIED by the AUTHORS and COMPARED to CASES in the LITERATURE 
Total 
Predominating pattern• Probable Possible 
This study Literature 
(n= 19) (n=44) 
ACUTE 
Cholestasis 5,27 20 16% 7% 
Necrosis 47% 18% 
'spotty' 36 6 
centrilobular/bridging 15, 32, 34, 
40,48,51 
massive 13 
CHRONIC 
Chronic active hepatitis 32% 57% 
without early cirrhosis 16,25,44 
with early cirrhosis 21,49,50 
Cirrhosis 2% 
MISCELLANEOUS 
Steatosis 2% 
Granulomas 7% 
Undetermined 18 5% 
Normal 7% 
Total 16 3 100% 100% 
*) Numericals in bold printing refer to the NARD no. of the cases in the study 
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in 21%, and fever in 29 percent. The biochemical pattern of 
the probable cases was hepatocellular in almost 50 percent 
(figure 1). One patient died secondary to hepatic failure, 
after prolonged treatment with nitrofurantoin. A follow-up 
revealed that 4 other patients had died due to causes 
unrelated to liver disease. 
Clinical features in the possible-group were largely si-
milar to those in the probable-group but mild to moderate 
liver enzyme elevations were more common in the possible-
group (73 %). Only one patient in the possible-group had no 
symptoms. One patient in this group died secondary to mas-
sive necrosis. 
In 63 percent of probable-cases other drugs had been 
used, mostly cardiovascular agents. None of the other 
drugs, however, was causative. Either the intake of these 
drugs was temporarily unrelated to the onset of hepatic 
injury or they were continued without problems. In one 
patient with cholestasis (no.27), both nitrofurantoin and 
oral contraceptives were discontinued; a rechallenge with 
nitrofurantoin alone was positive. In the possible-group 
other drugs may have played a causative role in three cases 
(methyldopa, sulfamethizole and an analgesic mixture). 
HLA Typing 
With the exception of two antigen types no differences 
were found between these patients (n=9) and a control group 
of healthy donors of blood from The Netherlands (n=505). 
HLA DR2 and HLA DRw6 were each present in 5 of our 9 
patients (56%) with chronic liver damage whereas the 
incidence was 29 percent in the group of controls. The 
combination of HLA DR2 and HLA DRw6 was present in 3 of 9 
patients (33%) as against 8 percent in the control-group. 
These differences, however, were not statistically 
significant. 
HISTOPATHOLOGY 
A biopsy or autopsy had been performed in 21 patients. On 
our request slides of liver tissue from these patients were 
submitted for review. In 2 cases a causal relationship with 
use of nitrofurantoin was considered •unlikely' and these 
are not discussed here. Of the remaining 19 cases, 16 con-
sisted of a 'probable' and 3 of a 'possible' causal rela-
tionship (see table 3). All slides had been stained with 
hematoxylin-eosin and most series included periodic acid 
Schiff (PAS) with and without diastase, staining for iron 
(Perls or Turnbull) and trichrome staining (Azan or van 
Giesen). 
Cholestasis 
In two 'probable' and one 'possible' case the pattern was 
predominantly cholestatic. Whereas in the latter case the 
pattern was that of 'pure' cholestasis, the two 'probable' 
cases showed some portal infiltration and an occasional 
area of intralobular spotty infiltration without or with 
minimal necrosis. In both cases there was marked chole-
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Fig.2: 
Fig.3: 
(HE 500x) Case 27. Cholestasis; centrilobular area 
with bile plugging (arrows) and cellular degenera-
tion (by courtesy of Dr.Elias) 
(HE 125x) Case 36. 'Spotty' necrosis with areas of 
ballooning and marked anisokaryosis (by courtesy 
of Professor D.J.Ruiter) 
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Fig.4: 
Fig.5: 
(HE 125x) Case 34. Bridging necrosis (by courtesy 
of Dr.B.Kazzaz) 
(HE 320x) Case 51. Ballooning and acidophilic de-
generation. On the right a bile duct surrounded by 
mononuclear cells and neutrophils 
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Fig.6: (HE 320x) Case 50. Chronic active hepatitis; ex-
panded portal area with piecemeal necrosis (by 
courtesy of Dr.J.Grond) 
TABLE 4 
COMPARISON of CASES of HEPATIC INJURY to FURADANTINE® (n = 34) 
with PRESCRIPTION FIGURES as regards AGE and SEX 
FEMALE 
Incidence Prescription 
AGE 
0-19 years 2.9% 13.5% 
20-39 years 8.8% 20.8% 
40-64 years 29.4% 20.9% 
> 64 years 47 % 18.4% 
88.1% 73.6% 
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MALE 
Incidence Prescription 
11.8% 
11.8% 
2.3% 
6.2% 
10.2% 
7.2% 
25.9% 
stasis with, often large, bile plugs in zones II and III. 
Infiltration was predominantly lymphocytic. The lobular 
architecture was preserved. 
Spotty necrosis 
Case 6 showed a pattern of non-specific reactive hepa-
titis with minimal changes, with some Kupffer cell hyper-
plasia and an occasional spotty area of infiltration. More 
extensive, but nevertheless relatively mild, changes were 
present in case no.36 with several foci of necrosis 
surrounded by lymphocytes and Kupffer cells and minimal 
cholestasis. Lobular architecture was preserved in this 
case. 
Centrilobularjbridgingjmassive necrosis 
In 4 'probable' cases necrosis was not diffusely panlo-
bular but predominantly centrilobular, mostly with bridging 
(no.l5, 32, 40 and 48). The presence of periportal fibrosis 
without piecemeal necrosis - in three of these (no.l5, 40 
and 48) suggested that there had been a prolonged course or 
that these patients had had several relapses. High serum 
levels of gamma-globulin and low levels of albumin in two 
of these 3 patients were suggestive of some form of chronic 
hepatitis. Case 34 showed both areas of spotty necrosis and 
areas with mainly centrilobular necrosis with central-
central bridging and case 51 combined many acidophilic 
bodies in zones I-III with a few areas of bridge formation. 
Most biopsies showed minimal to mild cholestasis with some 
bilirubin in hepatocytes and occasional bile plugs. Four 
biopsies showed bile duct multiplication with signs of 
cholangiolitis. Although portal and lobular infiltration 
was mostly mononuclear with a predominance of lymphocytes, 
infiltration in areas surrounding bile ducts included many 
neutrophils. In patient 34 there were many eosinophils in 
the portal areas. Remarkable was a pattern of extensive 
steatosis in the control biopsy of case 32. This biopsy had 
been taken 2 months after a first biopsy which showed only 
minimal fatty degeneration. This patient had not been 
treated with corticosteroids, denied abuse of alcohol and 
had no underlying conditions which could explain this 
feature (e.g.diabetes mellitus, obesity). In one 'possible' 
case, necrosis varied from submassive with surviving 
hepatocytes in zone I, to massive with large areas of 
collapse, filled with cell debris and erythrocytes. 
Chronic active hepatitis 
Six 'probable' cases demonstrated either a pattern of 
chronic active hepatitis or a pattern suggesting that 
chronic active hepatitis had been present before discon-
tinuation of nitrofurantoin, several weeks earlier. In 
cases 16 and 21, besides expanded densily infiltrated 
portal tracts with a predominantly mononuclear infiltrate 
and conspicuous piecemeal necrosis, there was ballooning 
degeneration of hepatocytes in zones II and III. There was 
cell-dropout and acidophilic degeneration with bridging 
necrosis in case 16. In case 21 this was also present but 
only during the second episode after accidental rechal-
102 
lenge. In cases 21,49 and 50 the biopsy was suggestive of 
beginning cirrhosis. In case 49 this was confirmed by 
laparoscopy. In cases 25 and 44 biopsy was performed 1.5-3 
months after discontinuation of nitrofurantoin. At that 
time piecemeal necrosis was absent but expanded portal 
tracts with star-shaped periportal fibrosis suggested 
healed periportal necrosis. Mo.st biopsies showed varying 
degrees of bile duct multiplication with infiltration of 
neutrophils. In case 44 there were relatively many eosino-
phils in the portal tracts. 
DISCUSSION 
Several histological types of hepatic injury have been 
attributed to the intake of nitrofurantoin. An association 
with focal nodular hyperplasia has been suggested (52) but 
this has not been confirmed and remains somewhat specula-
tive. Sometimes symptoms may falsely suggest liver disease. 
Nitrofurantoin may cause jaundice by hemolysis (l). Some 
patients demonstrate brownish discolouration of urine which 
is caused by high urinary concentrations. of the drug (53) 
and a history of dark urine may falsely suggest biliru-
binuria and severe liver damage. This was indeed the case 
in two of our patients in whom mild liver enzyme elevations 
were accompanied by normal or near-normal serum bilirubin 
levels. Occasionally acute pancreatitis due to nitrofuran-
toin may cause extrahepatic bile duct obstruction by edema 
of the head of the pancreas and mimic gallstone disease 
(54). These causes, however, are usually easy to exclude by 
laboratory assessment and imaging procedures. 
In this study of 52 reports of hepatic injury associated 
with use of nitrofurantoin or nifurtoinol, 38 cases were 
considered to be 'possibly' or 'probably' related to the 
intake of the suspected drug. In order to outline the cli-
nicopathological pattern these two groups were presented 
separately since in the former other causes may have been 
responsible. In the 'probable'-group, cases were either 
proven by a positive reaction to rechallenge or other 
causes, such as hepatitis A, hepatitis B, cytomegalovirus 
infection, infectious mononucleosis and gallstones were 
excluded. In none of these patients was cardiac failure, 
sepsis or malignancy demonstrated and no transfusions or 
operations had preceded the onset of hepatic injury. Under-
lying liver disease (e.g.alcoholic liver disease, primary 
biliary cirrhosis, autoimmune or viral chronic active. he-
patitis) was unlikely considering the uneventful follow-up 
after discontinuation of nitrofurantoin in these cases for 
periods up to 10 years. We compared the 38 'possible' and 
'probable' cases with cases reported in the medical litera-
ture distinguishing between acute and chronic cases (Table 
1) . The existence of an intermediate form is suggested by 
the abnormal values for serum proteins in some of the acute 
cases in our study and in the literature (4,14). 
Table 1 shows some interesting features. Going by the 
literature, nitrofurantoin-associated chronic liver disease 
seems to be far more common than acute liver injury. cases 
of nitrofurantoin-associated hepatic injury have randomly 
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been reported in the literature from several countries all 
over the world. Since acceptance for publication in a me-
dical journal depends on several unknown factors, these 
numbers may give an unreliable picture of the relative 
incidence of acute versus chronic liver reactions. This 
problem is probably less serious with a national voluntary 
reporting system since it is unlikely that medical doctors 
in a particular country prefer to report acute instead of 
chronic liver reactions. Despite the fact that chronic 
liver injury may have an insidious course and remain un-
recognized, we believe that our figures indicate that the 
acute type is more common. 
our study shows a female preponderance of 89 percent. 
This is higher than the sex-related prescription rate in 
women in The Netherlands (femalejmale: 74/26 percent) (Dr T 
Stempels, Dr Brandt Rowles, Norwich Eaton Pharmaceuticals 
Inc,Personal Communication 1987). Although this difference 
is relatively small it possibly indicates that women are 
more likely to develop this adverse effect since we are not 
aware of any convincing reason for a preference to diagnose 
and report cases of drug-induced hepatic injury in this 
group. Sixty-three percent of our patients were 61 years or 
older as against 40 percent in the literature. We compared 
the incidence of hepatic injury in our study with the age-
related prescription data in The Netherlands (table 4). 
Under the age of forty years the reporting rate of hepatic 
injury to nitrofurantoin was lower than the prescription 
rate whereas there was a sharp increase in the number of 
cases in the elderly, especially those older than 64 years. 
Of diagnostic importance is the fact that whereas in our 
chronic cases (mean age 69 years; range:54-79) the clinico-
pathological pattern was very similar to autoimmune CAH, 
the latter is mostly diagnosed in young female (mean age 
ranging in several studies from 30-46 years (55)). 
The high incidence of fever (65 %), rash (59%) and 
eosinophilia (47 %) in the acute cases, described in the 
medical literature, is at variance with the incidences in 
our study of 28 %, 12 % and 16 % respectively. We have no 
explanation for this difference but think that the high 
figures are an overrepresentation. Perhaps it is caused by 
a preference to publish cases accompanied by hypersensi-
tivity signs, for instance because the first cases - which 
were accompanied by rash, eosinophilia and fever - stimu-
lated the description of similar cases or because concomi-
tant signs of hypersensitivity leave less doubt about a 
causal relationship. 
The prognosis of nitrofurantoin-associated chronic hepa-
tic injury seems to be good unless the intake of nitro-
furantoin is continued despite the appearance of sympto-
matic hepatic injury. In that case the course may be fatal 
(27,40). Occasionally, however, hepatic injury may have a 
fatal course despite discontinuation of nitrofurantoin as 
is demonstrated by our case no.l4 and by one case from the 
literature (26) . In both cases hepatic failure developed in 
one to three years after discontinuation of nitrofurantoin. 
In the acute cases the patients usually recovered within 
1-3 months following discontinuation. In the chronic cases 
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recovery usually took longer but the majority of patients 
recovered without use of corticosteroids. In 2 of our 
cases, however, there were signs of irreversible - albeit 
not life-threatening damage and also several other re-
ports describe irreversible damage (25-28). Moreover, since 
a control biopsy was performed in a minority of chronic 
cases, it is possible that even in the cases with normal 
liver enzymes mild post-necrotic scarring may be present. 
One of the weak points in the establishment of a diagnosis 
is that hepatic injury is considered to have another cause 
when discontinuation of the suspected drug is not followed 
by recovery. In one of our 52 cases we came to the conclu-
sion that autoimmune CAH was the more likely diagnosis 
since a pattern of chronic active hepatitis, accompanied by 
autoantibodies, was still present 5 years after discontinu-
ation. Nevertheless it seems possible (but difficult to 
prove) that some drugs induce a pattern of continuing chro-
nic active hepatitis despite discontinuation of their in-
take. 
Most literature cases concern either acute cholestatic 
hepatitis or CAH, whereas our study suggest that acute 
symptomatic hepatocellular injury and mild to moderate 
liver enzyme elevations are more common. In the chronic 
cases antinuclear and smooth muscle antibodies were mostly 
present. Antimitochondrial antibodies were absent in all 
assessed chronic cases in the literature (n=9) and in our 
study (n=9). One of four assessed chronic cases in our 
study had antibodies against double-stranded DNA but this 
was not reported in the cases from the literature. Remar-
kable is the high incidence of LE-cells in the chronic 
cases of our study (50%), which is much higher than the 
incidence reported in the literature (14%). It should be 
emphasized, however, that only 6 patients have been tested. 
It has been suggested that nitrofurantoin-induced CAH is 
associated with the HLA B8 haplotype (25,26). In order to 
test this hypothesis we obtained blood from 9 of our 13 
patients with chronic liver injury. In our patients HLA B8 
was not more frequent than in a control population (33% vs 
23%). Although in our cases HLA DR2 and HLA DRw6 were -
separately (56 %) as well as in combination (33%) - more 
frequent than in a control group (29% vs 8%), this dif-
ference was not significant when a correction was made for 
the number of assessed HLA groups. Mackay et al. found a 
marked increase of the HLA B8 and HLA DRw3 haplotype in 
cases of autoimmune CAH (56). The fact that these haplo-
types were not increased in our cases suggests that HLA 
typing may help in differentiating autoimmune from 
nitrofurantoin-induced CAH. 
Some histological features are of interest. Many of our 
cases showed cholangiolitis. Berry et al. (36) reported 
invasion of bile ducts by neutrophils and in a case des-
cribed by Jokela the second biopsy showed bile duct pro-
liferation and cholangitis (4). In the case described by 
Gonzalez et al. (3) cholangiolitis predominated. Some other 
cases with bile duct proliferation and portal infiltration 
with neutrophils suggest that perhaps (mild ?) cholangio-
litis may have been present in some cases (2,21,24,27). 
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Interesting is the fatty change of hepatocytes in some of 
our patients during the recovery phase. It is known that 
corticosteroids may induce steatosis but none of our 
patients had received such agents. Several literature 
reports also refer to steatosis (2,4,6,14,22,24,37,45) and 
in some of these fatty change is especially reported in the 
second (control) biopsy (2,14). Burns et al (13,14) repor-
ted cytoplasmic crystalline regions in hepatocytes but 
emphasized that this feature is not specific. 
The incidence of hepatic injury due to n~trofurantoin is 
difficult to estimate. In a study of 15000 patients admit-
ted to hospital 55 were found to have drug-induced hepatic 
injury. Twenty percent of them had used nitrofurantoin (in-
cidence: 0.00073 %) but mostly in combination with other 
potential hepatotoxins (10). Another study in outpatients 
found an incidence of drug-induced liver disease of 
1:100000 person-years but no nitrofurantoin-induced cases 
were reported in this series (57). In a recent survey of 
manufacturers data, D'Arcy estimated the incidence of 
hepatic adverse effects at 0.0003 % of courses of therapy 
with nitrofurantoin (58). Based on the estimated sales 
figures in The Netherlands during a ten-year period 
(1977-1986) (Dr T Stempels, Dr Brandt Rowles, Norwich Eaton 
Pharmaceuticals Inc, Personal Communication 1987), we think 
that the incidence may be higher. With an approximated 
ratio of 9:1 for the incidence of acute versus chronic 
infections of the lower urinary tract (Dr JAP Hooykaas, 
Personal Communication 1987), a mean treatment period of 10 
days (400 mgjday) and 6 months (100 mgjday) respectively, 
and an estimated mean of 3-5 acute urinary tract infections 
during a ten-year period (based on ref 59), we come to a 
denominator varying between 889160 and 1114445 treated 
individuals and a numerator varying between 23 (probable) 
and 32 (probable+possible) symptomatic cases during 
1977-1986. We have to correct, however, for the large 
underreporting of adverse reactions which has been 
estimated in the United Kingdom at approximately 80-90 
percent of serious reactions (60). This would suggest that 
the incidence of symptomatic nitrofurantoin-induced hepatic 
injury may be approximately 0.020-0.035 percent. We 
emphasize, however, that our calculation is based on 
estimated figures and may not reflect the actual situation. 
Moreover the reporting rate will differ per drug and per 
adverse effect (61). On the other hand it is important to 
realize that the reporting rate in The Netherlands is much 
lower than in the United Kingdom (62). 
The mechanism of nitrofurantoin-induced hepatic injury is 
either immunoallergic or secondary to metabolic idiosyncra-
sy. Direct toxicity is unlikely since the reaction does not 
seem to be dose-dependent and appears to be relatively rare 
and unpredictable. According to a review (63) nitrofuran-
toin caused fatty change in cats and necrosis in hamsters 
but no liver damage in mice, rats and dogs. Mice on 40 
mgjkgjday during 6 months, however, showed hepatocellular 
degeneration, vacuolated hepatocytes and portal lymphocytic 
infiltration, mainly surrounding bile ducts (64). In tur-
keys on furazolidone there was bile duct hyperplasia, 
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portal fibrosis and hepatocellular vacuolisation (65). 
Experiments in rats with furfural, which is a related 
furan-derivative, showed cirrhosis (66). These data are, 
however, difficult to extrapolate to the human situation 
because of species-related differences and the use of high 
doses in animal toxicity studies. with one exception none 
of our cases had renal function impairment and - unlike 
peripheral neuropathy, which is clearly a toxic adverse 
effect of nitrofurantoin we do not think that kidney 
function has any consequences as regards liyer injury. In 
our opinion immunoallergy is a more likely mechanism than 
metabolic idiosyncrasy. The acute reactions appear almost 
invariably within the first six weeks of therapy, and there 
is an accelerated reaction to rechallenge in our acute 
cases as well as in the literature (2,4,14). In those cases 
where hepatic injury emerged after 2-3 days of therapy the 
drug had been used before without apparent complaints. That 
low amounts of nitrofurantoin may cause hepatic injury in 
hypersensitive individuals is suggested by a case in which 
ingestion of milk from a nitrofurantoin-treated cow was 
followed by liver damage (36). In support of an immuno-
logically-mediated reaction is a case with apparent cross-
sensitivity to furazolidone and nifuroxime (16). Also the 
simultaneous occurrence of rash, fever and eosinophilia may 
be regarded as circumstantial evidence of a hypersensiti-
vity reaction. These signs are less frequent in cases of 
chronic liver injury but here the high incidence of auto-
antibodies suggests an immunoallergic mechanism. This is 
compatible with the clinical and histological similarity to 
autoimmune chronic active hepatitis. Sensitization by re-
peated use of nitrofurantoin as therapeutic agent or as a 
veterinary contaminant (36) is a likely explanation of a 
higher incidence in the elderly although a higher vulner-
ability of an ageing liver can not be excluded (67). 
Lymphocyte stimulation testing performed in six cases was 
negative in two (28,31) but positive in four cases 
(11,15,28). In rat mitochondria nitrofurantoin is reduced 
to nitro anion radicals followed by autoxidation to 
superoxide anions (68) and inhibition of mitochondrial 
respiration (69). Possibly an immunological reaction is 
involved, directed against cellular components which are 
structurally altered by these radicals either covalently or 
by lipid peroxidation. If so, it seems plausible that 
either acute hepatitis or chronic active hepatitis ensues, 
depending on the ferocity of the immunological reaction. In 
chronic cases, however, it is not excluded that nitrofuran-
toin by direct interference with the immunesystem -
facilitates the appearance of autoimmune CAH in susceptible 
persons. 
When compared to the chronic pulmonary and chronic hepa-
tic adverse effects of nitrofurantoin the acute reactions 
seem to be relatively innocuous. These are usually easily 
recognized and may lead to discontinuation in an early 
stage. Longterm use of nitrofurantoin should be discouraged 
unless the patient is kept under regular medical super-
vision. 
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Summary 
Four cases of hepatic injury attributed to the use of pirprofen (Rengasii) were reported to the Monitoring 
Centres for Adverse Reactions of Belgium, The Netherlands and the German Medical Association. One man 
and three women developed severe hepatic injury between 3Vz and 6Vz months after starting treatment with 
400-1200 mg pirprofen daily. 
Histology showed acute hepatocellular damage, often with bridging necrosis. Two patients died. The other 
two patients made an incomplete recovery. It is possible that this severe type of hepatic injury is due to a metabol-
ic idiosyncrasy to pirprofen, as this reaction seems to be rare and unpredictable but is not associated with immu-
noallergic signs. 
Introduction 
Pirprofen, a phenylpropionic acid derivative, is a 
new non-steroidal antiinflammatory drug. The inci-
dence of raised liver enzymes in patients using pir-
profen is low for this type of drug and ranges from 
0.6% [1] to 2.8% [2-4]. 
Symptomatic liver injury attributed to pirprofen 
has, however, recently been reported [5,6,10]. We 
describe four additional patients with severe liver in-
jury probably caused by pirprofen, two of whom 
died. 
Case Reports 
Case I 
A 75-year-old nun, living in a convent, was ad-
mitted on 1 August, 1985 because of weakness and 
jaundice. She complained of anorexia and weight 
loss of two weeks duration, without fever or abdomi-
nal pain. There was no history of alcohol abuse, he-
patitis contact, operations, transfusions or travel to 
tropical areas. Since 1983 she had been taken 50 mg 
of triamterene and 4 mg of epitizide on alternate days 
and occasionally 10 mg of oxazepam as a sedative. 
Correspondence address: B.H.Ch. Stricker, Medical Officer, Netherlands Centre for Monitoring of Adverse Reactions to Drugs, 
P.O. Box 439, Leidschendam, The Netherlands. 
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From 27 March, 1985 she had taken 400-1200 mg 
of pirprofen daily because of osteoarthritis. Physical 
examination revealed jaundice. There was no fever, 
lymphadenopathy or hepatosplenomegaly. Erythe-
ma palmare, spider naevi, ascites or other signs of 
chronic liver disease were absent. 
Laboratory results included a normal blood and 
differential count, normal renal function and normal 
values for serum amylase and lipase. On repeated 
testing, abnormal biochemical liver tests were ob-
tained with the following maximal values (normal 
values in brackets): aspartate aminotransferase 
(ASAT) 435 U/1 ( < 30), alanine aminotransferase 
(ALAT) 655 U/1 (< 30), alkaline phosphatase (APh) 
167 U/1 (< 100), total bilirubin 226.3,umol/l (< 17), 
conjugated bilirubin 146.2,umol/l ( < 5), total protein 
54 g/1 (65-80) and albumin 54% (50-65). The partial 
thromboplastin time was 71 s (30-40) and the 
Thrombotest (Nyegaard) was 14% (80-100%). Se-
W.W. DE HERDER et al. 
rologic tests for hepatitis A and B, infectious mono-
nucleosis, cytomegalovirus, toxoplasmosis, herpes 
simplex, Q fever and syphilis were negative. Slightly 
dilated intrahepatic bile ducts were seen by ultraso-
nography but endoscopic retrograde cholangiopan-
creatography showed normal bile ducts, a normal 
pancreatic duct and a normal gall-bladder. Esopha-
geal varices were not seen during endoscopy. All 
drugs were discontinued on admission. 
She gradually developed a bleeding tendency and 
bilateral leg oedema, and ascites despite treatment 
with diuretics. Peritoneoscopy showed ascites and a 
pale liver with a granular surface was seen. A liver 
biopsy showed extensive bridging necrosis and hepa-
tocyte ballooning, the latter mainly in zones I and II. 
Early fibrosis was present, especially in the expanded 
portal areas. Infiltration was mixed lymphocytic-
neutrophilic, with a predominance of the mononu-
clear cells. Cholestasis was absent (Fig. 1). The pa-
Fig. 1. Portal-central and central-central bridging necrosis with ballooning and acidophilic degeneration in zones I and II; mainly lym-
phocytic infiltration. HE, x 100. 
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tient's condition deteriorated. She became comatose 
and died 44 days after admission. Permission for 
postmortem examination was not given. 
Case2 
A 62-year-old woman was admitted on 17 Septem-
ber, 1985. For three weeks she had had abdominal 
discomfort, nausea and low-grade fever. One day be-
fore admission she became jaundiced. She had been 
treated since February 1985 with 400 mg of pirprofen 
daily because of osteoarthritis. Four days before ad-
mission this medication had been changed to 10 mg of 
piroxicam daily because of the abdominal discom-
fort. No other drug had been used. There was no his-
tory of transfusions, operation, chronic liver disease, 
alcohol abuse or hepatitis contact. Physical examina-
tion was unremarkable except for jaundice and hepa-
tomegaly. There was no ascites, erythema palmare 
or other signs of chronic liver disease and no lympha-
denopathy or splenomegaly. Laboratory data in-
eluded a normal blood and differential count and a 
normal renal function. Abnormal serum values were 
ASAT 571 U/1 (< 15), ALAT645 U/1 (< 19), APh 376 
U/1 (< 170), gamma-GT 288 U/1 (< 18), bilirubin to-
tal/conjugated 16.5/12.4 mg/dl ( < 110.25) and pro-
thrombin level: 50% (70-130% ). Serologic tests for 
hepatitis A and B, infectious mononucleosis and cy-
tomegalovirus were repeatedly negative. Antinu-
clear and antimitochondrial antibodies were absent. 
Piroxicam was discontinued on admission. Repeated 
ultrasonographic imaging showed cholecystolithiasis 
without signs of biliary obstruction. 
Follow-up examinations showed a decrease in liver 
size. 
Whereas serum values for ALAT and ASAT slow-
ly decreased, .total bilirubin increased to a peak of 
19.4 mg/dl on 1 October. The serum prothrombin 
level decreased to 20% of normal despite parenteral 
administration of vitamin K. The arterial ammonia 
was 110 ,ug/dl ( < 82) and she was treated with lactu-
Fig. 2. Massive necrosis with some areas of bile duct proliferation; lymphocytic infiltration. HE, X 100. 
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lose and parenteral nutrition. Diuretics were given 
for peripheral oedema. A liver biopsy on 19 Novem-
ber showed submassive to massive necrosis with ex-
tensive bridging and occasional small islands of intact 
hepatocytes. Infiltration was mononuclear. There 
was early diffuse fibrosis and periportal bile duct pro-
liferation (Fig. 2). She made a slow but incomplete 
recovery and was discharged on 20 December. At 
that time serum aminotransferases were normal. To-
tal bilirubin was 2.3 mg/dl and total protein 63 g/1. 
The serum prothrombin level was still abnormal on 
25 March (60%). 
Case3 
A 58-year-old woman was admitted in February 
1985 because of jaundice. She had been treated with 
0.2 mg of thyroxine daily for primary hypothyroidism 
since February 1984 and with 10 mg of flunarizine 
daily since June 1979 because of peripheral cold hy-
persensitivity. Because of osteoarthritis she had tak-
en 800 mg of pirpro~en daily since July 1984. There 
was no history of transfusions, recent operation, he-
patitis contacts, alcohol abuse or chronic liver dis-
ease. On examination she was found to be jaundiced. 
There was no lymphadenopathy or splenomegaly. 
Signs of chronic liver disease such as erythema pal-
mare or spider naevi were absent. Laboratory data, 
including a blood and differential count, were normal 
except for serum ASAT 916 U/1 (< 40), ALAT 431 
U/1 ( < 40), APh 876 U/1 ( < 115) and total bilirubin 
30.8 mg/dl ( < 1). Serology was negative for hepatitis 
A and B, coxsackie B, chickenpox, herpes- and cyto-
megalovirus. Antimitochondrial and smooth muscle 
antibodies were absent. Antinuclear factor was pres-
ent in low titre (1/40 immunofluorescence) as were 
antibodies to DNA: 39 U/ml (normal value < 25). 
Endoscopic retrograde cholangiopancreatography 
demonstrated normal bile ducts, gall-bladder and 
pancreatic ducts. Liver biopsy showed expanded por-
tal areas with inflammatory infiltration. The infil-
trate was mostly mononuclear. Periportal 'piece-
meal' necrosis and mild cholestasis were present. In 
the lobules, signs of regeneration were found with 
mitosis in the hepatocytes. 
Initially the cause of this hepatocellular type of liv-
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er injury was considered to be viral but later pirpro-
fen was suspected. This drug had been discontinued 
on admission. There was a progressive but slow nor-
malization of serum bilirubin and aminotransferases 
after discontinuation of pirprofen. One year later 
laboratory values had almost normalized. 
Thyroxine was continued. Flunarizine was consi-
dered unlikely to be the cause of hepatitis as the labo-
ratory values were already significantly improving by 
the time flunarizine was discontinued on 1 March. 
Case4 
A 26-year-old male student was admitted in March 
1985 with nausea and jaundice. He had ingested pir-
profen irregularly and in unknown quantities since 
November 1984 because of psoriatic arthritis. In the 
first days of March he had discontinued pirprofen, 
presumably because of nausea. On admission serum 
aminotransferases and bilirubin were markedly ele-
vated. Hepatitis A and B, cytomegalovirus disease 
and infectious mononucleosis were excluded serolo-
gically. The patient developed hepatic coma and died 
at the end of Apri11985. 
Discussion 
The absence of other demonstrable causes and a 
compatible temporal relationship make pirprofen a 
probable cause of the liver damage in these four pa-
tients [7]. There was no history of excessive alcohol 
intake or signs of underlying liver disease and histolo-
gy confirmed the acute, non-alcoholic type of liver in-
jury. Hepatitis A, hepatitis B and cytomegalovirus 
infection were serologically excluded in four and in-
fectious mononucleosis in three of our patients. Since 
no transfusions, injections or recent operation pre-
ceded the illness and since there was no hepatitis con-
tact, non A non B viral hepatitis seems unlikely as a 
cause. Also concomitant medication does not seem 
to have played a causative role. Of the other drugs 
used, only piroxicam has been associated with liver 
injury [7-9] but patient 2 had changed to this drug a 
few days before admission, at a time when she al-
ready had symptoms of acute hepatitis. In patient 3 
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flunarizine was discontinued when laboratory values 
were already improving. Oxazepam and epitizide be-
long to therapeutic classes which rarely have been as-
sociated with hepatic injury [7]. These drugs had 
moreover already been used by patient 1 for two 
years without adverse effects. The rate of recovery 
was slow in the two surviving patients described by 
us, and it is possible that progression to post-necrotic 
scarring or even cirrhosis has occurred, since even af-
ter one year of follow-up liver enzymes were still mild-
ly abnormal. 
The temporal relationship between starting treat-
ment with pirprofen and the appearance of the first 
symptoms varied from 3lfz to 6lfz months, which is 
comparable with the 3-9 months found in other re-
ports [5,6,10]. Only in one case-report [10] onset was 
within 6 weeks after starting treatment with pirpro-
fen but in that case ajmaline had been used concur-
rently since 1 week. Three of our patients were wo-
men over 50 years of age, as were most patients in the 
other reports [5,6,10]. A more frequent use of non-
steroidal antiinflammatory drugs by this age group 
possibly explains this preponderance. In our opinion 
the number of cases is too small to decide whether 
women are more likely to develop pirprofen-asso-
ciated hepatic injury than men. 
Biochemically and histologically, the pattern of 
liver damage was mainly hepatocellular and was se-
vere in all 14 reported cases. Four patients died. He-
patocellular necrosis, predominating in zone III and 
often with collapse, was prominent in all patients in 
whom a biopsy was done [5,6,10] and may be exten-
sive [6]. In one patient the pattern resembled chronic 
active hepatitis [5]. We did not find microvesicular 
steatosis, as described by Danan eta!. [6], in any of 
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Chapter 12 
SUMMARIZING DISCUSSION 
There were three reasons to perform these studies. First-
ly, the aim was to demonstrate that, apart from the gene-
ration of signals concerning unknown adverse reactions to 
drugs, a voluntary reporting scheme may be used for in-
depth studies. Although the former remains the most impor-
tant aim of the scheme, it is clear that important additi-
onal information can be obtained with series of cases. A 
good example is the study of Inman and Mushin of 170 re-
ports to the Committee on Safety of Medicines of halothane-
associated jaundice (1). They elegantly demonstrated that 
most cases of halothane-associated jaundice occurred after 
multiple exposure and that in these cases the delay period 
between administration of halothane and onset of hepatic 
injury was reduced. Another successful example of studying 
series of cases, as reported to a national adverse reaction 
monitoring centre, is described in the paper on 57 cases of 
glibenclamide-associated hypoglycaemia (2). If only the 
alerting function of a voluntary reporting scheme would be 
of importance only a few well-documented cases of a par-
ticular adverse effect would be enough. Because of under-
reporting and the absence of sales data the only use of 
subsequent cases would be to get a rough estimate of the 
incidence. Secondly, one of the objectives was to show that 
"Intensive Case Monitoring" can also be performed with 
cases from other countries. Thirdly, the clinical and his-
tological patterns of hepatic injury induced by glafenine 
(Glifanan), ketoconazole (Nizoral), and nitrofurantoin (Fu-
radantine, Ceduran, Furophen Tc)jnifurtoinol (Urfadyn, Uri-
durine) were characterized. Starting with the third reason 
for performing the studies, discussion here will be 
restricted to common features since the clinicopathological 
patterns of these drugs have been reviewed extensively in 
Chapters 8-11. 
It is impossible to outline the clinicopathological 
pattern of a particular adverse effect without making a 
selection of cases in which a causal relationship with drug 
use is probable. The reason for this is that cases in which 
a causal relationship is 'unclassified' or 'possible' may 
have had an other cause. Especially the 'unclassified' 
cases can not be used because of scanty documentation. In 
the 'possible' cases documentation is usually relatively 
good but in these cases either another concomitantly used 
drug may have been responsible or another common cause has 
not been excluded. 
Whereas the literature on glafenine-associated hepatic 
injury suggested a pattern varying from mild/moderate liver 
enzyme elevations to a mixed cholestatic-hepatocellular 
pattern of injury, the study in this thesis (Chapter 8) 
showed a predominance of hepatocellular damage with a high 
case-fatality rate. The clinicopathological pattern showed 
a remarkable resemblance to hepatic injury by cinchophen. 
Immunoallergic phenomena accompany the adverse reaction 
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of the liver to both drugs in a minority of cases and the 
latent period between first intake and onset of the 
reaction is the same. As the chemical structures show some 
resemblance it seems possible that a metabolic 
idiosyncratic reaction is the cause. 
Unlike the cases reported in the medical literature, he-
patic injury induced by ketoconazole was not always found 
to be hepatocellular. The study of 'probable' cases in-
cluded several patients in whom cholestasis predominated. 
Besides the study presented in Chapter 9, an earlier study 
performed by Lewis et al. (3), gave comparable results. The 
biochemical pattern they found was similar to the study in 
this thesis. In the study by Lewis et al., however, cho-
lestatis was not confirmed by biopsy and histology was 
available in only three cases. Their study also showed a 
female preponderance, albeit less .strongly than that re-
ported in this thesis, and liver damage also appeared most-
ly within the first six weeks of therapy. The fatality rate 
in both studies was low. Lewis et al. found a higher in-
cidence of jaundice, however, probably because the study in 
this thesis included a number of patients with mild to 
moderate liver enzyme elevations. Most medical prac-
titioners in The Netherlands are now aware of the potential 
hepatotoxicity of ketoconazole, which means that they 
regularly assess liver enzymes during therapy and discon-
tinue the drug at an early stage. The latter explains the 
low fatality rate in the study in this thesis. A recently 
published paper on 78 cases of ketoconazole-associated 
hepatic injury gave similar results (4). Despite the fact 
that the criteria in the study of Lake-Bakaar et al. were 
less strict than in this study only 16 'probable'-cases 
were reported. Either the cases in their study were less 
well-documented or medical practitioners in the United 
Kingdom rarely exclude other possible causes of hepatic 
injury. The latter seems to be unlikely. Details of the 78 
cases originated from reports to the Committee on Safety of 
Medicines. It seems plausible that careful documentation at 
the moment of reporting would have led to a higher number 
of 'probable'-cases in the study of Lake-Bakaar et al. (4). 
This underlines the importance · of adequate documentation 
and evaluation at the moment of receiving the report and 
confirms the value of "Intensive Case Monitoring". 
The literature about nitrofurantoin suggests that most 
patients with hepatic injury to this drug have chronic ac-
tive hepatitis. The study in Chapter 10 suggests, however, 
that acute hepatic injury is more common. Unfortunately it 
was impossible to relate the acute/chronic cases to the 
ratio of short-termjlong-term treatment so that the exact 
figures about the incidence remain unknown. Nevertheless it 
was possible to approximate the incidence with the help of 
an estimation of the prescription data. It should be re-
alized, however, that this approximation is based on a num-
ber of assumptions, which may mean that it does not reflect 
the real incidence. The study revealed some interesting 
characteristics in that the frequency of nitrofurantoin-
induced hepatic injury shows a clear increase in the el-
derly. Especially for the differentiation between chronic 
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cases of nitrofurantoin-induced hepatic injury and auto-
immune chronic active hepatitis this is of importance since 
the latter usually appears in a younger age-group. Com-
parison of the sex-related sales figures with our cases 
suggest that women are somewhat more susceptible. Since the 
data of voluntary reporting schemes are not suitable for 
calculation of incidences, however, it was not possible to 
assess the statistical significance of a sex-related 
difference in susceptibility. Interesting is the fact that 
the chronic cases differ from autoimmune chronic active 
hepatitis as regards HLA-typing. Whereas the latter is 
mainly associated with HLA-DRw3 the cases in this study 
showed no such association. 
The small study about hepatic injury by pirprofen and 
also the other cases reported in the medical literature 
suggest that the type of injury induced by this drug is 
mainly hepatocellular. It should be emphasized, however, 
that the number of reported cases is small. The study 
demonstrated that "Intensive Case Monitoring" is a method 
which is not restricted to the national area of monitoring. 
The term "Intensive Case Monitoring" is used when, after 
receiving information suggestive of an unknown adverse 
effect, the reporting medical practitioner is contacted at 
an early stage and advised on the studies which should be 
done for adequate documentation. The aim of all medical 
practitioners is to treat their patients, if possible at 
low expenses, rather than to prove the causal relationship 
of adverse effects. For this justified reason they some-
times have to be convinced of the need for additional, 
often expensive, investigation. Most of them, however, are 
willing to co-operate, especially when the importance of 
early detection of unknown adverse effects is reiterated. 
Contact in the early phase of the disease is highly impor-
tant since it facilitates extensive documentation. On an 
international basis exchange of information by telephone 
about the results of additional investigation and the 
exchange of liver slides made it possible to document these 
cases adequately. Communicating with reporting medical 
practitioners from other countries on the results of 
physical examination and laboratory investigation in a 
particular case and consultation about additional 
investigation are usually not a problem in Europe since 
most of them are familiar with the English language. 
The first and most important objective of this thesis -
the question whether voluntary reporting schemes can be 
used for more than merely generating alerts about unknown 
adverse effects - has several aspects. 
These studies demonstrated that not only careful investi-
gation but also follow-up of each individual case is very 
important. This concept of "Intensive case Monitoring" is 
especially successful when the reporting doctor contacts 
the monitoring centre at an early stage. A clear example is 
the ·case of jaundice attributed to glafenine in which hemo-
lysis was not excluded because of insufficient documenta-
tion and late presentation. As discussed above for pirpro-
fen-associated hepatic injury, it was often possible to 
improve the quality of documentation of a particular case 
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by advising on additional investigation. In many cases of 
follow-up the general practitioner was asked to assess 
liver enzymes when this had not been done already in the 
preceding year. A drug monitoring centre should not absorb 
data passively but should actively endeavour to improve the 
documentation of signals. By strongly advising on additi-
onal investigations; e.g. ultrasonography and the exclusion 
of hepatitis A and B, cytomegalovirus infection and infec-
tious mononucleosis (when it concerns hepatic injury) the 
quality of the report can be enhanced significantly. When 
the report is received in an early phase of the illness it 
is possible to have an important influence on the quality 
of the report. This means that medical practitioners en-
countering adverse effects should contact the adverse re-
action monitoring centre as early as possible. This type of 
"Intensive Case Monitoring" requires, however, much time 
and can not be done with all reports of adverse effects 
received by a drug monitoring centre without an increase in 
the number of medical assessors. Especially the follow-up 
may prove that a case is not drug-related at all and this 
means that it is not only an indispensible part of these 
studies but that it should be done with every important 
report of drug-induced disease. The patient with chole-
static hepatitis attributed to the intake of nitrofurantoin 
who later proved to have a deficiency of al-antitrypsin is 
a convincing example of the importance of a follow-up. An 
other example is the patient who had all features, which 
are considered characteristic of nitrofurantoin-induced 
chronic active hepatitis, but in whom a follow-up over 
several years made it more likely that the actual diagnosis 
was autoimmune chronic active hepatitis. It is clear that 
studies of series of cases require extensive documentation 
and follow-up of all cases for several years. A pre-
requisite is that enough medical doctors are willing to 
co-operate. All reports came from medical practitioners, 
mostly general practitioners and specialists in internal 
medicine. In most cases several medical specialties were 
involved, mostly general practitioners, internists and 
pathologists. None of the medical doctors refused to give 
additional data and in all cases where biopsy or autopsy 
was available it was possible to review the original liver 
slides. Most data could be obtained by copies of lists of 
laboratory data and specialists letters. Additional infor-
mation was easily obtained by telephone. Especially the 
follow-up was done by telephone. 
It is obvious that - even when a particular adverse re-
action is relatively rare - over a period of several years 
enough case-reports may be received to facilitate further 
study. No single medical practitioner or department of a 
large hospital can collect the numbers of patients which 
have been covered in the studies in this thesis. Although 
manufacturers also receive many reports about patients 
developing adverse reactions to their products, they are 
not always willing to publish these series, presumably 
because they fear negative advertising. There are, however, 
exceptions since in some cases external experts are given 
the opportunity to use the manufacturers data base as has 
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been done, for instance, with ketoconazole (3) and val-
proate (5). 
Voluntary reporting schemes probably give a more realis-
tic picture of the spectrum of hepatotoxicity of a drug 
than individual case-histories in the literature. Acute 
hepatocellular necrosis, cholestatic hepatitis and chronic 
active hepatitis are all severe adverse effects. It is not 
very likely that the average general practitioner or in-
ternist preferentially reports only one of these patterns. 
It may be assumed that the relative incidence of these 
patterns is fairly well reflected by their distribution in 
a study of 30-50 cases as reported to an adverse reaction 
monitoring centre. The estimation of the distribution of 
these patterns with the help of the literature seems to be 
less reliable, possibly because many subsequent publi-
cations tend to follow previous ones by reporting analogous 
cases. Moreover the decision about publication of a case 
also depends on the opinion of the editors and referees of 
medical journals. 
There are no reasons to suggest that an in-depth study of 
the clinicopathological pattern is only possible with drug-
induced hepatic injury. Although the studies in this thesis 
were concentrated on this subject any organ- or bodily sys-
tem-related adverse effect may be investigated. It should 
be admitted that there are some aspects, which make drug-
induced hepatic injury an attractive issue for in-depth 
studies: the adverse reaction is objective and may be 
assessed easily by noninvasive methods (liver enzyme 
assessment, serology, ultrasonography). Collection of 
affected tissue samples by liver biopsy is relatively easy 
and not associated with significant morbidity and mor-
tality, especially when compared to other tissues (e.g. 
kidney) . On the other hand it must be clear that in-depth 
studies by careful documentation and follow-up of every 
case-history will reveal important characteristics of any 
type of adverse effect. The wide range of central and 
peripheral nervous system disorders, for example, may be 
investigated with the help of many methods, e.g. physical 
examination, electroencephalography, electromyography and 
investigation of visual or auditive evoked potentials. 
Every objective and careful study of patients will help to 
outline the clinicopathological characteristics of a par-
ticular type of adverse reaction irrespective of the in-
volved organ or bodily system. 
Well-documented series of a particular adverse reaction 
can also be used for studies about mechanisms and diagnos-
tic methods. As has been outlined in previous chapters, the 
frequent and dose-dependent adverse effects are almost in-
variably discovered during pre-marketing studies. The dose-
independent adverse effects have a low incidence and are 
usually discovered with one of the postmarketing studies. 
Since patients developing a particular type of reaction may 
have a common characteristic, such groups can be used for 
further study. When it concerns mechanisms, a cohort of 
these patients may be investigated, e.g. for certain me-
tabolic features. Examples are the study of acetylator sta-
tus in patients with hepatic injury to isoniazid (6) and of 
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oxidative capacity in patients with hepatic injury to per-
hexiline (7). Another example is the study of the effect of 
terfenadine, a new antihistamine, on the driving perfor-
mance of patients with drowsiness to this drug, reported to 
the Netherlands Centre for Monitoring of Adverse Reactions 
to Drugs (NARD) , which will be published soon. For an 
example of the possibility to study diagnostic features in 
a particular cohort the reader is referred to the afore-
mentioned study of patients with chronic active hepatitis 
(CAH) to nitrofurantoin (Chapter 10) who did not exhibit 
the same HLA-haplotype as patients with autoimmune CAH. The 
voluntary reporting scheme also facilitates case-control 
studies. An example is the prospective case-control study 
on a possible association between the Guillain-Barre syn-
drome and drug use, as is currently performed by the NARD. 
Underreporting of suspected adverse reactions to national 
monitoring centres remains a problem. Unfortunately there 
is not much known about the reasons for non-reporting. An 
enquiry among 348 British general practitioners revealed 
that 97 percent of them claimed that they would be likely 
to report severe adverse reactions to the national adverse 
reaction monitoring centre, whereas reasons for non-repor-
ting were the fact that the adverse reaction was in the 
data sheet or well-documented (47 percent), that the ad-
verse effect was trivial (24 percent), or that the doctor 
was unsure about a causal relationship (15 percent) (8). It 
is very important to emphasize again and again that also 
known adverse effects should be reported, especially the 
severe ones. 
It may be concluded that it is highly important that 
every report of an important adverse effect received via 
the voluntary reporting scheme of an adverse reaction mon-
itoring centre should be documented carefully and that in 
all cases a follow-up should be performed. Active parti-
cipation at an early stage may significantly improve the 
quality of the report. This is not necessarily restricted 
to the area which is covered by a national monitoring 
centre: "Intensive Case Monitoring" may be done on an 
international basis. It is also concluded that through 
voluntary reporting schemes enough cases may be collected 
to perform in-depth studies and that these studies give a 
reliable picture of the clinicopathological patterns. 
Moreover the collected cases can be used for further 
study as demonstrated by the assessment of HLA-status in 13 
cases of chronic hepatitis by nitrofurantoin. Another 
important conclusion is that medical practitioners should 
not stop reporting adverse effects which are already known. 
Especially the severe adverse effects should be used for 
further study. 
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SAMENVATTING 
Dit proefschrift omvat 12 hoofdstukken en bestaat uit twee 
gedee1ten. In het eerste gedee1te - de hoofdstukken 1 tot 
en met 4 - worden achtereenvo1gens besproken de historische 
ontwikke1ing met betrekking tot de herkenning van bijwer-
kingen van geneesmidde1en (hoofdstuk 1) , de verschi11ende 
soorten bijwerkingen en het ontdekken van deze bijwerkingen 
gedurende de verschi11ende fasen van toxicologisch en kli-
nisch onderzoek die voorafgaan aan het registreren en in de 
handel brengen van een geneesmidde1 (hoofdstuk 2). In de 
hoofdstukken 3 en 4 komen respectieve1ijk aan de orde de 
verschi11ende types van studie na registratie van het ge-
neesmiddel en de methodes en resultaten van het Bureau 
Bijwerkingen Geneesmidde1en. 
In het tweede gedee1te - de hoofdstukken 5 tot en met 12 
worden de doelstellingen van het promotie-onderzoek ge-
formu1eerd (hoofdstuk 5) en methodes en resu1taten van de 
studies gepresenteerd en bediscussieerd. Als onderwerp van 
studie werd gekozen voor 'leverbeschadiging door genees-
middelen'. Ter verduidelijking worden in hoofdstuk 6 de 
verschi11ende histo1ogische bee1den van 1everbeschadiging 
door geneesmiddelen beschreven en wordt in hoofdstuk 7 aan-
gegeven hoe men tot de diagnose 'leverbeschadiging door 
geneesmiddelen' kan komen. De hoofdstukken 8, 9 en 10 be-
treffen descriptieve studies van 3 series patienten met 
1everbeschadiging, toegeschreven aan het gebruik van 
respectievelijk g1afenine en ketoconazole en aan het 
gebruik van nitrofuraanderivaten. Hoofdstuk 11 geeft een 
internationaa1 verrichte studie weer van een aanta1 
gevallen van leverbeschadiging, toegeschreven aan het 
gebruik van pirprofen. In hoofdstuk 12 worden de resu1taten 
besproken. 
Er waren drie redenen om de studies te verrichten, die tot 
dit proefschrift hebben ge1eid. Beoogd werd om: 
1. Aan te tonen dat het nut van een systeem voor het vrij-
willig me1den van bijwerkingen niet beperkt is tot het 
opsporen van onbekende bijwerkingen, maar dat de me1-
dingen ook bruikbaar zijn voor verder onderzoek. 
2. Vast te stellen of het systeem van "Intensive Case 
Monitoring" ook internationaal kan worden toegepast. 
3. De klinisch-histologische patronen van leverbescha-
diging door glafenine (Glifanan) , ketoconazol (Nizoral) 
en nitrofurantoine (Furadantine, Ceduran, Furophen Tc)/ 
nifurtoinol (Urfadyn, Uridurine) te bestuderen. 
Deze drie punten worden hier achtereenvolgens toegelicht. 
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ad.l. 
Alvorens een geneesmiddel in de handel mag worden ge-
bracht, dient experimenteel onderzoek te Z1Jn verricht 
teneinde werkzaamheid en (relatieve) onschadelijkheid aan 
te tonen. Dit meestal zeer uitvoerig onderzoek (een onder-
zoekperiode van 10 jaar is niet ongewoon) vindt plaats in 
verschillende diersoorten (toxicologisch) , vrijwilligers 
(farmacokinetiek) en geselecteerde groepen patienten (far-
macokinetiek en -dynamiek) . Gedurende deze verschillende 
fasen worden het gewenste farmacologische effect (thera-
peutische werking) , de ongewenste effecten (bijwerkingen) 
en de optimale dosering vastgesteld. Een geneesmiddel wordt 
"geregistreerd" mag in de handel worden gebracht - wan-
neer een afweging van werkzaamheid en potentiele schade-
lijkheid in het voordeel van de werkzaamheid uitvalt. 
Ondanks uitvoerig onderzoek echter, Z1Jn meestal op het 
moment van registratie van een geneesmiddel een aantal 
bijwerkingen nog onbekend. Vaak betreft dit ongewenste 
effecten die ofwel niet ontdekt werden tijdens het aan 
registratie voorafgaande onderzoek, ofwel relatief zeldzame 
reacties, die tijdens de experimentele behandeling niet 
zijn opgetreden. Om deze onbekende bijwerkingen op het 
spoor te komen, beschikken de meeste ontwikkelde landen 
over een nationaal centrum waar gegevens over vermoedelijke 
bijwerkingen van geneesmiddelen verzameld, onderzocht en 
geinterpreteerd worden. Deze centra werken internationaal 
samen. Artsen die tijdens de behandeling van een of meer-
dere patienten een hen onbekende bijwerking menen te sig-
naleren, worden geacht deze verdenking ter kennis te bren-
gen van het centrum. Daar beschikt men veelal over de mees-
te gegevens en heeft men de kennis om een signaal verder 
uit te zoeken. Met behulp van een dergelijk systeem kunnen 
dus onbekende bijwerkingen ontdekt worden. Helaas kan men 
op deze W1JZe geen nauwkeurige kennis verzamelen over de 
frequentie waarmee een bepaalde bijwerking v66rkomt. Deze 
frequentie kan men namelijk slechts bepalen wanneer men 
alle bijwerkingen gedurende een bepaalde periode zou delen 
door gegevens over het gebruik van alle geneesmiddelen ge-
durende dezelfde periode. Om verschillende redenen is dit 
niet mogelijk. Ten eerste worden niet alle - door een ge-
neesmiddel veroorzaakte - ongewenste effecten, die bij een 
bepaalde patient optreden, herkend. Ten tweede worden niet 
alle ongewenste effecten, die wel herkend zijn, ook aan het 
geneesmiddel toegeschreven en~en derde worden niet alle 
herkende bijwerkingen gemeld. Bovendien ontbreken vaak 
gegevens over het aantal gebruikers van een bepaald ge-
neesmiddel. Als complicerende factor geldt voorts dat ten-
minste een aantal van de - wel gemelde - vermoedelijke bij-
werkingen niet werkelijk door een geneesmiddel veroorzaakt 
is, en dat vaak niet kan worden vastgesteld in welke geval-
len het wel en in welke gevallen het geen bijwerking be-
treft. 
Betekent dit dat meldingen alleen bruikbaar zijn voor de 
ontdekking van onbekende bijwerkingen ? 
Indien alleen dit laatste van belang was, zou men kunnen 
volstaan met enkele goed gedocumenteerde gevallen van een 
nieuwe bijwerking. Verdere gevallen zouden dan nog slechts 
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gebruikt kunnen worden om een zeer grove schatting te maken 
van de frequentie van v66rkomen van die bepaalde bijwer-
king. Alvorens deze vraag te beantwoorden, is het belang-
rijk om kort in te gaan op het begrip "klinisch-histolo-
gisch patroon". 
Het menselijk lichaam heeft slechts een beperkt aantal 
reactiemogelijkheden op schadelijke effecten. Dat betekent 
dat bepaalde ziektebeelden meerdere oorzaken kunnen hebben, 
zeals bijvoorbeeld bacteriele of virale infecties, maar ook 
dat deze het ongewenste gevolg van het gebruik van een ge-
neesmiddel kunnen zijn. Omdat kennis over de ontstaanswijze 
van een ziekte zeer belangrijk is, bijvoorbeeld omdat dit 
consequenties kan hebben voor de preventie en behandeling, 
is het gewenst om de verschillende oorzaken te kunnen on-
derscheiden. In het geval van bijwerkingen betekent dit dat 
het van belang kan zijn om door grondige bestudering van 
alle bekende gevallen van een bepaalde bijwerking kennis te 
verwerven over de kenmerken. Op basis van deze kennis zou 
men dan bij volgende patienten met een bepaald ziektebeeld 
kunnen uitmaken of men met een bijwerking of met een andere 
oorzaak te maken heeft. Wat verstaan wij nu onder het 
klinisch-histologisch patroon van een bepaalde bijwerking ? 
"Klinisch" verwijst naar de verschijnselen, die de patient 
met de bijwerking vertoont. Dat kan varieren van buikpijn 
en geelzucht tot huiduitslag of lymfklierzwelling. 
Daarnaast zijn er nog bepaalde laboratoriumbepalingen te 
verrichten, die de bestaande beschadiging objectiveren. Een 
voorbeeld van dit laatste vormt de bepaling van serum ami-
notransferasen. Dit zijn enzymen die in de levercel betrok-
ken zijn bij bepaalde stofwisselingsprocessen en die norma-
liter slechts in geringe hoeveelheden in het bleed voor-
komen. Bij beschadiging van de levercellen komen deze en-
zymen in het bleed en vormen de, dan tot abnormale waarden 
gestegen, hoeveelheden van deze enzymen een objectieve 
graadmeter. "Histologisch" verwijst naar het beeld dat wij 
onder de microscoop waarnemen. Zo kan bij leverbeschadiging 
het beeld voornamelijk "hepatocellulair" (levercelbeschadi-
ging domineert) of voornamelijk "cholestatisch" (galstuwing 
domineert) zijn, maar komen ook mengvormen frequent voor. 
Het klinisch-histologisch patroon, dat dus de combinatie 
vormt van klinische en histologische kenmerken van een be-
paalde bijwerking, zal per bijwerking verschillen. Het kli-
nisch-histologisch patroon kan echter oak bij eenzelfde 
soort bijwerking (het proefschrift is geconcentreerd op le-
verbeschadiging als bijwerking) per geneesmiddel verschil-
len. Bovendien kan het aspect van eenzelfde soort bijwer-
king tijdens gebruik van hetzelfde geneesmiddel per indi-
vidu verschillen. Tenslotte werd zelfs in zeldzame gevallen 
waargenomen dat een bepaald geneesmiddel in een en hetzelf-
de individu op verschillende tijdstippen verschillende vor-
men van leverbeschadiging veroorzaakte. Door een serie ge-
vallen van een bepaalde (verdachte) bijwerking te onder-
zoeken, kan men meer te weten komen over de meest frequent 
voorkomende of over de meest kenmerkende vorm. Met deze 
kennis kan men bij volgende ziektegevallen gemakkelijker 
tot een diagnose komen. Indien een geneesmiddel bij voor-
keur een bepaald klinisch-histologisch patroon veroorzaakt 
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zal de bijwerking gemakkelijker als zodanig herkend kunnen 
worden. Wanneer men nu het klinisch-histologisch patroon 
van een bepaalde bijwerking aan de hand van een serie ziek-
tegeschiedenissen wil uitzoeken, zal men dit vanzelfspre-
kend op de 'waarschijnlijke' en 'hoogst waarschijnlijke' 
gevallen moeten baseren. In de gevallen waarin een causaal 
verband 'onwaarschijnlijk', 'niet te classificeren' of 
'mogelijk' is, zal namelijk een andere oorzaak aanwezig 
zijn, respectievelijk aanwezig kunnen zijn. Dit betekent 
dat elke ziektegeschiedenis apart bestudeerd meet worden, 
waarna met behulp van de beschikbare gegevens beslist meet 
worden over de mate van waarschijnlijkheid dat het verdach-
te geneesmiddel verantwoordelijk was voor de leverbeschadi-
ging van een bepaalde patient. Vanzelfsprekend meet dit op 
consequente wijze gedaan worden met behulp van tevoren 
vastgelegde criteria. Alle klinische en histologische ken-
merken van de op deze wijze verzamelde en geed gedocumen-
teerde gevallen kunnen zo geinventariseerd worden (voor een 
nadere toelichting op de aangehaalde causaliteitsbegrippen 
wordt verwezen naar de "Material and Methods" van de hoofd-
stukken 8 tot en met 10, en naar hoofdstuk 7). 
Grondige bestudering van drie series van patienten met 
leverbeschadiging, toegeschreven aan respectievelijk gla-
fenine, ketoconazole en nitrofuraanderivaten, toonde aan 
dat de meldingen hiervoor bruikbaar zijn. 
ad.2. 
De kleine studie van gevallen van leverbeschadiging, toe-
geschreven aan het gebruik van pirprofen, toont dat de po-
g~ngen om onbekende bijwerkingen te ontdekken niet tot het 
e~gen land beperkt behoeven te zijn. "Intensive Case 
Monitoring" bleek oak buiten de grenzen van Nede;r-land te 
werken. Deze benadering bestaat uit de, in een vroeg sta-
dium startende, begeleiding van de meldend arts ten aanzien 
van het stellen van de diagnose. In een dergelijk vroege 
fase kan men adviseren over eventueel aanvullend onderzoek 
zodat de ziektegeschiedenis optimaal gedocumenteerd is. Dit 
is vooral bij nieuwe bijwerkingen zeer belangrijk omdat op 
deze wijze de bewijsvoering in belangrijke mate ondersteund 
kan worden. De procedure is hetzelfde als in ons land. De 
Duitse en de Belgische arts, die bij de studie (hoofdstuk 
11) betrokken waren, hadden ieder een patient behandeld met 
aan pirprofen toegeschreven - leverbeschadiging. Zij wer-
den telefonisch benaderd en de ziektegeschiedenissen van de 
patienten werden doorgesproken. Daarna werd overlegd we1k 
aanvullend onderzoek van be1ang was en werden de leverpre-
paraten ter inzage gevraagd. Tenslotte werd in alle geval-
len een "follow-up" gedaan. Het is duidelijk dat men, door 
vergroting van het gebied dat bestreken wordt, sneller een 
behoorlijk aantal geed gedocumenteerde ziektegeschiedenis-
sen verzamelen kan. Dit kan betekenen dat een onbekende 
bijwerking eerder ontdekt kan worden maar ook dat aanvul-
lend onderzoek sneller kan plaatsvinden. 
ad.3 
Afgaand op de studie van leverbeschadiging, toegeschreven 
aan het gebruik van glafenine, is het klinisch-histologisch 
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beeld voornamelijk hepatocellulair. Bovendien blijkt de re-
actie vaak een ernstig beloop te hebben. Het beeld vertoont 
gelijkenis met het beeld dat gezien werd bij leverbeschadi-
ging door cinchophen. Het laatste geneesmiddel werd in de 
u.s.A. reeds in de dertiger jaren uit de handel genomen 
vanwege ernstige leverbeschadiging in daarvoor gevoelige 
individuen. 
In tegenstelling tot hetgeen de medische literatuur sug-
gereert, kan ketoconazole ook cholestatische hepatitis ver-
oorzaken. Opmerkelijk is het geringe aantal gevallen van 
leverbeschadiging met een fataal beloop in onze studie, 
ondanks het feit dat ketoconazole ernstige leverbeschadi-
ging kan veroorzaken. Dit zou verklaard kunnen worden door 
de ervaring dat een aantal artsen, gezien de bekendheid van 
deze bijwerking, frequent leverenzymen in het serum bepalen 
en het gebruik door hun patienten meestal laten staken bij 
de eerste tekenen van leverbeschadiging. 
De meeste, in de medische literatuur beschreven, gevallen 
van leverbeschadiging door nitrofurantoine betreffen chro-
nisch actieve hepatitis. Onze studie suggereert echter dat 
acute hepatitis, hetzij cholestatisch of hepatocellulair, 
frequenter voorkomt. De kans op leverbeschadiging door ni-
trofurantoine lijkt toe te nemen met de leeftijd van de 
gebruiker. Dit komt het meest duidelijk naar voren bij 
vrouwen. Dit leeftijdsaspect maakt het gemakkelijker om 
onderscheid te maken tussen chronisch actieve hepatitis 
door nitrofurantoine en chronisch actieve hepatitis op 
autoimmuun basis. Bovendien bleken de, bij chronisch ac-
tieve hepatitis op autoimmuun basis frequent voorkomende, 
haplotypes HLA B8 en HLA DRw3 niet vaker voor te komen in 
de patienten met chronisch actieve hepatitis door nitro-
furantoine dan in een controlegroep. 
De belangrijkste conclusie die uit de studies in dit 
proefschrift getrokken kan worden, is dat naast de belang-
rijke signaalfunctie, meldingen van bijwerkingen van ge-
neesmiddelen ook bruikbaar zijn voor verder onderzoek. Dit 
betekent dat het ook belangrijk is om bekende bijwerkingen 
te melden. Over een langere periode kan zo een serie worden 
opgebouwd, die een grondige studie van de verschillende 
klinische en histologische aspecten van een bepaalde bij-
werking mogelijk maakt. Aangezien veel bijwerkingen een re-
latief lage frequentie van v66rkomen hebben, zal het voor 
een individuele arts meestal niet mogelijk zijn om een der-
gelijke serie op te bouwen. Dit laatste blijkt ook uit de 
medische literatuur, die veel beschrijvingen van ziekte-
geschiedenissen telt van een of enkele patienten, maar 
weinig studies van enige omvang. 
Bovendien wordt op deze wijze een bestand van gegevens 
opgebouwd over individuen die op een bepaalde wijze op een 
geneesmiddel reageren. Vaak betreft dit overgevoeligheids-
reacties, waarvan het optreden onvoorspelbaar is zodat, 
voordat de reactie zich ontwikkelt, niet bekend is bij wie 
zich deze zal voordoen. Eventueel onderzoek naar ontstaans-
wijze en diagnostische methodes (bijvoorbeeld immunologisch 
onderzoek naar geneesmiddel-afhankelijke antilichamen) zal 
slechts kunnen worden verricht met behulp van de gegevens 
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van een groep van dergelijke individuen. Zo kunnen de mel-
dingen van vermoedelijke bijwerkingen, zeals het Bureau 
Bijwerkingen Geneesmiddelen deze ontvangt, tevens dienen 
als basis voor verder onderzoek. 
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